angiotensin
convert
enzym
inhibitor
acei
standard
care
treatment
congest
heart
failur
aldosteron
breakthrough
occur
acei
use
dog
human
combin
angiotensinreceptor
blockerneprilysin
inhibitor
show
superior
reduc
mortal
human
patient
heart
failur
compar
enalapril
pharmacodynam
evalu
healthi
dog
show
efficaci
alter
reninangiotensinaldosteron
system
raa
without
caus
advers
effect
aim
prospect
blind
random
placebocontrol
studi
compar
pharmacodynam
effect
placebo
dog
preclin
myxomat
mitral
valv
diseas
mmvd
evalu
safeti
profil
dog
cardiac
diseas
clientown
dog
weigh
kg
acvim
stage
mmvd
enrol
dog
clinic
signific
pulmonari
hypertens
system
diseas
exclud
dog
medic
known
alter
raa
dog
receiv
pimobendan
throughout
studi
period
patient
evalu
three
time
point
day
day
day
echocardiographi
thorac
radiograph
cxr
doppler
system
arteri
pressur
sap
complet
blood
count
serum
biochem
profil
plasma
ntermin
probrain
natriuret
peptid
ntprobnp
concentr
urinari
aldosteron
creatinin
ratio
ualdo
c
evalu
day
day
dog
randomli
alloc
treatment
group
mgkg
bid
placebo
group
attend
pharmacist
investig
veterinari
technician
owner
blind
treatment
serum
renal
enzym
electrolyt
concentr
sap
recheck
day
echocardiographi
cxr
sap
renal
panel
plasma
ntprobnp
concentr
ualdo
c
recheck
day
thirteen
dog
recruit
n
placebo
n
median
percent
increas
ualdo
c
day
day
significantli
lower
group
p
compar
placebo
group
median
percent
decreas
ntprobnp
concentr
day
day
statist
differ
group
p
statist
differ
seen
echocardiograph
cxr
sap
biochem
profil
measur
time
point
group
advers
event
note
owner
dog
either
group
studi
suggest
effici
inhibit
raa
dog
cardiomegali
secondari
mmvd
comparison
placebo
safe
regard
sap
renal
enzym
electrolyt
concentr
advers
effect
note
dog
take
futur
studi
compar
acei
evalu
concomit
use
diuret
evalu
longterm
day
effect
warrant
trimethylamin
noxid
tmao
oxid
product
trimethylamin
produc
gastrointestin
microbiota
certain
dietari
nutrient
includ
cholin
lcarnitin
elev
plasma
concentr
tmao
cholin
lcarnitin
shown
associ
presenc
sever
cardiovascular
diseas
peopl
independ
predictor
advers
cardiac
event
mortal
prospect
studi
investig
whether
differ
concentr
circul
tmao
cholin
lcarnitin
dog
degen
mitral
valv
diseas
dmvd
compar
healthi
control
control
thirti
clientown
dog
recruit
includ
dog
chf
secondari
dmvd
dog
asymptomat
dmvd
control
echocardiographi
perform
fast
plasma
concentr
tmao
cholin
carnitin
fraction
measur
data
compar
among
three
group
use
anova
kruskalw
test
trimethylamin
noxid
p
total
lcarnitin
p
carnitin
ester
carnitin
ester
free
carnitin
ratio
ef
ratio
significantli
higher
dog
chf
compar
asymptomat
dmvd
trimethylamin
noxid
p
cholin
p
total
lcarnitin
p
carnitin
ester
free
carnitin
ef
ratio
significantli
higher
dog
chf
compar
control
differ
detect
asymptomat
dmvd
dog
control
dog
dmvd
chf
higher
concentr
tmao
compar
asymptomat
dmvd
dog
control
prospect
studi
warrant
determin
tmao
concentr
alter
dietari
gut
microflora
modif
whether
alter
tmao
concentr
could
impact
diseas
progress
loop
diuret
provid
symptomat
relief
congest
heart
failur
yet
stimul
reninangiotensinaldosteron
system
raa
hypothes
two
potent
loop
diuret
torsemid
furosemid
approxim
equipot
dosag
similar
diuresi
would
compar
effect
circul
raa
six
healthi
middleag
male
beagl
random
receiv
torsemid
po
furosemid
po
placebo
day
separ
experi
crossov
design
washout
period
experi
blood
collect
day
urin
collect
end
day
repeat
measur
analysi
bonferonni
correct
variabl
adjust
p
investig
use
tukey
method
twentyfour
hour
urin
product
differ
significantli
diuret
day
torsemid
caus
greater
diuresi
furosemid
howev
signific
differ
averag
diuresi
signific
differ
diuret
urinari
excret
na
cl
k
though
furosemid
caus
less
kaliuresi
torsemid
serum
renin
angiotensin
ii
aldosteron
urin
aldosteronetocreatinin
ratio
significantli
increas
diuret
group
compar
placebo
day
signific
differ
paramet
diuret
creatinin
bun
concentr
rose
compar
diuret
group
remain
within
refer
interv
dog
approxim
equipot
dosag
torsemid
furosemid
produc
compar
raa
activ
torsemid
greater
kaliuret
effect
decreas
support
torsemid
hypothes
mineralocorticoidreceptor
block
capabl
transven
pacemak
implant
definit
treatment
patholog
bradyarrhythmia
though
report
complic
rate
histor
high
purpos
studi
determin
surviv
time
complic
rate
dog
underw
transveatenolol
receptor
antagonist
commonli
prescrib
cat
affect
hypertroph
obstruct
cardiomyopathi
tradit
oral
dose
mg
per
cat
oral
tablet
highli
bioavail
peak
atenolol
concentr
occur
hour
post
administr
cat
howev
result
sever
studi
indic
owner
complianc
may
poor
longterm
oral
treatment
felin
disposit
present
specif
challeng
owner
chronic
oral
medic
administr
previou
object
assess
diagnost
util
feasibl
use
french
intracardiac
echocardiographi
ice
cathet
acuson
evalu
cardiac
structur
function
consciou
hors
sedat
xylazin
ten
appar
healthi
hors
texa
uni
procedur
well
toler
mild
intermitt
ventricular
supraventricular
arrhythmia
resolv
ice
cathet
reposit
conclud
ice
feasibl
safe
allow
acquisit
repeat
diagnost
imag
plane
consciou
sedat
hors
could
potenti
use
clinic
situat
tte
may
technic
difficult
perform
poorli
toler
hors
julia
r
tresed
nicol
l
leblanc
katherin
f
scollan
oregon
state
univers
corval
usa
sotalol
class
iii
antiarrhythm
drug
commonli
prescrib
treatment
ventricular
tachyarrhythmia
dog
antiarrhythm
effect
sotalol
mediat
increas
action
potenti
durat
prolong
atrial
ventricular
repolar
via
antagon
delay
rectifi
potassium
current
effect
demonstr
independ
sotalol
properti
howev
blockad
may
result
reduc
myocardi
contractil
also
contribut
slow
sinu
rate
patient
exist
heart
diseas
cardiodepress
drug
effect
may
clinic
relev
yet
inotrop
properti
sotalol
wellcharacter
dog
aim
studi
investig
inotrop
chronotrop
effect
sotalol
healthi
awak
dog
ten
adult
largebre
dog
recruit
veterinari
commun
oregon
state
univers
colleg
veterinari
medicin
dog
consid
healthi
base
histori
physic
exam
oscillometr
blood
pressur
measur
transthorac
echocardiographi
electrocardiogram
dog
also
baselin
hour
holter
monitor
perform
sotalol
dose
mgkg
oral
administ
day
follow
second
evalu
includ
diagnost
test
physic
exam
paramet
blood
pressur
measur
holter
data
echocardiograph
measur
includ
threedimension
left
ventricular
lv
volum
strain
measur
evalu
baselin
posttreat
measur
assess
normal
compar
statist
pair
ttest
normal
distribut
data
wilcoxon
sign
rank
test
nonnorm
distribut
data
data
avail
dog
correct
made
multipl
comparison
ten
dog
includ
studi
mean
age
year
rang
year
mean
weight
kg
rang
kg
mean
sotalol
dose
administ
mgkg
heart
rate
exam
significantli
p
lower
posttreat
bpm
pretreat
bpm
maximum
heart
rate
holter
monitor
also
significantli
p
lower
sotalol
bpm
baselin
bpm
sever
echocardiograph
indic
systol
function
alter
compar
baselin
fraction
shorten
fs
use
twodimension
mmode
mm
measur
significantli
reduc
sotalol
interquartil
rang
iqr
mm
compar
baselin
iqr
mm
p
p
mmode
measur
respect
similarli
eject
fraction
ef
via
simpson
method
disk
smod
significantli
p
lower
sotalol
baselin
sotalol
increas
lv
endsystol
dimens
increas
mmode
measur
p
p
respect
signific
differ
left
ventricular
volum
global
longitudin
circumferenti
strain
twist
torsion
result
studi
suggest
sotalol
neg
inotrop
chronotrop
effect
healthi
dog
standard
echocardiograph
measur
systol
function
show
small
statist
signific
decreas
sotalol
treatment
mean
reduct
ef
smod
lack
signific
imag
may
reflect
variabl
measur
small
sampl
size
effect
sotalol
dog
structur
heart
diseas
prospect
assess
elucid
clinic
signific
decreas
systol
function
implic
reduct
patient
risk
heart
failur
nou
pacemak
implant
larg
number
institut
addit
wish
identifi
factor
may
predispos
patient
develop
complic
multicent
retrospect
analysi
dog
underw
transven
pacemak
implant
januari
signific
differ
surviv
time
sss
p
major
complic
includ
lead
dislodg
episod
lead
perfor
episod
transven
pacemak
implant
associ
rel
high
complic
rate
predispos
factor
specif
complic
unabl
identifi
associ
longer
surviv
time
compar
sss
though
differ
bradyarrhythmia
veterinari
studi
investig
transderm
atenolol
equival
oral
atenolol
dosag
found
major
cat
receiv
transderm
atenolol
therapeut
plasma
atenolol
concentr
hour
administr
none
therapeut
plasma
atenolol
concentr
hour
administr
result
rais
question
regard
direct
substitut
transderm
dose
equival
oral
dose
inher
variabl
compound
medic
therefor
goal
studi
optim
nonpat
transderm
atenolol
formul
assess
atenolol
dosag
amount
frequenc
healthi
cat
use
formul
hypothes
optim
transderm
atenolol
formula
higher
transderm
dosag
rate
administ
result
therapeut
ngml
atenolol
concentr
healthi
cat
collabor
oregon
state
univers
osu
colleg
pharmaci
research
creat
transderm
atenolol
formul
optim
drug
releas
good
permeat
steadyst
manner
differ
concentr
atenolol
gel
hypomellos
carrier
carbom
base
evalu
vitro
diffus
studi
use
treatment
transderm
atenolol
administ
blood
sampl
collect
atenolol
serum
concentr
hour
topic
applic
phlebotomi
hour
postatenolol
administr
ecg
also
perform
averag
heart
rate
hr
measur
gradual
taper
transderm
atenolol
subsequ
occur
day
enrol
cat
success
complet
drug
trial
cat
experienc
advers
sideeffect
two
cat
initi
receiv
maximum
transderm
dose
mg
serum
atenolol
concentr
subtherapeut
ngml
hour
postatenolol
transderm
atenolol
dose
increas
mg
cat
reenrol
studi
use
higher
atenolol
dosag
week
washout
period
three
cat
complet
updat
studi
protocol
higher
atenolol
dosag
two
cat
popul
major
gsd
type
ii
pda
anatomi
amen
acdo
deploy
predisposit
larg
mdd
occasion
unusu
pda
anatomi
suggest
transesophag
echocardiographi
may
benefici
optim
procedur
plan
breed
six
healthi
middleag
male
beagl
random
receiv
torsemid
po
furosemid
po
placebo
day
separ
experi
crossov
design
separ
washout
period
blood
collect
day
urin
sampl
collect
end
day
serum
aldosteron
quantifi
via
liquid
chromatographymass
spectrometri
lcm
ms
angiotensin
metabolit
quantifi
lcmsm
equilibrium
analysi
attoqu
diagnost
vienna
austria
urin
aldosteron
quantifi
via
radioimmunoassay
beckman
coulter
use
calcul
urin
aldosteronetocreatinin
ratio
ualdo
c
repeat
measur
analysi
bonferonni
correct
variabl
adjust
p
investig
use
tukey
method
serum
angi
angii
angiv
aldosteron
ualdo
c
significantli
increas
diuret
group
compar
placebo
day
increas
paramet
greatest
torsemid
group
fail
reach
signific
serum
angiii
increas
diuret
therapi
yet
valu
differ
significantli
placebo
novel
compon
circul
raa
significantli
increas
therapi
torsemid
furosemid
mirror
chang
classic
raa
repeat
intraobserv
interobserv
imag
acquisit
variabl
measur
variabl
quantifi
averag
coeffici
variat
cv
lower
upper
limit
bound
coeffici
variat
calcul
use
exact
theori
logist
regress
upper
limit
repetit
use
determin
highest
precis
modal
evalu
left
ventricular
size
mmode
highest
repeat
cv
lowest
intraand
interobserv
variabl
imag
acquisit
cv
measur
cv
repeat
imag
acquisit
cv
measur
cv
slightli
better
imag
acquisit
cv
measur
cv
intraand
interobserv
variabl
cv
also
slightli
better
cv
left
atrial
aortic
ratio
measur
higher
repeat
cv
less
variabl
cv
volum
assess
imag
acquisit
identifi
among
gfd
dog
test
taurin
carnitin
twentyseven
dog
dcm
fed
ngfd
test
taurin
defici
vegetarian
echocardiogram
dog
dcm
fed
gfd
specif
suggest
advanc
diseas
dietenhanc
pathophysiolog
compar
dog
eat
ngfd
cat
chf
higher
serum
leucinerich
compar
healthi
control
higher
serum
amyloid
compar
asymptomat
cm
healthi
control
higher
ceruloplasmin
compar
asymptomat
cm
p
univari
surviv
analysi
model
serum
glycoprotein
agp
level
found
associ
higher
risk
death
chf
cat
p
multivari
analysi
suggest
serum
agp
p
bodi
weight
p
laao
ratio
p
independ
prognost
factor
chf
cat
find
suggest
system
inflammatori
respons
occur
felin
congest
heart
failur
due
primari
cardiomyopathi
acut
phase
protein
use
clinic
paramet
biomark
diseas
monitor
prognost
felin
cardiomyopathi
chf
pancreat
human
dog
aim
prospect
studi
assess
fpli
tli
valu
healthi
cat
cat
primari
cm
without
chf
addit
retrospect
evalu
pancreat
histolog
cat
cm
perform
cat
prospect
recruit
three
group
healthi
control
h
group
primari
cm
cm
group
cm
activ
histor
chf
determin
boardcertifi
cardiologist
chf
group
includ
cat
underw
physic
exam
blood
pressur
echocardiogram
fpli
tli
complet
blood
count
cbc
chemistri
panel
cat
evid
hypertroph
cardiomyopathi
hcm
also
total
measur
routin
pancreat
histopatholog
cat
affect
primari
cm
retrospect
review
boardcertifi
anatom
pathologist
histolog
evid
pancreat
injuri
differ
group
assess
kruskalw
test
associ
assess
fisher
exact
test
total
cat
includ
classifi
h
cm
chf
group
statist
differ
age
bodi
weight
bodi
condit
score
group
cm
diagnos
includ
hcm
cm
chf
hypertroph
obstruct
cardiomyopathi
cm
chf
unclassifi
cardiomyopathi
cm
chf
restrict
cardiomyopathi
chf
chf
group
cat
activ
chf
pulmonari
edema
pleural
effus
time
blood
collect
gastrointestin
sign
includ
vomit
cm
chf
anorexia
cm
chf
weight
loss
cm
chf
median
valu
control
cm
chf
group
differ
fpli
tli
five
cm
chf
cat
fpli
valu
greater
felin
refer
rang
cm
cat
increas
tli
valu
cm
cat
deceas
tli
valu
activ
chf
statist
associ
abnorm
fpli
tli
result
p
p
retrospect
pancreat
histopatholog
cat
cm
found
spectrum
morpholog
lesion
potenti
relat
pancreat
ischemia
includ
exocrin
vacuol
focal
multifoc
coagul
necrosi
saponif
pancreasassoci
adipos
tissu
cat
possibl
cardiacrel
pancreat
ischemia
activ
histor
chf
common
felin
pancreat
lesion
also
identifi
includ
islet
amyloidosi
mild
moder
lymphocyt
inflamm
periductular
fibrosi
preliminari
data
demonstr
statist
signific
differ
pancreat
biomark
cardiomyopath
cat
without
chf
potenti
relev
histopatholog
pancreat
chang
identifi
suggest
biomark
may
vari
time
diseas
sever
reflect
cardiacinduc
injuri
left
atrium
may
enlarg
variou
direct
although
convent
measur
echocardiographi
onedimens
use
shortaxi
right
parastern
view
index
aortic
diamet
la
ao
maxim
diamet
right
parastern
longaxi
view
also
util
assess
la
size
twodimension
measur
volum
calcul
replac
onedimension
linear
measur
chamber
quantif
human
canin
echocardiograph
exam
aim
retrospect
studi
compar
la
size
convent
linear
measur
calcul
la
volum
lav
compar
minim
maxim
valu
hypothesi
lav
would
provid
superior
sensit
se
specif
sp
identifi
cat
chf
without
chf
medic
record
review
cat
complet
echocardiograph
exam
perform
oregon
state
univers
veterinari
teach
hospit
osuvth
januari
juli
maxim
left
atrial
diamet
lad
right
parastern
longaxi
view
volum
calcul
use
monoplan
modifi
simpson
method
disc
mod
volum
measur
also
index
bodi
weight
kg
minim
measur
made
p
wave
maximum
measur
made
wave
simultan
record
ecg
receiv
oper
curv
use
assess
area
curv
auc
optim
cutoff
associ
se
sp
distinguish
group
total
cat
includ
studi
classifi
healthi
cm
chf
healthi
cat
younger
cm
chf
group
p
group
differ
bodi
weight
lav
measur
rla
lap
view
statist
differ
p
classifi
accord
whether
increas
decreas
maintain
interv
enter
explanatori
variabl
addit
explanatori
variabl
includ
model
record
first
examin
interv
associ
chang
heart
murmur
intens
rate
cardiac
remodel
provid
evidenti
support
util
longitudin
monitor
murmur
grade
clinic
practic
increas
murmur
grade
may
indic
rapid
rate
dmvd
progress
occur
could
use
recommend
echocardiograph
evalu
dog
ste
data
obtain
three
scan
plane
mean
peak
radial
strain
apex
ar
mean
peak
radial
strain
papillari
muscl
level
pmr
mean
peak
radial
strain
base
br
mean
peak
circumferenti
strain
apex
ac
mean
peak
circumferenti
strain
papillari
muscl
level
pmc
mean
peak
circumferenti
strain
base
bc
cat
increas
bc
p
insulin
p
ntprobnp
p
ctni
p
correl
present
ntprobnp
maxivsd
p
maxlvwd
p
sumlvwd
p
laremodel
p
ctni
sumivsd
p
laremodel
p
saa
sumivsd
p
nivsd
p
age
correl
la
max
p
glucos
p
bw
bc
correl
nlvwd
p
mlvwd
p
p
insulin
p
glucos
p
p
respect
cat
la
remodel
n
higher
maxlvwd
p
sumlvwd
p
ntprobnp
p
ctni
p
cat
gener
hypertrophi
n
higher
maxivsd
p
sumivsd
p
maxlvwd
p
sumlvwd
p
saa
p
result
suggest
role
insulin
metabol
inflamm
ahcm
research
contribut
ahcm
need
studi
design
random
blind
control
experiment
trial
spragu
dawley
rat
assign
equal
six
treatment
group
salin
neg
control
serotonin
posit
control
inhibit
posit
control
inhibit
plu
serotonin
synergist
inhibitor
plu
cyproheptadin
serotonin
antagonist
inhibitor
plu
clopidogrel
antiplatelet
group
treat
day
sacrif
heart
collect
stain
hematoxylin
eosin
h
e
histopatholog
examin
result
score
base
previous
publish
semiquantit
method
mitral
valv
patholog
score
rang
chang
sever
chang
median
rang
treatment
group
follow
neg
control
posit
control
posit
control
univers
sayama
saitama
japan
shiraishi
anim
hospitalanim
cardiovascular
thorac
surgeri
centertokyo
univers
agricultur
technolog
sayamashi
saitama
japan
tokyo
univers
agricultur
technolog
fuchu
tokyo
japan
univers
tokyoanim
cardiovascular
thorac
surgeri
center
bunkoku
tokyo
japan
nihon
univ
fujsawa
kanagawa
japan
nihon
univers
fujisawa
kanagawa
japan
studi
purpos
clarifi
chang
blood
ga
surgeri
mitral
valv
plasti
surgeri
perform
use
cardiopulmonari
bypass
cpb
subject
dog
mitral
regurgitationfor
anesthesia
inhal
anesthesia
combin
moder
hypothermia
method
time
conduct
blood
ga
sampl
examin
pre
initi
cpb
partial
start
cpb
total
aortic
crossclamp
rebeat
aortic
declamp
post
complet
cpb
conclus
toceranib
elicit
weaker
revers
properti
pulmonari
arteri
remodel
rvh
therefor
low
dose
toceranib
comparison
sorafenib
may
promis
therapeut
agent
cardiopulmonari
remodel
pah
obes
common
nutrit
diseas
cat
increas
preval
excess
bodi
fat
predispos
anim
deleteri
effect
heart
function
systol
blood
pressur
sbp
alter
arrhythmia
radiograph
echocardiograph
chang
describ
howev
much
inform
regard
effect
obes
cardiovascular
system
cat
studi
aim
evalu
effect
cardiovascular
system
domest
cat
compar
cat
normal
bodi
condit
thirtysix
cat
alloc
two
group
obes
cat
cat
normal
bodi
condit
submit
sbp
measur
electrocardiogram
ecg
chest
radiograph
evalu
cardiac
silhouett
vertebr
heart
size
vh
echocardiograph
measur
evalu
establish
relationship
data
obtain
bodi
weight
bodi
condit
score
bc
bodi
mass
index
bmi
sbp
vh
statist
higher
obes
anim
contrast
normal
cat
obes
cat
mean
sbp
weight
quadrat
relationship
also
observ
left
atrialtoaort
root
diamet
ratio
la
ao
bodi
weight
addit
relationship
lvfwd
bmi
although
consid
signific
present
p
valu
slightli
obes
cat
show
higher
bp
vh
normal
cat
led
increas
echocardiograph
measur
studi
shown
obes
promot
cardiac
function
impair
studi
cat
therefor
import
monitor
anim
sinc
even
asymptomat
one
may
present
chang
cardiac
paramet
studi
aim
measur
heart
rate
variabl
holstein
cow
fetus
neonat
descript
evalu
continu
fetomatern
neonat
electrocardiogram
record
perinat
period
heart
rate
hr
heart
rate
variabl
hrv
assess
fetomatern
electrocardiographi
ecg
fetomatern
measur
taken
six
time
prepartum
neonat
six
time
calv
heart
rate
timedomain
variabl
frequencydomain
variabl
analyz
holstein
cow
neonat
signific
chang
observ
matern
fetal
rr
interv
hr
fetus
standard
deviat
beattobeat
interv
sdnn
decreas
significantli
ms
ms
p
root
mean
squar
success
beattobeat
differ
rmssd
chang
significantli
fetal
heart
rate
rr
interv
differ
statist
day
deliveri
bpm
ms
day
calv
bpm
equin
matern
pheromon
emp
use
tool
calm
equin
face
new
stress
situat
forc
physiolog
adapt
alter
relat
mainli
increas
heartrat
hr
behavior
alter
studi
aim
assess
effect
emp
treatment
colt
undergo
hoof
trim
first
time
employ
behavior
heartrat
variabl
hrv
main
paramet
assess
colt
averag
age
month
underw
hoof
trim
first
time
anim
divid
two
group
random
doubl
blind
experiment
design
employ
treatment
emp
placebo
administ
holter
monitor
put
place
minut
procedur
start
hr
measur
convent
method
hrv
measur
two
moment
minut
trim
immedi
trim
measur
heart
rate
variabl
hrv
report
accept
method
assess
level
stress
numer
express
neurohormon
effect
exert
heart
rate
normal
valu
physiolog
paramet
larger
breed
often
use
refer
valu
poni
howev
heart
rate
increas
smaller
anim
adult
poni
higher
adult
warmblood
hors
littl
known
effect
pregnanc
signal
heart
rate
variabl
valu
equin
speci
studi
aim
determin
physiolog
rang
heart
rate
beat
per
minut
heart
rate
variabl
equin
mare
differ
month
gestat
month
ecg
record
made
month
data
use
analysi
heart
rate
hr
hrv
assess
matern
electrocardiographi
ecg
matern
measur
taken
ten
time
prepartum
heart
rate
variabl
analyz
timedomain
signific
chang
observ
fourth
tenth
month
pregnanc
rr
interv
ms
ms
hr
bpm
bpm
p
correspond
smallest
largest
valu
respect
signific
chang
observ
standard
deviat
beattobeat
interv
sdnn
p
root
mean
squar
success
beattobeat
differ
rmssd
p
timedomain
analysi
demonstr
signific
increas
mean
rr
interv
hr
progress
pregnanc
also
establish
hrv
influenc
hr
higher
hr
associ
lower
hrv
mare
renal
dysfunct
caus
primari
cardiovascular
diseas
consid
class
cardiovascular
renal
disord
cvrd
small
anim
medicin
cvrd
cardiac
patient
novel
research
area
studi
aim
evalu
cvrd
cat
congest
heart
failur
chf
primari
cardiomyopathi
cm
measur
cardiac
renal
function
marker
twentyon
client
own
cat
diagnos
primari
cm
chf
asymptomat
referr
cardiolog
servic
enrol
twenti
healthi
cat
use
control
serum
nterminalpro
brain
naturet
peptid
ntprobnp
symmetr
dimethylarginin
sdma
creatinin
level
measur
refer
laboratori
relev
clinic
inform
surviv
statu
chf
cat
record
oneway
analysi
varianc
anova
student
test
spearman
rho
cox
proport
hazard
model
use
statist
analysi
abstract
ntprobnp
sdma
creatinin
level
posit
correl
significantli
differ
among
three
group
cat
chf
cat
higher
serum
ntprobnp
asymptomat
cm
cat
healthi
control
cat
higher
sdma
creatinin
healthi
control
p
cat
chf
die
higher
ntprobnp
p
sdma
p
creatinin
p
compar
survivor
howev
neither
marker
signific
prognost
factor
multivari
surviv
analysi
model
studi
result
suggest
cvrd
present
chf
cat
primari
cardiomyopathi
furthermor
sdma
novel
biomark
cat
chf
primari
cm
could
use
diseas
manag
prognost
consequ
turbul
highveloc
flow
chang
fluid
shear
stress
around
mitral
valv
chang
platelet
function
may
involv
pathogenesi
myxomat
mitral
valv
diseas
mmvd
aim
studi
investig
whether
chang
coagul
vari
sever
mmvd
dog
retrospect
review
chart
dog
mmvd
classif
mmvd
dog
base
acvim
stage
compar
result
follow
test
white
blood
cell
count
wbc
platelet
count
plt
mean
platelet
volum
mpv
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
fibrinogen
fib
creactiv
protein
crp
antithrombin
iii
atiii
fibrin
degrad
product
fdp
activ
clot
time
act
platelet
function
pf
clot
rate
cr
total
dog
evalu
dog
acvim
stage
dog
stage
c
dog
stage
fibrinogen
crp
significantli
increas
diseas
progress
p
dog
stage
significantli
higher
wbc
plt
pf
compar
dog
stage
p
signific
differ
mpv
pt
aptt
atiii
fdp
among
group
platelet
function
activ
declin
dog
mmvd
wbc
crp
fib
increas
consist
increas
inflamm
mmvd
progress
inflammatori
respons
may
play
import
role
increas
platelet
function
mitral
valv
function
deterior
ntermin
probtyp
natriuret
peptid
ntprobnp
left
atrial
ruptur
lar
uncommon
complic
myxomat
mitral
valv
diseas
usual
lead
patient
die
suddenli
hour
dog
surviv
long
period
time
congest
heart
failur
chf
previous
hypothet
reduc
long
term
surviv
doppler
deriv
echocardiograph
paramet
influenc
atrial
pressur
peak
earli
e
left
ventricular
fill
wave
veloc
e
isovolum
relax
time
e
ivrt
ratio
usual
provid
inform
congest
heart
failur
although
echocardiograph
predict
chf
time
lar
diagnosi
would
help
prognosi
reduct
left
atrial
pressur
due
chamber
empti
pericardi
space
could
hinder
predict
analysi
studi
retrospect
review
hospit
record
dog
diagnosi
lar
base
necropsi
andor
echocardiograph
find
includ
follow
criteria
myxomat
mitral
valv
diseas
mitral
regurgit
flow
alias
color
doppler
studi
fill
left
atrium
la
ao
ratio
twodimension
right
parastern
shortaxi
view
pericardi
effus
organ
echogen
materi
suggest
cloth
within
pericardi
space
dog
die
non
cardiac
caus
includ
six
dog
met
criteria
inclus
male
femal
differ
breed
toy
poodl
n
pinscher
n
chihuahua
n
mean
age
year
rang
year
mean
bodi
weight
kg
rang
kg
clinic
sign
includ
cough
weak
colaps
tachypnea
dog
n
systol
system
arteri
blood
pressur
lower
mmhg
dog
hospit
diagnosi
system
arteri
blood
pressur
greater
mmhg
therapi
intraven
crystalloid
dobutamin
n
noradrenalin
n
andor
pericardiocentesi
n
thorac
radiograph
perform
time
lar
diagnosi
dog
mark
interstiti
alveolar
perihilar
infiltr
chf
group
remaind
dog
pulmonari
abnorm
also
prior
histori
decompens
heart
failur
nonchf
group
diabet
mellitu
dm
common
endocrinopathi
dog
impact
cardiovascular
system
still
unclear
speci
human
medicin
serum
fructosamin
concentr
sfc
use
cardiovascular
prognost
grow
aim
studi
evalu
correl
among
systol
blood
pressur
sbp
sfc
insulin
dose
use
diabet
dog
crosssect
studi
design
includ
diabet
dog
treatment
nph
insulin
mean
dose
u
ukg
rang
ukg
period
month
month
patient
assess
doppler
vascular
method
verifi
sbp
agreement
acvim
guidelin
sfc
measur
colorimetr
assay
eighteen
diabet
dog
kg
twelv
healthi
control
dog
year
kg
pair
breed
sex
age
includ
significantli
posit
correl
sbp
sfc
diabet
dog
r
p
well
control
dog
r
p
insulin
dose
sbp
correl
approach
signific
r
p
also
correl
time
diagnosi
sbp
r
p
find
suggest
associ
sfc
hypertens
dog
result
emphas
import
sbp
monitor
diabet
dog
suggest
insulin
dose
may
import
factor
time
diagnosi
risk
factor
hypertens
canin
diabet
patient
amiodaron
predominantli
class
iii
antiarrhythm
drug
also
block
sodium
channel
calcium
channel
receptor
commonli
use
treatment
tachyarrhythmia
notabl
ventricular
tachyarrhythmia
lipophil
iodin
benzofuranderiv
medic
amiodaron
uniqu
pharmacolog
structur
properti
distinguish
antiarrhythm
warrant
care
surveil
certain
metabol
process
composit
lead
inhibit
activ
result
decreas
triiodothyronin
product
amiodaron
main
metabolit
desethylamiodaron
may
also
block
bind
respect
receptor
amiodaron
induc
thyroid
dysfunct
document
peopl
aim
determin
amiodaron
alter
thyroid
function
dog
treat
signific
tachyarrhythmia
record
institut
review
find
dog
treat
tachyarrhythmia
amiodaron
whose
retriev
inform
complet
regard
amiodaron
dose
thyroid
function
test
start
amiodaron
ten
clientown
dog
identifi
record
evalu
data
regard
histori
signal
antiarrhythm
medic
echocardiograph
find
cardiac
medic
electrocardiogram
find
total
thyroid
stimul
hormon
tsh
level
initi
amiodaron
amiodaron
dose
length
time
initi
amiodaron
post
tsh
test
median
age
evalu
patient
year
rang
male
femal
sexual
intact
patient
eight
dog
initi
receiv
antiarrhythm
therapi
mexiletin
monotherapi
sotalol
monotherapi
mexiletinesotalol
dual
therapi
sotaloldiltiazem
dual
therapi
two
dog
receiv
antiarrhythm
medic
prior
evalu
amiodaron
institut
commonli
dog
systol
dysfunct
congest
heart
failur
intoler
particular
antiarrhythm
tachyarrhythmia
refractori
antiarrhythm
median
mainten
amiodaron
dose
mgkgd
rang
preced
median
amiodaron
load
dose
mgkgd
rang
day
median
preamiodaron
valu
nmoll
rang
median
preamiodaron
tsh
valu
ngml
rang
median
postamiodaron
nmoll
rang
median
postamiodaron
tsh
ngml
rang
wilcoxon
signedrank
analysi
show
tsh
increas
p
amiodaron
initi
median
time
postamiodaron
thyroid
test
day
rang
day
rang
tsh
start
drug
median
time
preamiodaron
postamiodaron
test
day
rang
day
rang
tsh
clinic
sign
hypothyroid
note
time
recheck
amiodaron
administr
shown
alter
thyroid
function
human
retrospect
studi
aim
find
relationship
amiodaron
administr
thyroid
paramet
dog
studi
popul
tsh
increas
amiodaron
administr
though
sign
hypothyroid
observ
knowledg
thyroid
paramet
chang
previous
document
dog
treat
amiodaron
addit
prospect
evalu
larger
popul
need
determin
signific
find
shiraishi
anim
hospitalanim
cardiovascular
thorac
surgeri
centernihon
univers
sayama
saitama
japan
nihon
univers
fujisawa
kanagawa
japan
shiraishi
anim
hospitalanim
cardiovascular
thorac
surgeri
centertokyo
univers
agricultur
technolog
sayamashi
saitama
japan
univers
tokyoanim
cardiovascular
thorac
surgeri
center
bunkoku
tokyo
japan
anim
cardiovascular
thorac
surgeri
center
japan
small
anim
medic
center
tokorozawa
saitama
japan
tokyo
univers
agricultur
technolog
fuchu
tokyo
japan
purpos
studi
assess
effect
mitral
valv
plasti
mvp
treat
pulmonari
hypertens
ph
secondari
mitral
valv
diseas
dog
twentythre
dog
year
age
preoper
ph
underw
mvp
cardiopulmonari
bypass
includ
ph
diagnos
peak
tricuspid
valv
regurgit
tr
veloc
ms
echocardiographi
cardiac
examin
perform
oper
followup
month
month
sildenafil
administ
dog
residu
ph
sever
rightsid
heart
overload
flatten
ventricular
septum
andor
clinic
sign
exercis
intoler
cyanosi
observ
median
tr
ms
rang
ms
preoper
examin
death
due
residu
ph
month
surgeri
ph
improv
patient
month
tr
disappear
patient
tr
veloc
decreas
median
ms
rang
ms
eleven
patient
exhibit
residu
ph
median
tr
ms
rang
ms
sildenafil
administ
patient
ph
neg
prognost
factor
dog
mitral
valv
regurgit
result
suggest
mvp
effect
treatment
dog
ph
secondari
mitral
valv
diseas
studi
need
clarifi
longterm
prognosi
treatment
patient
exhibit
residu
ph
surgeri
detect
equin
kidney
injuri
initi
stage
intervent
like
success
hinder
limit
marker
earli
renal
damag
hors
nag
lysosom
enzym
renal
tubular
cell
releas
urin
tubular
insult
shown
promis
earli
identif
acut
kidney
injuri
human
speci
aim
studi
valid
assay
urinari
nag
unag
hors
correl
unag
index
marker
renal
tubular
dysfunct
enzymat
assay
valid
use
coeffici
variat
cv
spike
recoveri
linear
dilut
urin
plasma
collect
nonazotem
azotem
hors
spearman
rank
correl
wilcoxon
rank
sum
test
use
compar
unag
index
plasma
creatinin
urinari
fraction
excret
sodium
fe
na
urinari
gammaglutamyltransferas
uggt
index
intraand
interrun
cv
percent
recoveri
spike
linear
dilut
satisfactori
signific
correl
unag
index
plasma
creatinin
pvalu
unag
index
fe
na
pvalu
median
unag
indic
significantli
higher
pvalu
azotem
hors
hors
increas
fe
na
hors
increas
uggt
index
urinari
nag
measur
hors
show
correl
current
biomark
renal
dysfunct
addit
work
need
determin
time
increas
unag
index
rel
onset
kidney
injuri
hors
evalu
clinic
util
equin
patient
twentyeight
case
identifi
preval
uti
equin
case
trakehn
holstein
hors
significantli
overrepres
compar
hospit
popul
p
uti
frequent
femal
p
urinari
tract
infect
associ
diagnost
involv
urinari
tract
bladder
empti
problem
case
eightyfour
bacteria
isol
cultur
escherichia
coli
enterococcu
spp
common
bacteria
repres
respect
isol
bacteria
trimethoprimsulfonamid
enrofloxacin
ceftiofur
commonli
use
antibiot
especi
begin
hospit
respect
isol
bacteria
sensibl
drug
seventi
percent
isol
bacteria
multidrug
resist
result
place
context
two
equin
patient
repres
isol
bacteria
evalu
respons
treatment
limit
studi
design
conclus
uti
uncommon
hors
identifi
breed
sex
predisposit
gram
posit
neg
bacteria
identifi
high
preval
multidrug
resist
bacteria
repres
therapeut
challeng
hors
urinari
tract
infect
hospit
set
studi
aim
appli
valid
canin
score
system
assess
incid
acut
kidney
injuri
hospit
hors
hypothes
incid
acut
kidney
injuri
hors
similar
report
speci
clinic
record
hospit
adult
hors
august
review
hors
must
hospit
day
serum
creatinin
concentr
measur
twice
hors
diagnos
primari
renal
patholog
azotaem
baselin
serum
biochemistri
exclud
veterinari
acut
kidney
injuri
score
system
appli
base
percentag
increas
serum
creatinin
concentr
baselin
stage
stage
stage
stage
hors
includ
acut
kidney
injuri
classifi
stage
stage
hors
stage
acut
kidney
injuri
incid
acut
kidney
injuri
popul
hospit
hors
similar
report
dog
human
serum
creatinin
concentr
could
monitor
hospit
hors
allow
identif
earli
treatment
acut
kidney
injuri
work
requir
establish
impact
stage
acut
kidney
injuri
long
term
equin
health
comparison
two
collect
method
cerebrospin
fluid
analysi
stand
sedat
adult
hors
practic
howev
csf
collect
space
first
second
cervic
vertebra
also
describ
purpos
studi
compar
collect
time
csf
cytolog
result
equin
protozo
myeliti
epm
titer
two
collect
site
healthi
adult
hors
hors
complaint
neurolog
diseas
use
cerebrospin
fluid
collect
site
random
order
continu
data
analyz
use
mixedeffect
linear
model
count
data
use
mixedeffect
neg
binomi
regress
statist
signific
set
p
medic
record
adult
hors
foal
admit
veterinari
teach
hospit
examin
case
present
sign
diffus
brain
diseas
serolog
postmortem
diagnosi
eastern
equin
enceph
case
met
inclus
criteria
data
retriev
includ
season
admiss
signal
physic
examin
neurolog
evalu
clinicopatholog
find
present
well
durat
hospit
treatment
case
outcom
avail
histor
inform
ie
vaccin
statu
treatment
prior
referr
also
includ
median
age
present
year
rang
year
thoroughbr
quarter
hors
breed
common
case
typic
admit
summer
less
frequent
spring
fall
winter
prognosi
associ
equin
lymphoma
often
grave
treatment
often
noncur
studi
evalu
longterm
outcom
follow
chemotherapi
hors
treat
lymphoma
purpos
studi
report
longterm
outcom
hors
lymphoma
treat
chemotherapeut
protocol
eleven
hors
includ
follow
medic
record
search
case
recruit
via
acvim
laim
oncolog
diplom
listserv
eight
hors
multicentr
lymphoma
three
hors
cutan
lymphoma
tcell
rich
larg
bcell
lymphoma
common
immunohistochem
classif
n
three
hors
posit
biopsi
sampl
neoplast
tissu
chemotherapeut
agent
includ
cyclophosphamid
n
vincristin
n
lomustin
n
lasparaginas
n
doxorubicin
n
cytosin
arabinosid
n
chlorambucil
n
intralesion
cisplatin
n
adjunct
treatment
includ
corticosteroid
n
valacyclovir
n
complet
remiss
achiev
hors
partial
respons
achiev
hors
stabl
diseas
achiev
hors
hors
die
treatment
overal
respons
rate
hors
associ
lymphoma
achiev
complet
remiss
two
pregnant
mare
treat
one
mare
surviv
foal
overal
median
surviv
time
month
rang
month
median
surviv
time
multicentr
lymphoma
n
month
rang
month
median
surviv
time
cutan
lymphoma
n
month
rang
month
seven
hors
exhibit
total
advers
effect
directli
attribut
chemotherapi
advers
effect
grade
accord
vcogctca
grade
system
grade
alopecia
n
grade
combin
neutropenia
lymphopenia
n
grade
lymphopenia
n
grade
lethargi
n
grade
gastrointestin
sign
n
grade
inject
site
reaction
n
grade
hypersensit
n
grade
hypersensit
n
grade
hypersensit
n
higher
grade
advers
effect
commonli
associ
doxorubicin
administr
n
includ
one
hors
die
hour
postadministr
report
limit
retrospect
natur
particularli
variat
treatment
howev
find
show
chemotherapi
use
success
treatment
equin
lymphoma
advers
effect
commonli
mild
occur
approxim
twothird
treat
case
medic
surgic
treatment
primari
hyperparathyroid
equid
parathyroid
hormon
pth
normal
pth
high
calcium
neg
pthrelat
protein
histopatholog
identif
parathyroid
adenoma
sixteen
hors
one
mule
fulfil
inclus
criteria
common
present
complaint
includ
weight
loss
hypercalcemia
anorexia
colic
median
ioniz
calcium
present
mmoll
rang
mmoll
refer
rang
mmoll
median
pth
concentr
pmoll
rang
pmoll
refer
rang
pmoll
suspect
abnorm
parathyroid
tissu
local
equid
ultrasonographi
andor
technetium
sestamibi
scintigraphi
five
five
success
excis
tumor
locat
thorac
inlet
surgeri
result
complet
cure
one
perithyroid
tumor
excis
howev
hors
remain
hypercalcem
follow
surgeri
four
addit
case
treat
surgic
five
treat
medic
two
treat
also
remain
hypercalcem
parathyroid
adenoma
equid
success
local
ultrasonographi
andor
scintigraphi
surgic
excis
appear
like
success
singl
abnorm
gland
identifi
thorac
inlet
clientown
hors
recruit
hors
abnorm
physic
examin
complet
blood
cell
count
incomplet
data
sign
pituitari
par
intermedia
dysfunct
exclud
test
cgit
perform
overnight
grain
fast
serum
sampl
store
c
biomark
test
via
previous
valid
elisa
colorimetr
assay
age
bodi
condit
score
bc
cresti
neck
score
cn
baselin
glucos
baselin
insulin
triglycerid
also
record
characterist
hors
categor
insulin
dysregul
compar
hors
met
inclus
criteria
hors
determin
insulin
dysregul
age
bc
baselin
glucos
triglycerid
mg
dlactat
llactat
differ
significantli
two
group
hors
univari
analysi
baselin
insulin
significantli
associ
insulin
dysregul
p
multivari
logist
regress
note
hors
cn
time
higher
odd
insulin
dysregul
ci
p
studi
inflammatori
marker
mg
dlactat
good
predictor
insulin
dysregul
eia
evalu
hors
howev
inform
lack
healthi
sick
newborn
foal
studi
sought
evalu
total
activ
gip
insulin
respons
fast
dextros
oral
intraven
administr
healthi
newborn
foal
oral
intraven
glucos
toler
test
perform
healthi
standardbr
foal
hour
old
follow
hour
fast
bolu
dextros
mgkg
administ
oral
intraven
blood
incretin
insulin
concentr
measur
foal
allow
nurs
incretin
concentr
increas
baselin
within
minut
nurs
minim
incretin
respons
oral
dextros
rapid
incretin
releas
nurs
indic
mgkg
insuffici
strong
eia
stimul
higher
dextros
dose
requir
factor
milk
may
import
activ
eia
newborn
foal
aim
studi
determin
hyperinsulinaemia
could
reduc
lamin
prevent
insulindysregul
poni
use
sodiumglucos
cotransport
inhibitor
velagliflozin
fortynin
poni
vari
degre
insulin
dysregul
base
oral
glucos
test
g
dextrosekg
bw
receiv
either
velagliflozin
mgkg
po
sid
n
placebo
n
throughout
studi
mainten
diet
lucern
hay
fed
week
follow
highnsc
challeng
diet
g
nsckg
bwday
day
second
day
diet
challeng
blood
glucos
serum
insulin
measur
h
feed
result
express
geometr
mean
ci
maximum
concentr
glucos
lower
p
velagliflozin
group
mm
versu
mm
oral
glucos
test
ogt
current
recommend
diagnosi
insulin
dysregul
id
hors
suffer
id
prone
lamin
especi
expos
high
amount
sugar
would
desir
reduc
amount
diagnost
glucos
furthermor
reduc
glucos
amount
enabl
variou
rout
applic
aim
studi
determin
whether
dosag
glucos
per
kg
bodyweight
bw
instead
bw
would
use
clinic
set
suffici
distinguish
insulin
sensit
insulin
dysregul
hors
eighteen
iceland
hors
differ
sex
age
bodyweight
uncertain
metabol
statu
test
applic
bw
logt
bw
mogt
bw
ogt
glucos
dissolv
water
administ
via
nasogastrictub
blood
sampl
collect
five
hour
analyz
insulin
glucos
blood
glucos
concentr
significantli
lower
logt
compar
ogt
p
minut
significantli
lower
mogt
compar
ogt
minut
p
applic
insulin
concentr
minut
significantli
lower
logt
compar
mogt
p
ogt
p
statist
differ
insulin
concentr
detect
mogt
ogt
minut
p
moreov
insulin
dynam
mogt
ogt
allow
satisfi
differenti
insulin
sensit
insulin
dysregul
hors
sum
reduct
glucos
bw
ogt
recommend
without
loss
diagnost
valu
experi
hors
allow
access
hay
pastur
prior
ost
experi
hors
fast
overnight
prior
ost
studi
corn
syrup
formul
order
random
oral
sugar
test
perform
one
week
apart
blood
drawn
measur
blood
glucos
insulin
concentr
prior
administr
corn
syrup
minut
administr
corn
syrup
blood
glucos
measur
use
handheld
glucomet
serum
insulin
measur
use
radioimmunoassay
data
analyz
normal
insulin
concentr
log
transform
normal
chang
glucos
insulin
concentr
time
point
area
curv
auc
maximum
concentr
c
max
time
c
max
max
compar
formul
use
two
way
analysi
varianc
repeat
measur
bland
altman
analysi
use
determin
agreement
insulin
concentr
formul
signific
differ
karo
crown
syrup
formul
individu
time
point
insulin
glucos
concentr
either
experi
p
signific
differ
area
curv
max
c
max
insulin
glucos
concentr
karo
compar
crown
syrup
p
blandaltman
analysi
insulin
concentr
indic
mean
bia
karocrown
limit
agreement
experi
mean
bia
limit
agreement
experi
insulin
concentr
minut
studi
suggest
hors
similar
glucos
insulin
respons
two
formul
corn
syrup
remona
horn
bertin
univers
queensland
gatton
queensland
australia
equin
metabol
syndrom
em
pituitari
par
intermedia
dysfunct
ppid
common
hormon
disord
hors
coexist
patient
aim
studi
combin
two
diagnost
tool
diagnos
ppid
em
within
minut
hypothesis
measur
valu
insulin
respons
test
thyrotropinreleas
hormon
trh
stimul
test
perform
combin
would
differ
valu
obtain
test
perform
independ
twentyon
hors
test
em
ppid
use
insulin
respons
test
trh
stimul
test
respect
classifi
em
ppid
em
ppid
control
combin
test
insulin
trh
inject
simultan
result
compar
among
protocol
pair
test
wilcoxon
sign
rank
test
blandaltman
analysi
base
independ
test
hors
consid
control
em
ppid
em
ppid
independ
combin
test
condit
significantli
affect
acth
concentr
trh
inject
chang
percentag
reduct
blood
glucos
insulin
inject
compar
within
group
overal
p
one
control
hors
combin
test
result
larger
increas
acth
trh
inject
consist
diagnosi
ppid
combin
trh
stimul
test
insulin
sensit
test
appear
attract
rapid
tool
diagnos
em
ppid
time
hors
curv
auc
peak
concentr
insulin
glucos
assess
use
oneway
anova
signific
p
repeat
assess
use
blandaltman
plot
signific
differ
note
klc
fc
either
auc
peak
concentr
howev
insulin
result
compar
id
posit
insulin
cut
test
fructos
correctli
identifi
hors
id
time
ost
without
fructos
identifi
id
test
base
fructos
substanti
impact
glucos
metabol
hors
may
interfer
insulin
respons
ost
vitamin
e
essenti
neuromuscular
function
oral
supplement
natur
rrr
mainstay
therapi
hors
hypovitaminosi
e
howev
subset
nonrespons
hors
object
pilot
trial
evalu
safeti
efficaci
inject
prepar
deliv
subcutan
hypothes
inject
would
increas
serum
cerebrospin
fluid
csf
concentr
healthi
adult
hors
six
mix
breed
hors
mare
geld
two
untreat
hors
mare
geld
enrol
phase
hors
randomli
assign
receiv
iuml
subcutan
oral
administr
moder
tissu
reaction
follow
inject
necessit
adjust
prepar
reduct
concentr
iuml
follow
washout
period
hors
receiv
reciproc
treatment
phase
ii
new
prepar
equival
dose
alphatocopherol
concentr
serum
csf
collect
period
determin
hplc
differ
baselin
serum
csf
concentr
residu
effect
note
indic
appropri
washout
serum
p
csf
concentr
increas
significantli
postinject
iuml
product
administ
serum
concentr
peak
postinject
inject
formul
may
therefor
use
case
refractori
oral
supplement
howev
caution
warrant
due
mark
local
tissu
reaction
observ
hors
hypophosphatemia
hypokalemia
hypomagnesemia
associ
variou
diseas
equid
despit
interact
analyt
energi
metabol
evalu
concentr
critic
ill
equid
lipid
disord
frequent
perform
therefor
incid
abnorm
patient
remain
unclear
medic
record
hospit
small
equid
poni
multipl
breed
american
miniatur
hors
donkey
greater
year
age
serum
triglycerid
concentr
greater
mgdl
admit
review
relationship
biochem
analyt
assess
chisquar
analysi
patient
surviv
discharg
euthan
die
patient
stratifi
quartil
base
triglycerid
concentr
st
quartil
mgdl
nd
quartil
mgdl
rd
quartil
mgdl
th
quartil
mgdl
equid
triglycerid
st
nd
quartil
like
surviv
triglycerid
concentr
rd
th
quartil
p
hypophosphatemia
p
mgdl
hypokalemia
k
meql
hypomagnesemia
total
mg
mgdl
observ
case
respect
potassium
concentr
significantli
correl
triglycerid
concentr
p
equid
triglycerid
concentr
rd
th
quartil
like
hypokalem
p
hypophosphatemia
associ
surviv
equid
hypertriglyceridemia
hypophosphatemia
surviv
evalu
phosphoru
potassium
magnesium
recommend
equid
dyslipidemia
hors
endur
race
influenc
perform
studi
inform
lack
thoroughbr
racehors
object
assess
effect
supramaxim
exercis
lipidom
racehors
four
thoroughbr
geld
similar
bodi
condit
age
use
hors
hous
barn
fed
diet
hors
underw
treadmil
exercis
fatigu
vo
max
slope
venou
plasma
sampl
obtain
immedi
postexercis
evalu
use
untarget
lipidom
approach
west
coast
metabolom
center
data
analyz
use
princip
compon
analysi
rm
anova
signific
set
p
plasma
lipid
detect
known
spectra
retent
index
link
librari
entri
exercis
plasma
level
eight
lipid
chang
significantli
like
reflect
occurr
lipolysi
briefli
increas
unsatur
fatti
acid
acid
decreas
satur
fatti
acid
icosano
heptadecano
lauric
myrist
acid
phospholipid
sphingomyelin
observ
pilot
studi
provid
valuabl
inform
regard
chang
lipidom
thoroughbr
associ
supramaxim
exercis
serv
refer
guid
futur
studi
racehors
metabolom
analys
recent
describ
feasibl
method
quantifi
la
function
healthi
hors
aim
provid
proof
concept
use
detect
compromis
la
booster
pump
function
hors
warmblood
hors
atrial
fibril
success
tvec
continu
normal
sinu
rhythm
least
one
month
thereaft
includ
studi
echocardiographi
perform
tvec
maximum
la
area
laa
max
la
diamet
lad
max
well
activ
passiv
la
fraction
area
chang
fac
measur
use
rightparastern
view
focus
left
atrium
la
dimens
measur
endsystol
allometr
scale
bodi
weight
kg
global
longitudin
peak
strain
l
strain
rate
sr
l
activ
booster
pump
function
measur
record
use
analys
measur
judg
relat
previous
establish
refer
interv
friedman
oneway
anova
dunn
multipl
comparison
test
perform
detect
differ
timepoint
linear
regress
analysi
perform
describ
associ
l
sr
l
convent
measur
la
size
function
consid
repeat
measur
within
hors
p
consid
signific
thirteen
warmblood
hors
fulfil
inclus
criteria
measur
indic
timepoint
feasibl
hors
wherea
sever
la
enlarg
prevent
measur
hors
la
contractil
dysfunct
tvec
detect
hors
base
activ
la
fac
global
l
activ
la
fac
chang
time
p
remain
refer
limit
hors
global
l
significantli
increas
tvec
p
time
l
hors
within
lower
rang
refer
interv
sr
l
refer
interv
hors
tvec
within
refer
limit
hors
tvec
p
strain
strain
rate
significantli
associ
activ
fac
adj
adj
passiv
fac
r
adj
r
adj
laa
max
adj
adj
lad
max
adj
adj
lower
l
sr
l
larger
atria
studi
show
use
detect
compromis
la
contractil
function
hors
convers
af
nsr
use
tvec
strain
strain
rate
neg
relat
la
enlarg
clinic
valu
predict
risk
recurr
atrial
fibril
establish
futur
studi
monensin
highli
toxic
hors
inadvert
ingest
result
cardiac
dysfunct
death
object
prospect
studi
determin
cardiovascular
athlet
outcom
hors
expos
monensin
physic
examin
exercis
stress
test
ecg
preand
exercis
echocardiographi
preand
postexercis
perform
hors
expos
monensincontamin
feed
four
hors
examin
within
week
exposur
acut
period
twentynin
hors
examin
day
postexposur
subacut
period
hors
examin
month
rest
chronic
period
followup
inform
obtain
telephon
interview
approxim
month
exposur
hors
three
hors
present
acut
period
die
euthan
hors
clinic
sign
cardiac
anomali
rest
nineteen
hors
examin
subacut
period
cardiac
anomali
upon
physic
examin
cardiac
examin
rest
exercis
four
month
exposur
hors
cardiac
abnorm
upon
physic
examin
cardiac
examin
rest
exercis
sixteen
month
exposur
hors
known
outcom
return
intend
use
includ
hors
cardiac
anomali
previou
month
clinic
outcom
hors
expos
subleth
dose
monensin
highli
variabl
commonli
result
longterm
cardiac
dysfunct
lead
exercis
intoler
even
death
comparison
noninvas
invas
central
invas
peripher
blood
pressur
stand
hors
coccyg
measur
use
commerci
oscillometr
devic
mindray
passport
correct
vertic
distanc
base
tail
heart
base
measur
obtain
baselin
high
dobutamin
low
acepromazin
blood
pressur
mean
bia
sd
bia
pearson
product
correl
r
calcul
data
obtain
hors
mean
biassd
biasr
ibpc
ibp
mmhg
systol
mmhg
mmhg
mean
mmhg
mmhg
diastol
pressur
mean
biassd
biasr
ibpc
nibp
mmhg
mmhg
systol
mmhg
mmhg
mean
mmhg
mmhg
diastol
pressur
mean
biassd
biasr
ibp
nibp
mmhg
mmhg
systol
mmhg
mmhg
mean
mmhg
mmhg
diastol
pressur
measur
ibpc
without
surgic
approach
feasibl
ibp
accept
surrog
ibpc
interchang
circumst
nibp
devic
test
accept
accuraci
precis
systol
pressur
follow
acvim
suggest
criteria
approxim
criteria
mean
blood
pressur
diastol
pressur
measur
less
accur
precis
continu
glycolysi
erythrocyt
blood
collect
may
caus
artifactu
vitro
increas
methylglyox
consequ
metabolit
dlactat
sodium
fluorid
naf
inhibit
enolas
glycolysi
pathway
hypothes
equin
blood
collect
naf
tube
would
result
valid
lower
dlactat
valu
compar
serum
tube
dlactat
concentr
would
stabl
month
c
blood
collect
serum
naf
tube
hors
kept
ice
centrifug
separ
serum
plasma
sampl
frozen
c
analysi
month
previous
valid
commerci
assay
dlactat
colorimetr
assay
kit
biovis
inc
milpita
ca
usa
dlactat
valu
measur
blood
collect
serum
tube
mean
sd
concentr
month
respect
naf
tube
mean
dlactat
concentr
month
respect
dlactat
significantli
differ
p
serum
naf
sampl
compar
month
month
within
naf
tube
type
p
use
naf
tube
recommend
equin
blood
collect
determin
dlactat
concentr
use
serum
tube
result
inflat
inaccur
valu
furthermor
longerterm
storag
month
c
appear
result
sampl
degrad
interpret
caution
adult
hors
poni
fulfil
least
two
criteria
adapt
sirsscor
includ
standard
human
protocol
measur
activ
platelet
plateletleukocyteaggreg
pla
fluoresc
flow
cytometri
plateletleukocyterichplasma
plrp
establish
hors
activ
platelet
determin
increas
present
platelet
activ
pla
measur
vitro
activ
platelet
collagen
ten
healthi
adult
hors
poni
serv
control
statist
analysi
includ
proof
normal
distribut
follow
twoway
anova
posthoc
bonferroni
test
includ
hors
poni
sir
significantli
activ
platelet
pla
nativ
plrp
control
sir
control
p
respect
p
pla
respect
p
six
hors
surviv
trend
activ
pla
nonsurviv
hors
furthermor
trend
reduc
vitro
activ
collagen
detect
nonsurvivor
first
studi
demonstr
increas
platelet
activ
plateletleukocyteaggreg
fluoresc
flow
cytometri
clinic
case
equin
sir
likewis
platelet
activ
could
prognost
factor
patient
antiplatelet
therapi
eg
clopidogrel
could
addit
therapeut
option
clinic
case
sir
inflammatori
diseas
prevent
complic
improv
outcom
crosssect
studi
serum
sampl
thoroughbr
foal
age
analys
antieqhv
nonstructur
ns
antibodi
ab
luciferas
immunoprecipit
system
lip
eqhv
rna
quantit
realtim
polymeras
chain
reaction
qrtpcr
farm
origin
situat
western
cape
provinc
south
africa
descript
analysi
perform
studi
associ
eqhv
infect
statu
age
gender
identifi
eqhv
isol
sequenc
subsequ
phylogenet
analysi
genom
portion
locat
ab
detect
sampl
highest
seropreval
report
yet
equin
popul
rna
preval
within
previous
report
rang
increas
foalag
associ
decreas
preval
ab
increas
preval
eqhv
viraemia
south
african
eqhv
strain
cluster
separ
publish
sequenc
eqhv
strain
conclus
eqhv
circul
south
african
thoroughbr
popul
appear
preval
hors
popul
worldwid
valid
inclin
enzymelink
immunosorb
assay
diagnosi
leptospirosi
hors
serum
natur
infect
hors
randomli
select
sampl
submit
anim
health
diagnost
center
cornel
univers
identifi
posit
mat
serovar
n
random
select
mat
neg
sampl
also
includ
test
n
sampl
n
test
idexx
snap
lepto
perform
test
kit
compar
mat
accuraci
measur
term
rel
sensit
specif
cutoff
point
posit
mat
relationship
mat
titer
probabl
posit
idexx
snap
lepto
assess
use
logist
regress
analysi
result
indic
test
kit
high
specif
sensit
poor
titer
moder
titer
excel
titer
idexx
snap
lepto
provid
rapid
inclin
test
evid
antibodi
respons
leptospira
speci
hors
excel
specif
high
sensit
increas
titer
leptospirosi
associ
abort
acut
renal
diseas
often
result
mat
titer
test
kit
may
allow
prompt
stallsid
field
determin
leptospirosi
statu
case
bacteri
viral
microbiota
often
inhabit
share
microenviron
howev
interest
potenti
contribut
promot
health
diseas
recent
gain
attent
object
studi
character
nasal
bacteri
microbiota
healthi
hors
control
hors
shed
equin
herp
use
next
gener
sequenc
technolog
nasal
bacteri
microbiota
control
hors
singl
farm
experienc
outbreak
character
use
illumina
miseq
platform
target
region
rrna
gene
hors
fever
limb
edema
posit
pcr
nasal
swab
within
one
week
first
case
confirm
posit
control
hors
anim
farm
show
clinic
sign
outbreak
neg
pcr
nasal
bacteri
microbiota
healthi
significantli
differ
commun
membership
jaccard
index
structur
dorsal
displac
soft
palat
ddsp
well
describ
race
hors
even
though
link
ddsp
lower
airway
inflamm
suggest
race
hors
treatment
choic
remain
surgic
ddsp
also
describ
sport
hors
although
effort
made
correl
lower
airway
inflamm
retrospect
studi
perform
period
year
phone
contact
hors
treatment
success
case
hors
stop
cough
make
nois
perform
expect
treatment
failur
occur
chronic
case
case
ddsp
occur
tie
back
surgeri
studi
show
sport
hors
popul
ddsp
associ
lower
airway
inflamm
larg
proport
case
manag
medic
signific
increas
pge
level
ischemicinjur
tissu
treat
ttucb
compar
untreat
ischemicinjur
tissu
p
untreat
ttucbtreat
ischemicinjur
tissu
significantli
reduc
ter
compar
nonischem
tissu
p
p
howev
statist
differ
ischemicinjur
tissu
treat
without
ttucb
conclud
ttucb
novel
modul
pg
level
result
increas
pge
tissu
injur
ischemia
without
significantli
impair
recoveri
barrier
function
therefor
ttucb
may
futur
use
treat
anim
diseas
strangul
obstruct
pharmacokinet
day
discharg
day
sampl
semiquantit
cultur
esblagar
differ
group
analys
use
chisquar
test
odd
ratio
twoway
repeat
measur
anova
preval
day
differ
group
p
hors
treat
cef
pg
like
shed
esblproduc
enterobacteriacea
compar
noamd
day
p
p
respect
day
p
p
respect
esbl
count
increas
day
day
group
cef
p
pg
p
noamd
p
esbl
bacteri
count
significantli
higher
pg
group
compar
cef
noamd
group
p
p
respect
also
significantli
higher
cef
group
compar
noamd
group
p
esblproduc
enterobacteriacea
administr
cefquinom
induc
higher
shed
rate
compar
administr
penicillingentamicin
standard
antibiosi
highlight
need
reduc
antimicrobi
use
overal
jennif
r
bauquier
simon
r
bailey
univers
melbourn
werribe
victoria
australia
mitochondri
product
especi
mitochondri
dna
proinflammatori
human
studi
presum
due
bacteri
evolutionari
origin
therefor
releas
tissu
necrosi
may
import
contributor
inflammatori
respons
hors
aim
studi
determin
inflammatori
respons
mitochondri
product
vitro
equin
whole
blood
assay
mitochondria
isol
liver
tissu
system
healthi
hors
cell
lysi
centrifug
mitochondria
fragment
freezethaw
serial
dilut
pb
ad
aliquot
whole
blood
healthi
hors
mix
rpmi
medium
one
aliquot
serv
neg
control
aliquot
incub
rotat
c
hour
inflammatori
respons
determin
measur
supernat
use
murin
fibroblast
bioassay
mitochondri
fragment
caus
inflammatori
effect
equin
whole
blood
produc
concentrationdepend
increas
releas
plasmasupernat
fit
sigmoid
concentrationrespons
curv
increas
product
lowest
dilut
mitochondri
fragment
pgml
dilut
compar
pgml
whole
blood
incub
fragment
releas
mitochondri
fragment
local
tissu
damag
inflamm
necrosi
might
contribut
clinic
sever
sir
possibl
offer
mechan
develop
sir
hors
absenc
obviou
gastrointestin
diseas
infect
work
warrant
investig
signific
inflamm
caus
mitochondri
fragment
hors
includ
novel
antiinflammatori
therapi
electrocardiogram
indispens
tool
diagnosi
arrhythmia
electr
conduct
disord
equin
heart
howev
sever
electrocardiograph
variabl
may
influenc
factor
speci
age
gender
breed
morphofunct
constitut
highlight
import
know
normal
characterist
distinct
speci
breed
develop
stage
studi
aim
assess
electrocardiograph
develop
frontal
plane
apicaltobas
deriv
last
day
pregnanc
day
birth
donkey
pega
breed
therefor
electrocardiogram
conduct
computerinterpret
electrocardiographi
devic
frontal
plane
apicaltobas
deriv
minut
without
sed
tranquil
anesthet
result
shown
tabl
observ
physiolog
patholog
cardiac
arrhythmia
electr
conduct
disord
anim
assess
heartrat
observ
frontal
plane
apicaltobas
deriv
present
minim
chang
studi
moment
pregnanc
predomin
cardiac
rhythm
observ
femal
sinu
tachycardia
heartrat
increas
birth
got
closer
bpm
th
day
birth
bpm
birth
bifid
biphas
p
wave
predomin
moment
observ
signific
differ
durat
pr
interv
ms
frontal
plane
apicaltobas
deriv
qt
interv
ms
deriv
well
signific
increas
r
wave
amplitud
electrocardiograph
paramet
pregnant
donkey
diverg
term
durat
amplitud
morpholog
contrast
donkey
equin
breed
find
highlight
import
obtain
specif
valu
distinct
speci
breed
pregnanc
stage
safer
prenat
care
achiev
key
gene
involv
transport
calcium
ca
across
sarcoplasm
reticulum
sr
encod
protein
ryanodin
receptor
ryr
releas
ca
sr
sr
calcium
atpas
serca
pump
ca
back
sr
newli
discov
regulatori
micropeptid
mrln
pln
sln
inhibit
serca
therebi
control
intracellular
ca
contractil
transcript
express
protein
abund
micropeptid
hors
unknown
purpos
studi
determin
rel
express
equin
ca
regulatori
gene
left
ventricl
right
atrium
gluteal
muscl
rna
extract
tissu
collect
hors
revers
transcrib
cdna
transcript
abund
quantifi
use
qrtpcr
data
normal
gapdh
within
sampl
data
compar
use
anova
gluteal
use
baselin
result
correct
multipl
test
follow
singl
dose
mean
maximum
concentr
c
max
ugml
hour
max
apap
remain
presum
therapeut
concentr
ugml
two
hour
postadministr
undetect
hour
elimin
halflif
signific
accumul
note
follow
multipl
dose
averag
c
max
apap
follow
repeat
oral
dose
ugml
max
hour
hour
sdh
significantli
decreas
pre
ul
post
ul
p
total
bilirubin
significantli
increas
pre
mgdl
post
mgdl
p
follow
last
dose
statist
signific
chang
note
gastroscopi
score
pre
mean
post
mean
p
dose
simul
suggest
higher
dose
andor
shorter
dose
interv
may
indic
studi
demonstr
safeti
acetaminophen
repeat
oral
dose
day
studi
also
confirm
mgkg
dose
use
previou
clinic
report
reach
propos
therapeut
concentr
oral
administr
fed
hors
howev
shorter
hour
dosag
interv
may
requir
improv
efficaci
heart
rate
detect
studi
identifi
dexmedetomidin
rapidli
incomplet
absorb
subcutan
administr
higher
plasma
concentr
intraven
administr
associ
increas
blood
pressur
compar
subcutan
administr
result
suggest
need
dosag
adjust
base
rout
administr
dexmedetomidin
lucia
mentink
simon
r
bailey
jennif
r
bauquier
univers
melbourn
wollongong
new
south
wale
australia
univers
melbourn
werribe
victoria
australia
plasma
phosphat
concentr
p
plasma
calcium
concentr
ca
chang
human
sepsi
experimentallyinduc
system
inflammatori
respons
syndrom
hors
easili
measur
paramet
might
use
biomark
equin
colic
studi
aim
determin
use
p
ca
prognost
diagnost
biomark
hors
colic
record
hors
present
colic
includ
coliti
review
control
healthi
teach
hors
p
ca
ca
p
compar
hors
colic
control
addit
comparison
made
hors
strangul
nonstrangul
inflammatori
colic
lesion
survivor
nonsurvivor
correl
haematocrit
white
cell
count
wcc
fibrinogen
examin
record
colic
case
control
includ
colic
case
significantli
higher
p
increas
significantli
lower
ca
decreas
ca
p
decreas
control
differ
p
ca
ca
p
colic
lesion
group
ca
significantli
lower
strangul
inflammatori
lesion
compar
control
p
ca
p
significantli
lower
inflammatori
lesion
compar
control
p
weak
signific
correl
found
p
haematocrit
wcc
fibrinogen
ca
paramet
ca
p
significantli
correl
fibrinogen
haematocrit
wcc
ca
p
significantli
correl
associ
p
ca
ca
p
surviv
neither
p
ca
ca
p
use
alon
biomark
contribut
overal
clinic
pictur
nine
halterbr
american
quarter
hors
foal
age
rang
day
month
singl
farm
central
ohio
present
osu
cvm
evalu
diarrhea
lethargi
inappet
one
foal
die
within
hour
admiss
two
foal
euthan
within
hour
admiss
poor
respons
resuscit
one
suspect
gastrointestin
ruptur
anoth
rotaviru
pcr
perform
fece
posit
foal
one
foal
posit
clostridium
difficil
fecal
cultur
rest
neg
clostridium
perfringensdifficil
salmonella
coronaviru
four
foal
discharg
hospit
repres
within
week
persist
inappet
lethargi
failur
thrive
subsequ
diagnos
pylor
outflow
obstruct
base
gastroscopi
persist
nasogastr
reflux
barium
gastrographi
one
foal
repres
caudal
esophag
strictur
euthan
poor
respons
treatment
three
foal
euthan
due
pylor
outflow
obstruct
discharg
necropsi
perform
foal
reveal
sever
gastric
distent
pyloricduoden
stenosi
gastroduoden
ulcer
egu
suspect
associ
rotaviru
incid
multipl
case
pylor
outflow
obstruct
associ
rotavir
enter
document
well
hors
human
neonat
egu
foal
common
preval
rang
frequent
clinic
inappar
rare
lesion
may
produc
strictur
gastric
outflow
obstruct
report
describ
gastric
outflow
obstruct
diagnos
multipl
foal
associ
outbreak
rotaviru
stephani
vijan
katarzyna
dembek
steven
reed
nathan
slovi
ramiro
toribio
septicemia
lead
caus
mortal
newborn
foal
progesteron
mainli
known
role
pregnanc
howev
also
precursor
adrenocort
neuroact
steroid
like
play
import
function
equin
neonat
human
studi
demonstr
progesteron
modul
immun
predispos
inflammatori
condit
howev
mechan
progesteron
influenc
outcom
sick
foal
remain
unclear
goal
studi
measur
blood
concentr
inflammatori
cytokin
serum
amyloid
saa
healthi
hospit
foal
determin
associ
progesteron
sever
diseas
mortal
hypothes
hospit
foal
higher
progesteron
hydroxyprogesteron
cortisol
concentr
associ
inflammatori
respons
diseas
sever
mortal
foal
n
divid
three
group
base
sever
diseas
septic
n
sick
nonsept
sn
n
healthi
n
hospit
foal
sn
septic
divid
two
group
base
surviv
survivor
nonsurvivor
blood
sampl
collect
admiss
hormon
measur
radioimmunoassay
cytokin
elisa
progesteron
hydroxyprogesteron
cortisol
interleukin
concentr
significantli
higher
septic
sn
compar
healthi
foal
p
leukocyt
neutrophil
count
well
igg
concentr
lower
saa
concentr
significantli
higher
hospit
compar
healthi
foal
p
interleukin
concentr
significantli
higher
nonsurvivor
survivor
igg
interleukin
concentr
posit
correl
progesteron
significantli
lower
nonsurvivor
neg
correl
saa
p
result
suggest
progesteron
addit
cortisol
may
involv
adrenocort
respons
stress
critic
ill
could
influenc
inflammatori
respons
sick
foal
first
studi
associ
progestogen
marker
inflamm
hospit
foal
anim
model
sepsi
fda
approv
use
hors
us
object
pilot
studi
evalu
singl
dose
novel
antitnf
antibodi
neonat
foal
sepsi
studi
singledos
multicent
clinic
trial
foal
age
hour
sepsi
defin
sepsi
score
sick
nonsept
defin
rectal
temperatur
f
blood
glucos
mgdl
enrol
foal
administ
antitnf
antibodi
acth
level
measur
day
baselin
time
variabl
storag
method
plasma
sampl
store
either
c
c
sampl
place
ice
pack
store
c
plasma
sampl
store
c
day
store
c
day
store
ice
pack
c
day
prior
determin
rest
acth
concentr
plasma
sampl
ship
anim
health
diagnost
center
cornel
univers
ithaca
ny
measur
rest
acth
concentr
within
storag
method
acth
level
time
compar
baselin
nonfrozen
day
plasma
use
pair
ttest
ie
hors
serv
control
p
consid
statist
signific
data
summar
mean
standard
error
se
percent
chang
baselin
cfb
mean
acth
level
day
plasma
store
c
pgml
declin
pgml
day
day
cfb
never
vari
day
cfb
although
reach
statist
signific
p
trend
toward
signific
degrad
observ
mean
acth
level
day
plasma
store
c
pgml
declin
pgml
day
cfb
statist
signific
p
day
although
decreas
trend
observ
mean
acth
level
day
plasma
store
ice
pack
c
pgml
declin
pgml
day
signific
degrad
p
acth
observ
day
none
storag
method
result
sampl
degrad
differ
significantli
baselin
trend
toward
degrad
observ
day
c
store
sampl
day
c
store
sampl
signific
degrad
observ
acth
plasma
sampl
store
ice
pack
c
day
freez
plasma
short
period
time
c
c
least
day
result
statist
signific
degrad
plasma
acth
compar
nonfrozen
plasma
baselin
sampl
studi
conduct
evalu
effect
freez
plasma
acth
concentr
larger
popul
hors
aim
studi
evalu
effect
weight
gain
achiev
provid
healthi
hors
lowcarbohydr
fat
rich
diet
follow
pastur
insulin
sensit
blood
pressur
serum
cortisol
concentr
weight
gain
induc
standardbr
mare
fed
fat
supplement
forag
diet
time
daili
requir
week
hors
turn
pastur
week
insulin
sensit
measur
weight
gain
week
pastur
use
euglycem
hyperinsulinem
clamp
method
bodi
weight
bodi
condit
bc
blood
pressur
serum
cortisol
monitor
throughout
studi
hors
becam
obes
weight
gain
period
bc
mean
arteri
blood
pressur
increas
gradual
weight
gain
period
significantli
higher
initi
valu
end
weight
gain
period
mmhg
vs
mmhg
mean
arteri
blood
pressur
remain
higher
level
pastur
mmhg
insulin
sensit
chang
weight
gain
conclus
obes
associ
increas
blood
pressur
associ
chang
insulin
sensit
purpos
studi
compar
cortic
bone
thick
densiti
third
metacarp
bone
hors
ppid
ppid
par
intermedia
pi
histolog
score
n
age
hors
without
ppid
ppid
pi
histolog
score
n
young
hors
young
year
n
follow
euthanasia
right
third
metacarp
bone
remov
ct
scan
perform
imag
use
measur
thick
mm
densiti
hounsfield
unit
hu
region
interest
dorsal
palmar
medial
later
cortic
midpoint
diaphysi
data
analyz
anova
anova
rank
signific
p
differ
found
palmar
cortex
thick
ppid
young
young
greater
later
cortex
thick
ppidand
ppid
young
ppidgreat
ppid
young
bone
densiti
signific
p
differ
detect
palmar
hu
ppid
young
young
greater
although
minor
differ
found
cortic
bone
thick
hu
group
consist
effect
ppid
compar
ppidand
young
difficult
separ
effect
age
ppid
statu
conclus
substanti
chang
third
metacarp
cortic
thick
densiti
found
cohort
ppid
hors
sixtyon
percent
femal
geld
stallion
fiftyeight
percent
surviv
discharg
die
euthan
degre
hyperlipemia
associ
surviv
common
primari
diagnosi
enterocol
diagnos
form
colic
medic
surgic
diagnos
includ
primari
hyperlipemia
botul
pneumonia
dystocia
guttur
pouch
empyema
lymphoma
thirtythre
percent
treat
via
voluntari
alimentari
intak
administ
intraven
dextros
ivd
administ
enter
nutrit
via
nasogastr
tube
enngt
administ
ivd
enngt
thirteen
percent
treat
partial
parenter
nutrit
often
combin
nasogastr
feed
intraven
dextros
fourteen
percent
treat
insulin
averag
durat
hospit
day
hyperlipemia
hospit
equid
common
comorbid
disord
necessarili
requir
expens
intens
treatment
prognosi
surviv
fair
associ
degre
hypertriglyceridemia
object
identifi
risk
factor
associ
withinherd
preval
blvinfect
cow
hypothes
well
previous
establish
risk
factor
manag
practic
associ
calf
rear
fli
control
would
affect
withinherd
blv
preval
risk
assess
manag
program
questionnair
rampq
develop
distribut
bovin
veterinarian
atlant
canada
dairi
farm
ship
milk
bulk
tank
milk
btm
sampl
collect
januari
april
elig
particip
rampq
btm
sampl
test
elisa
level
antiblv
antibodi
estim
withinherd
preval
rampq
result
combin
demograph
inform
collect
farm
mean
btm
elisa
result
multivari
linear
regress
perform
investig
associ
rampq
risk
factor
withinherd
preval
blv
infect
one
hundr
rampq
return
particip
provinc
atlant
canada
new
brunswick
newfoundland
nova
scotia
princ
edward
island
factor
significantli
associ
increas
level
withinherd
blv
preval
includ
histori
clinic
blv
within
herd
increas
ci
histori
purchas
blvsuspect
cattl
increas
ci
signific
differ
withinherd
preval
associ
needl
inject
pvalu
fli
control
pvalu
rectal
sleev
practic
pvalu
use
bull
natur
breed
pvalu
import
factor
associ
increas
withinherd
blv
preval
includ
histori
prior
diagnosi
clinic
blv
histori
purchas
cow
unknown
blv
statu
studi
signific
associ
previous
establish
risk
factor
increas
withinherd
preval
blv
infect
purpos
prospect
casecontrol
studi
describ
bacteri
commun
nasopharynx
np
prewean
dairi
calv
without
ultrasonograph
lung
lesion
addit
object
includ
evalu
effect
previou
antibiot
therapi
age
np
microbiota
composit
total
holstein
heifer
calv
enrol
separ
studi
investig
genom
resist
bovin
respiratori
diseas
brd
follow
period
calv
examin
twice
use
thorac
ultrasound
clinic
respiratori
score
earli
exam
week
old
late
exam
week
old
popul
case
agematch
control
select
undergo
deep
np
swab
current
studi
case
defin
presenc
signific
ultrasonograph
lung
lesion
lobe
complet
consolid
control
defin
lack
lesion
np
swab
taken
time
exam
calf
inform
collect
farm
manag
softwar
swab
place
phosphat
buffer
solut
store
c
follow
dna
extract
region
rrna
gene
amplifi
use
pcr
librari
sequenc
use
miseq
platform
divers
data
analyz
use
ttest
gener
linear
model
comparison
rel
abund
ra
genera
group
perform
use
kruskal
walli
test
multipl
linear
regress
use
investig
impact
time
point
exam
antibiot
treatment
month
prior
examin
ra
genera
total
swab
case
control
collect
two
swab
lost
transport
therefor
swab
case
control
obtain
calv
use
analysi
thirtyf
swab
collect
late
exam
overal
common
genera
acinetobact
sp
escherichia
sp
mycoplasma
sp
pasteurella
sp
psychrobact
sp
alpha
divers
differ
case
control
p
earli
late
time
point
p
ra
mycoplasma
sp
higher
control
p
ra
pasteurella
sp
tend
higher
control
p
ra
mycoplasma
sp
pasteurella
sp
affect
exam
time
point
antibiot
treatment
p
p
respect
author
knowledg
first
studi
evalu
commun
dynam
np
microbiota
calv
without
ultrasonograph
lung
lesion
expect
identifi
higher
ra
mycoplasma
sp
control
calv
previou
studi
shown
higher
ra
mycoplasma
sp
calv
brd
compar
healthi
calv
futur
studi
need
better
understand
discrep
includ
metagenom
studi
infer
speciat
determin
pathogen
identifi
mycoplasma
genu
would
also
import
know
durat
ultrasound
lesion
affect
ra
pathogen
bacteria
studi
help
demonstr
complex
identifi
np
microbiota
chang
associ
diseas
statu
may
impact
futur
attempt
util
np
microbiota
characterist
diagnosi
treatment
brd
diagnost
test
evalu
perform
fecal
sampl
collect
per
rectum
calv
less
month
age
studi
popul
stratifi
diseas
statu
healthi
scour
twogram
sampl
fix
test
via
commerci
avail
rapid
test
market
use
human
healthcar
ifa
recogn
gold
standard
test
method
isol
submit
genet
type
toxic
chang
hypoglycemia
rang
mmol
l
hyperkaliemia
rang
mmoll
acidemia
rang
neutropenia
rang
l
base
univari
statist
analysi
fatal
outcom
significantli
p
relat
dehydr
recumb
hypothermia
metabol
acidosi
hypoproteinemia
leucopenia
neutropenia
fatal
rate
necropsi
perform
calv
confirm
clinic
diagnosi
abomas
guard
prognosi
calv
clinic
clinicopatholog
find
shown
associ
fatal
outcom
diego
gomeznieto
laura
avellanedafranco
alejandro
rey
lui
arroyo
j
scott
wees
univers
florida
gainesvil
fl
usa
depart
biolog
scienc
universidad
de
lo
and
colombia
bogota
cundinamarca
colombia
ontario
veterinari
colleg
guelph
canada
dept
pathobiolog
ontario
veterinari
colleg
univers
guelph
guelph
canada
concept
exist
gut
virom
recent
although
presenc
virus
pathogen
calf
intestin
document
year
contrast
bacteri
microbiota
littl
known
regard
develop
establish
factor
modifi
gut
virom
neonat
period
object
studi
character
fecal
virom
healthi
diarrheic
neonat
dairi
calv
twenti
diarrheic
calv
dc
age
day
agematch
healthi
control
calv
hc
enrol
viral
nucleic
extract
perform
use
commerci
kit
synthesi
viral
cdna
complet
use
primer
contain
fix
plu
random
nonam
twenti
sampl
hc
mix
equimolar
quantiti
set
well
dc
sampl
total
pool
sampl
sequenc
use
miseqllluminaplatform
raw
sequenc
qualiti
assess
use
fastqc
lowqual
read
remov
trimmomat
cdhitest
use
cluster
read
sequenc
ident
five
repres
sequenc
cluster
use
perform
de
novo
assembl
use
spade
lefs
use
obtain
molecular
marker
use
diagnosi
caudoviral
virus
mainli
virus
belong
myovirida
famili
found
pool
total
contig
could
associ
neonat
calf
diarrhea
identifi
avail
annot
databas
sequenc
belong
retrovirida
famili
found
predominantli
associ
dc
escherichia
phage
found
pool
compos
dc
group
hc
share
enterobacteria
phage
sensu
lato
dc
share
blood
collect
alpin
goat
kid
hour
age
prior
receiv
colostrum
hour
age
receiv
colostrum
day
age
serum
harvest
protein
measur
use
digit
brix
refractomet
optic
refractomet
beckman
colorimetr
method
commerci
laboratori
linear
regress
correl
coeffici
analysi
perform
twoway
result
brix
x
optic
brix
x
laboratori
colorimetr
optic
x
laboratori
colorimetr
signific
relationship
three
serum
protein
analysi
method
high
degre
posit
correl
digit
brix
optic
refractomet
p
r
moder
posit
correl
laboratori
colorimetr
measur
digit
brix
p
r
optic
refractomet
p
r
regress
analysi
show
digit
brix
percentag
could
use
predict
serum
pro
surviv
rate
downer
cow
treat
farm
hospit
set
estim
identifi
prognost
indic
could
use
reduc
unnecessari
treatment
anim
poor
prognosi
primari
object
studi
predict
prognosi
associ
downer
cow
treat
referr
hospit
secondari
object
identifi
prognost
factor
associ
outcom
retrospect
studi
includ
recumb
dairi
cattl
older
month
present
case
inform
regard
histori
age
lactat
statu
durat
recumb
hospit
outcom
durat
number
day
flotat
therapi
diagnosi
blood
analysi
result
cbc
biochemistri
obtain
multivari
logist
regress
model
built
explor
associ
hematolog
biochemistri
paramet
surviv
overal
surviv
rate
cow
surviv
significantli
younger
recumb
shorter
period
time
lower
fibrinogen
valu
higher
neutrophil
count
arriv
cow
surviv
final
cow
surviv
significantli
lower
valu
ast
ck
bun
creatinin
phosphoru
higher
total
co
valu
arriv
cow
surviv
increas
fibrinogen
ast
creatinin
valu
significantli
associ
lower
odd
surviv
conclud
overal
surviv
rate
downer
cow
treat
inhospit
flotat
therapi
approxim
histor
element
cbc
biochemistri
valu
use
select
case
better
chanc
surviv
evelyn
mackay
texa
univers
colleg
station
tx
usa
macrolid
import
antimicrobi
may
use
agent
control
infecti
ovin
abort
econom
anim
health
human
health
impact
pregnant
ewe
given
singl
dose
tulathromycin
subcutan
drug
concentr
measur
fetal
plasma
matern
plasma
amniot
fluid
cathet
surgic
place
fetal
vasculatur
amnion
day
gestat
sampl
hour
administr
matern
plasma
sampl
collect
time
point
hour
serum
concentr
pharmacokinet
valu
ewe
similar
previous
report
nonpregn
ewe
tulathromycin
present
fetal
plasma
amniot
fluid
indic
therapeut
potenti
use
organ
compart
though
concentr
lower
found
matern
plasma
notabl
pharmacokinet
fetu
quit
differ
found
ewe
plasma
concentr
reach
plateau
hour
remain
concentr
remaind
sampl
period
hour
rais
question
drug
handl
metabol
fetu
prewean
dairi
calv
suggest
potenti
prevent
strategi
respiratori
diseas
object
studi
evalu
effect
oral
administ
nai
brd
treatment
frequenc
wean
weight
prewean
dairi
calv
femal
prewean
dairi
calv
age
day
hous
individu
hutch
ranch
central
california
use
studi
calv
divid
treatment
nai
oral
day
day
control
group
treatment
subset
calv
group
treatment
calv
control
calv
given
respiratori
ultrasound
score
day
baselin
day
medic
treatment
record
entir
studi
period
calv
weigh
wean
ultrasound
score
chang
ultrasound
score
baselin
respiratori
score
treatment
calv
day
significantli
higher
respect
control
calv
addit
higher
respiratori
ultrasound
score
treatment
calv
higher
odd
treat
respiratori
diseas
control
despit
appar
increas
respiratori
diseas
treatment
group
averag
daili
gain
wean
weight
differ
group
find
studi
support
use
oral
nai
prevent
strategi
respiratori
diseas
prewean
dairi
calv
cur
nonresect
lesion
difficult
manag
treatment
modal
case
radiat
therapi
photodynam
therapi
limit
tertiari
referr
hospit
recent
immunomodul
drug
approv
mix
mammari
carcinoma
dog
cat
sarcoid
hors
via
intralesion
inject
product
mycobacteri
cell
wall
extract
immunomodul
effect
work
nonspecif
immunotherapi
activ
natur
killer
cell
monocyt
macrophag
report
describ
use
two
matur
bovin
nonresect
oscc
anim
consid
companion
anim
client
agre
would
enter
food
chain
buck
bull
examin
rapidli
grow
mass
lower
lid
medial
canthu
twoweek
durat
extirp
perform
local
block
sedat
reoccurr
note
sutur
remov
mass
debulk
cryotherapi
appli
aggress
reoccurr
occur
within
two
week
total
four
intralesion
inject
administ
two
week
interv
month
therapi
bull
regress
oscc
bull
continu
well
reoccurr
time
month
first
appoint
longhorn
cow
examin
extens
ocular
periocular
mass
sever
month
durat
extirp
region
debulk
perform
gener
anesthesia
intralesion
inject
perform
initi
surgeri
twice
week
interv
initi
result
promis
howev
owner
report
longhorn
health
regress
difficulti
chew
hear
develop
head
tilt
could
see
remain
eye
extern
growth
surgic
site
found
dead
pastur
one
morn
three
month
initi
surgeri
limit
case
seri
hope
util
oscc
case
understand
treatment
agent
may
appropri
altern
treatment
econom
emot
valuabl
anim
consum
test
follow
uteru
lavagew
hypothesis
influx
function
pmnl
uteru
achiev
differ
mcwf
concentr
dosedepend
manner
follow
iu
administr
anticip
increas
presenc
activ
pmnl
would
benefici
effect
reproduct
perform
dairi
cow
reduc
incid
clinic
subclin
endometr
end
histolog
puerpuerium
thu
improv
concept
rate
studi
conduct
commerci
dairi
oper
milk
holstein
cow
experiment
studi
protocol
review
approv
institut
anim
care
committe
prior
studi
start
forti
lactat
cow
averag
day
postpartum
select
studi
purpos
inclus
criteria
includ
histori
easi
calv
retain
placenta
absenc
sign
clinic
endometr
averag
bodi
condit
score
scale
prior
mcwf
treatment
baselin
statu
uterin
line
determin
cytolog
examin
stain
slide
evalu
microscop
determin
percentag
pmnl
per
cell
follow
cytolog
assess
cow
randomli
assign
four
experiment
group
cow
per
group
day
cow
control
group
treat
iu
oysterglycogen
proven
pmnl
attract
dissolv
ml
nacl
anim
mcwf
group
receiv
iu
dose
either
mcwf
dilut
nacl
total
volum
twentyfour
hour
later
uterin
cytolog
sampl
spot
corpu
uteri
taken
subject
new
cytomorpholog
analysi
pmnl
count
addit
uterin
lavag
sampl
obtain
immedi
second
cytolog
sampl
pmnl
activ
analyz
flowauto
none
cow
elev
pmnl
count
prior
treatment
determin
cytolog
post
treatment
pmnl
count
group
elev
howev
statist
signific
differ
note
group
receiv
ml
mcwf
p
p
respect
even
though
statist
signific
differ
observ
control
mcwf
group
trend
pmn
increas
increas
respect
p
p
compar
day
fac
analysi
ro
activ
reveal
similar
ro
experiment
group
control
mcwf
group
respect
calcul
obi
demonstr
cow
receiv
mcwf
highest
reaction
respect
compar
control
mcwf
data
reproduct
perform
show
cow
mcwf
group
cow
hypothet
popul
cow
gener
use
mont
carlo
simul
milk
discard
time
determin
simul
popul
result
method
compar
safeconcentrationbylinearregress
safeconcentrationpermilk
timeuntilsafeconcentr
method
recommend
regulatori
agenc
compar
milk
discard
time
gener
method
suggest
longer
milk
discard
time
necessari
cohort
cow
mastiti
predict
popul
method
sensit
rang
milk
product
volum
select
simul
novel
method
util
avail
data
includ
data
assay
quantif
limit
studi
demonstr
viabil
popul
physiologicallybas
model
estim
milk
discard
time
augment
innat
mucos
defens
mechan
iodin
effect
kill
bovin
bacteri
viral
respiratori
pathogen
vitro
could
valuabl
prevent
strategi
respiratori
diseas
dairi
calv
object
studi
determin
kinet
iodin
nasal
secret
follow
oral
administr
inorgan
iodin
nai
order
assess
feasibl
use
nai
prevent
bovin
respiratori
diseas
vivo
femal
prewean
holstein
calv
age
week
hous
davi
ca
use
prospect
clinic
studi
calv
consum
nai
ad
milk
baselin
sampl
blood
nasal
secret
collect
consecut
sampl
obtain
hour
postadministr
sampl
submit
diagnost
lab
analysi
iodin
concentr
via
mass
spectrometri
iodin
concentr
significantli
elev
baselin
level
nasal
secret
p
serum
p
time
point
sampl
serum
nasal
fluid
iodin
concentr
peak
hour
serum
mean
concentr
nasal
fluid
mean
concentr
advers
effect
notic
calv
studi
show
oral
administr
nai
increas
iodin
concentr
airway
fluid
prewean
dairi
calv
effect
concentr
vitro
could
augment
upper
respiratori
defens
mechan
studi
need
determin
sodium
iodid
effect
prevent
strategi
respiratori
diseas
dairi
calv
object
retrospect
studi
describ
signal
histori
clinicopatholog
endoscop
ultrasonograph
radiograph
postmortem
find
well
treatment
outcom
adult
cattl
diagnos
pharyng
lacerationtraumamed
record
cattl
month
age
admit
veterinari
teach
hospit
januari
januari
pharyng
perforationtrauma
identifi
oral
endoscop
examin
review
twentyseven
case
met
inclus
criteria
case
one
primari
complaint
dysphagia
swell
pharyng
area
twelv
cow
histori
administ
bolu
monensin
calcium
magnet
iodin
aspirin
vitamin
unknown
bolu
report
clinic
sign
includ
subcutan
emphysema
cow
swell
throatlatch
pain
palpat
nasal
discharg
foul
odour
nose
mouth
ptyalism
dyspnea
upper
respiratori
nois
oral
examin
find
report
cow
foreign
bodi
fb
monensin
bolu
lodg
pharynx
observ
cow
pharyng
lacer
without
fb
report
cow
endoscop
examin
perform
cow
fb
lodg
pharynx
observ
cow
cow
perfor
identifi
dorsal
aspect
pharynx
radiograph
neck
throatlatch
perform
cow
fb
detect
cow
rumensin
bolu
magnet
presenc
ga
either
subcutan
fascial
plane
emphysema
pharyng
region
soft
tissu
swell
pneumomediastinum
commonli
report
treatment
attempt
cow
manual
retriev
monensin
bolu
lodg
pharynx
possibl
cow
fb
observ
oral
exam
surgic
remov
fb
carri
cow
cow
monensin
bolu
retriev
magnet
cow
combin
antimicrobi
agent
analges
antiinflammatori
drug
administ
treat
cow
seventeen
cow
discharg
hospit
wherea
euthan
eight
surviv
cow
pharyng
trauma
associ
monensin
iodin
bolu
magnet
vitamin
bolu
unknown
bolu
cow
suffer
pharyng
trauma
associ
administr
calcium
bolu
euthan
due
sever
clinic
sign
pharyng
trauma
rare
condit
adult
cattl
caus
seriou
morbid
mortal
diagnos
treat
earli
success
treatment
appear
relat
natur
penetr
fb
susan
arnold
simon
platt
georgina
stewart
marc
kent
rene
barber
univers
georgia
athen
ga
usa
univers
georgia
veterinari
teach
hospit
athen
ga
usa
primari
intraparenchym
brain
tumor
includ
astrocytoma
glioblastoma
oligodendroglioma
collect
compris
approxim
primari
brain
tumor
dog
prognosi
dog
tumor
type
gener
guard
poor
median
surviv
time
regardless
treatment
type
approxim
day
due
numer
challeng
associ
diagnos
grade
treat
report
surviv
outcom
current
gold
standard
therapi
tumor
dog
addit
similar
canin
human
primari
intraparenchym
brain
tumor
lend
translat
opportun
develop
novel
treatment
deliveri
system
canin
brain
tumor
glial
tumor
invad
migrat
along
white
matter
tract
blood
vessel
characterist
exploit
cathet
line
nanofib
particl
develop
structur
mimic
conduit
conform
guid
tumor
cell
away
tumor
site
extracrani
reservoir
studi
describ
techniqu
associ
stereotacticallyguid
implant
nanofiberlin
cathet
dog
natur
occur
histopatholog
confirm
astrocytoma
oligodendroglioma
purpos
studi
evalu
safeti
feasibl
stereotact
although
studi
small
prove
treatment
efficaci
find
support
hypothes
stereotact
guidanc
nanofib
cathet
safe
feasibl
encourag
tumor
cell
migrat
cranial
caviti
first
stage
larg
clinic
trial
ultim
aim
evalu
safeti
efficaci
nanofib
cathet
treatment
canin
brain
tumor
repetit
transcrani
magnet
stimul
rtm
noninvas
safe
painless
procedur
appli
human
modifi
activ
specif
neural
circuit
brain
via
electromagnet
induct
magnet
field
gener
produc
small
electr
current
cortic
neuron
order
affect
neuron
function
antiepilept
effect
rtm
demonstr
human
drugresist
epilepsi
therefor
singleblind
random
placebocontrol
clinic
trial
design
assess
efficaci
safeti
rtm
dog
drugresist
idiopath
epilepsi
random
assign
treatment
placebo
group
dog
receiv
activ
sham
stimul
respect
dog
group
sedat
whole
procedur
use
anesthet
protocol
group
receiv
repetit
activ
sham
stimul
minut
per
day
five
consecut
day
total
efficaci
procedur
evalu
compar
monthli
seizur
frequenc
msf
monthli
seizur
day
frequenc
msdf
retrospect
period
prospect
followup
period
three
month
sham
stimul
dog
placebo
group
also
receiv
treatment
advers
effect
complic
report
stage
five
dog
includ
four
treatment
one
placebo
group
treatment
group
median
msf
msdf
decreas
p
p
respect
show
statist
trend
potenti
interest
placebo
group
limit
sampl
size
n
permit
statist
current
stage
howev
dog
show
reduct
seizur
frequenc
follow
sham
stimul
seizur
frequenc
reduc
dog
receiv
activ
stimul
afterward
overal
procedur
seem
safe
signific
seriou
advers
effect
complic
report
conclus
preliminari
result
suggest
rtm
safe
procedur
might
decreas
median
msf
msdf
result
improv
seizur
manag
dog
drugresist
epilepsi
howev
larger
number
dog
requir
group
definit
conclus
made
use
nonrandom
crossov
design
nine
clinic
healthi
cat
receiv
singl
dose
mg
approv
erlev
po
thirteen
blood
csf
sampl
collect
hour
oneweek
washout
period
studi
repeat
singl
oral
dose
mg
compound
erlev
lev
quantit
immunoassay
plasma
pool
csf
lev
concentr
versu
time
data
subject
noncompartment
pharmacokinet
analysi
data
compar
formul
use
pair
ttest
regardless
formul
csf
lev
close
mimick
plasma
concentr
signific
differ
p
formul
limit
plasma
cmax
ugml
approv
compound
tmax
approv
compound
halflif
hour
approv
compound
respect
formul
maintain
concentr
human
therapeut
refer
interv
least
hour
studi
demonstr
approv
compound
erlev
maintain
human
therapeut
lev
concentr
healthi
cat
hour
oral
administr
support
dose
interv
studi
also
demonstr
plasma
lev
monitor
use
accur
represent
csf
lev
concentr
cat
print
spinal
model
exvivo
spine
comput
tomograph
ct
imag
eventu
goal
replac
cadav
spine
hypothes
spatial
accuraci
print
stereolithograph
model
canin
thoracolumbar
vertebr
column
would
differ
cadaver
bone
thoracolumbar
vertebr
column
harvest
adult
canin
cadav
ct
scan
acquir
render
surfac
model
stereolithograph
model
gener
print
stereolithographi
printer
clear
methacryl
photoactiv
resin
cadaver
specimen
prepar
heat
soft
tissu
macer
uniform
measur
acquir
cadav
spine
ct
imag
model
neurolog
examin
perform
prior
studi
daili
surgeri
standard
brain
mri
intraven
gadolinium
contrast
agent
perform
immedi
day
day
follow
surgeri
dog
human
euthan
histopatholog
analysi
brain
presenc
intratumor
chlorambucil
indic
alter
blood
brain
barrier
vari
case
case
despit
sporad
previou
report
neurotox
prolong
seizurefre
interv
support
high
safeti
margin
dose
speci
metronom
chlorambucil
well
toler
ventriculoperiton
shunt
obstruct
major
complic
canin
human
hydrocephalu
howev
obstruct
typic
occur
chronic
set
order
develop
selfclear
ventricular
cathet
hydrocephalu
model
prone
earli
shunt
obstruct
would
benefici
autolog
blood
inject
right
later
ventricl
kg
male
month
old
pig
termin
surviv
procedur
median
intraventricular
intracrani
pressur
mmhg
baselin
mmhg
peak
mmhg
minut
postblood
inject
ml
blood
caus
profound
hypertens
hydrocephalu
termin
procedur
first
surviv
pig
could
recov
anesthesia
use
ml
blood
hypertens
hydrocephalu
occur
pig
one
pig
subarachnoid
space
inadvert
inject
hydrocephalu
fenbendazol
produc
effect
mean
inhibitori
concentr
ic
ngml
might
initi
target
therapeut
csf
concentr
studi
aim
describ
time
cours
fenbendazol
plasma
csf
oral
administr
dog
dose
design
target
csf
concentr
approach
ngml
fenbendazol
detect
canin
plasma
csf
use
high
perform
liquid
chromatographi
limit
detect
ngml
ngml
respect
fenbendazol
administ
two
dog
mgkg
detect
dog
subsequ
treat
mgkg
n
mgkg
n
due
advers
effect
result
averag
peak
plasma
concentr
ngml
aim
studi
determin
precis
novel
mribas
patientindividu
stereotact
brain
biopsi
devic
dog
twentytwo
canin
cadav
target
point
use
determin
accuraci
first
specif
bone
anchor
mrimark
secur
canin
cadav
head
afterward
ct
mri
examin
head
perform
two
target
point
correspond
trajectori
defin
mri
left
caudat
nucleu
right
piriform
lobe
base
mrimag
patientindividu
frame
includ
rigid
needl
placement
port
reach
defin
target
point
construct
print
needl
enter
brain
gyru
penetr
ventricl
frame
secur
bone
anchor
minimalinvas
access
brain
creat
use
tool
guid
biopsi
needl
place
needl
placement
port
predetermin
depth
afterward
ct
examin
head
biopsi
needl
place
target
point
perform
needl
placement
error
determin
fusion
mri
ct
examin
error
defin
deviat
mm
needl
tip
anticip
target
point
total
median
needl
placement
error
target
point
mm
rang
outlier
median
needl
placement
error
caudat
nucleu
mm
rang
piriform
lobe
mm
rang
therefor
mribas
patientindividu
stereotact
brain
biopsi
devic
reach
higher
accuraci
describ
brain
biopsi
system
sm
dog
distanc
rostral
end
palat
sella
turcica
p
ii
foramen
magnum
basioccipit
p
significantli
reduc
maximum
distanc
palat
centroid
p
howev
reduc
distanc
brain
frontal
bone
highli
signific
p
reduct
distanc
olfactori
bulb
sella
turcica
may
interest
p
discrimin
analysislogist
regress
reveal
rostral
skull
flatten
domin
model
remov
ratio
maximum
distanc
palat
centroid
cerebr
height
cerebrum
height
highli
signific
p
characterist
ckc
sm
includ
osseou
insuffici
skull
chang
shape
soft
palat
implic
machin
learn
technolog
hand
activ
desaturas
desaturas
desaturas
metabol
epa
dha
precursor
report
lower
japanes
western
possibl
due
dietari
cultur
japanes
histor
ingest
epa
dha
directli
seafood
hypothes
japanes
dog
share
histor
similar
diet
japanes
may
lower
desaturas
activ
compar
western
dog
aim
pilot
studi
investig
composit
fa
erythrocyt
membran
plasma
evalu
desaturas
activ
japanes
dog
nonasian
dog
prospect
studi
twentyf
shiba
dog
without
ccd
nonasian
dog
without
ccd
use
fa
pufa
pufa
monounsatur
pufa
satur
pufa
composit
erythrocyt
membran
plasma
measur
blood
sampl
use
ga
chromatographi
differ
shiba
dog
nonasian
dog
evalu
use
wilcoxson
ranksum
test
shiba
dog
significantli
lower
composit
epa
median
find
might
suggest
shiba
dog
lower
desaturas
activ
nonasian
dog
high
incid
ccd
shiba
dog
may
associ
low
composit
fa
erythrocyt
membran
studi
fa
use
dog
unifi
diet
requir
clarifi
metabol
differ
japanes
dog
nonasian
dog
elucid
associ
fa
ccd
radiographi
valuabl
howev
publish
toy
breedspecif
radiograph
measur
lack
diagnosi
remain
larg
subject
purpos
studi
establish
object
radiograph
criteria
diagnosi
aa
instabl
toy
breed
dog
neutral
later
ventrodors
radiograph
toy
breed
dog
control
affect
retrospect
review
median
overlap
distanc
overlap
spinou
process
dorsal
arch
mm
control
dog
mm
aa
case
overlap
mm
sensit
specif
radiograph
measur
diagnosi
aa
instabl
perform
three
rel
measur
atlantodent
interv
dorsal
atlantodent
interv
ratio
adidadi
ratio
rel
den
length
angl
three
rel
measur
good
specif
respect
lower
sensit
influenc
bodi
weight
p
absolut
measur
eg
absolut
den
length
atlantoaxi
distanc
significantli
correl
bodi
weight
p
util
diagnosi
aa
instabl
could
establish
decreas
overlap
strongli
support
aa
instabl
adidadi
ratio
rel
den
length
angl
may
provid
support
may
normal
individu
case
mean
pre
trial
seizur
frequenc
group
calculatedgroup
seizur
everi
day
group
seizur
everi
day
overal
mean
post
trial
seizur
frequenc
group
decreas
group
seizur
everi
day
group
seizur
everi
day
side
effect
limit
dog
experienc
increas
seizur
frequenc
dog
display
neg
avers
behavior
devic
appli
conclus
treatment
modal
repres
possibl
addit
treatment
refractori
epilept
dog
noninvas
limit
side
effect
tradit
cervic
spondylomyelopathi
csm
classifi
discor
osseousassoci
form
howev
dog
suffer
form
thoroughli
evalu
goal
report
mri
find
associ
singl
multilevel
osseou
disc
ligament
compress
dog
diagnos
csm
retrospect
review
magnet
reson
imag
mri
case
previous
diagnos
csm
inclus
criteria
diagnosi
csm
use
mri
presenc
compress
two
direct
locat
compress
lesion
sever
compress
lesion
direct
compress
dorsal
ventral
later
combin
presenc
spinal
cord
hyperintens
record
fortyf
dog
met
inclus
criteria
largebre
doberman
giantbre
great
dane
major
older
year
age
male
forti
two
dog
dorsal
ventral
spinal
cord
compress
level
also
spinal
cord
compress
one
site
seven
dog
circumferenti
spinal
cord
compress
sever
compress
lesion
spinal
cord
hyperintens
imag
present
dog
find
indic
sizeabl
portion
csmaffect
dog
suffer
combin
compress
import
routin
care
evalu
cervic
level
make
sure
overlook
high
proport
spinal
cord
hyperintens
may
suggest
repres
sever
form
diseas
formalinfix
paraffinembed
section
gme
nme
total
dog
sampl
use
studi
stain
cabl
ckit
carri
use
standard
immunohistochem
procedur
develop
use
formalin
fix
tissu
immunohistochem
evalu
assess
stain
posit
tk
stain
intens
distribut
tk
posit
cell
overal
stain
intens
grade
immunostain
weak
immunostain
moder
intens
immunostain
magnif
distribut
posit
stain
cell
cell
affect
evalu
five
separ
field
magnif
grade
follow
sampl
stain
posit
major
sampl
exhibit
rel
intens
stain
broad
distribut
larg
number
sampl
also
weak
moder
stain
ckit
variou
distribut
cabl
identifi
rel
moder
stain
intens
distribut
sampl
show
weak
restrict
statist
signific
associ
gme
ne
sampl
term
tk
express
p
known
target
convent
multitarget
tki
express
canin
gme
nme
studi
tk
could
involv
key
aspect
pathogenesi
autoimmun
enceph
especi
may
import
role
biolog
activ
diseas
base
proof
target
therapi
overexpress
tk
may
potenti
new
treatment
modal
gme
nme
austin
kern
nina
kiev
lauri
cook
sarah
moor
ohio
state
univers
columbu
oh
usa
ohio
state
univers
columbu
oh
usa
electron
von
frey
anesthesiometri
vfa
previous
report
laboratori
other
use
method
mechan
quantit
sensori
test
qst
evalu
neuropath
pain
dog
intraobserv
agreement
previous
shown
good
excel
howev
interobserv
agreement
previous
report
vital
use
techniqu
multicent
veterinari
clinic
trial
neuropath
pain
goal
studi
evalu
interobserv
agreement
sensori
threshold
obtain
use
electron
vfa
group
normal
small
breed
dog
statist
differ
mtr
fa
note
group
ad
md
significantli
lower
dog
recov
find
support
quantit
imag
surrog
axon
integr
may
import
prognost
indic
dog
sci
despit
studi
demonstr
lower
dose
toceranib
mgkg
everi
day
provid
drug
exposur
suffici
target
inhibit
reduc
frequenc
drugrel
advers
event
gastrointestin
gi
toxic
continu
commonli
encount
side
effect
dog
receiv
toceranib
dose
degre
toxic
variabl
among
individu
dog
current
clinic
molecular
marker
identifi
dog
would
benefit
use
concomit
medic
prevent
gi
toxic
critic
develop
gi
toxic
significantli
impact
patient
morbid
qualiti
life
decreas
treatment
intens
increas
cost
treatment
lead
discontinu
therapi
univers
tokyo
bunkyoku
tokyo
japan
anicom
specialti
medic
institut
inc
shinjukuku
tokyo
japan
univers
tokyo
tokyo
tokyo
japan
gene
mutat
variou
canin
tumor
explor
canin
histiocyt
sarcoma
hs
mutat
gene
report
frequent
observ
howev
report
comprehens
analysi
gene
mutat
canin
hs
object
studi
conduct
comprehens
analysi
mutat
protein
code
gene
dog
hs
whole
exom
sequenc
genom
dna
extract
tumor
tissu
three
dog
histolog
diagnos
hs
analysi
germlin
dna
sequenc
genom
dna
also
extract
normal
tissu
peripher
blood
dog
whole
exom
sequenc
perform
use
illumina
nextseq
align
process
read
canin
refer
genom
canfam
carri
use
genom
analysi
toolkit
varscan
use
call
somat
variant
dog
snpeff
use
annot
variant
extract
somat
variant
filter
read
depth
put
impact
gene
function
variant
gene
known
associ
pathogenesi
human
tumor
valid
use
sanger
sequenc
whole
exom
sequenc
gener
mean
read
depth
uniqu
read
could
map
canin
refer
genom
averag
analysi
data
variant
gene
variant
gene
variant
gene
extract
somat
mutat
dog
respect
variant
mutat
dog
pdgfrb
dog
dog
confirm
sanger
sequenc
studi
reveal
somat
mutat
pdgfrb
gene
canin
hs
previous
report
high
incid
gene
mutat
canin
hs
report
interact
target
mapkerk
pathway
shown
induc
downregul
protein
tyrosin
kinas
activ
mapkerk
pathway
fig
although
studi
need
know
frequenc
gene
mutat
find
obtain
present
studi
lead
introduct
molecular
target
therapi
direct
mapkerk
pathway
canin
hs
ageand
breedmatch
dog
agematch
cat
case
sdma
creatinin
concentr
compar
case
control
cancer
type
sdma
concentr
significantli
higher
dog
cat
lymphoma
p
significantli
lower
dog
lipoma
mammari
adenocarcinoma
mammari
carcinoma
p
compar
control
creatinin
concentr
significantli
lower
dog
mammari
adenocarcinoma
mammari
carcinoma
cat
lymphoma
compar
control
odd
ratio
confid
interv
ci
calcul
determin
associ
sdma
tumor
type
tabl
result
indic
cat
dog
case
lymphoma
associ
increas
sdma
concentr
larg
portion
case
concurr
creatinin
concentr
within
refer
interv
although
etiolog
increas
sdma
concentr
case
determin
sdma
may
earli
marker
renal
involv
reduc
gfr
recent
diagnos
case
lymphoma
assess
impact
probiot
treatment
preval
sever
cid
randomis
doubleblind
placebocontrol
crossov
trial
perform
dog
cancer
schedul
receiv
doxorubicin
dog
receiv
treatment
day
start
day
doxorubicin
administr
either
probiot
formul
contain
enterococcu
faecium
ncimb
x
cfu
placebo
cid
assess
form
develop
daili
complet
owner
five
day
start
four
day
treatment
doxorubicin
score
calcul
describ
sever
event
addit
qualiti
life
qol
assess
form
develop
assess
qol
dog
treatment
period
faecal
sampl
collect
administr
doxorubicin
treatment
probiot
placebo
faecal
dna
extract
quantit
polymeras
chain
reaction
develop
detect
quantifi
presenc
specif
probiot
strain
fifti
dog
recruit
took
probiot
formul
placebo
took
either
product
seven
dog
die
cancer
remov
trial
leav
case
evalu
faecal
consist
describ
abnorm
dog
probiot
group
placebo
group
faecal
frequenc
increas
dog
probiot
group
placebo
group
differ
diarrhoea
event
score
whilst
dog
took
either
trial
product
p
addit
differ
qol
score
trial
period
signific
correl
qol
diarrhoea
score
qol
consid
wors
diarrhoea
sever
p
also
signific
correl
qol
tumour
type
dog
lymphoma
describ
significantli
wors
qol
compar
dog
sarcoma
carcinoma
uniqu
natur
nanoparticl
design
vibrat
expos
appropri
wavelength
light
gener
control
target
heat
hypothesi
heat
gener
laser
light
induc
nanoparticl
vibrat
caus
cancer
cell
death
therebi
provid
definit
therapi
low
grade
mast
cell
tumor
eighteen
low
grade
mast
cell
tumor
cm
random
either
treatment
control
group
dog
receiv
benadryl
hour
pepcid
ac
hour
day
one
dog
receiv
hour
iv
infus
nanoparticl
day
two
treatment
group
dog
light
therapi
appli
tumor
use
diod
laser
nm
dog
evalu
week
four
week
monthli
data
collect
includ
signal
tumor
size
preinfus
prelas
therapi
applic
respons
therapi
durat
respons
toxic
endpoint
mice
euthan
tumor
collect
histolog
necrot
area
tumor
tissu
evalu
final
immunohistochemistri
perform
use
urinari
bladder
tissu
dog
tcc
healthi
dog
intens
stain
local
cell
membran
defin
protein
overexpress
aim
studi
assess
toxic
efficaci
doxorubicin
cytarabin
dc
combin
protocol
dog
acut
myeloid
leukemia
aml
cohort
dog
persist
cytopenia
bone
marrow
cytolog
andor
core
biopsi
diagnosi
aml
treat
day
doxorubicin
mgm
mgkg
iv
minut
follow
cytarabin
mgm
constant
rate
iv
infus
hour
everi
day
prednison
mgkg
po
also
administ
hematolog
result
advers
effect
outcom
assess
everi
week
dc
therapi
six
dog
treat
dc
protocol
period
two
year
median
age
year
rang
median
weight
kg
rang
kg
dog
present
anemia
leukopenia
thrombocytopenia
two
dog
circul
blast
cell
median
number
treatment
cycl
rang
dose
reduct
requir
dog
due
grade
neutropenia
grade
gastrointestin
advers
effect
giae
one
dog
develop
dilat
cardiomyopathi
dcm
cumul
doxorubicin
dose
mgm
two
dog
still
aliv
day
diagnosi
one
dog
die
due
dcm
day
cytopenia
remiss
three
dog
die
progress
aml
day
diagnosi
respect
improv
cytopenia
note
two
dog
die
within
day
dc
protocol
overal
well
toler
four
dog
surviv
longer
month
studi
larger
sampl
size
warrant
purpos
studi
assess
role
palladia
treatment
inoper
metastat
recurr
canin
pheochromocytoma
retrospect
medic
record
dog
diagnosi
pheochromocytoma
treatment
palladia
review
inform
regard
respons
palladia
observ
side
effect
overal
outcom
five
dog
identifi
fit
inclus
cri
incur
infiltr
bone
lung
metastasi
tradit
therapeut
approach
less
effect
tumor
cell
reli
glycolysi
rather
mitochondri
oxid
phosphoryl
energi
product
even
oxygenrich
condit
term
warburg
effect
sinc
warburg
effect
characterist
tumor
cell
glucos
metabol
consid
therapeut
target
regard
studi
investig
contribut
glucos
transport
cell
growth
canin
melanoma
canin
melanoma
cell
cultur
dulbecco
modifi
eagl
medium
contain
gl
glucos
fetal
bovin
serum
cell
growth
measur
tetrazolium
bromid
reduct
assay
cell
prolifer
three
day
timedepend
manner
treat
panglucos
transport
inhibitor
cell
growth
clearli
attenu
observ
rtpcr
mrna
glucos
transport
subtyp
dominantli
express
canin
melanoma
protein
express
confirm
western
blot
investig
contribut
glut
subtyp
cell
growth
subtypespecif
knockdown
cell
transfect
sirna
cell
growth
inhibit
also
observ
express
prolifer
marker
inhibit
knockdown
cell
wherea
inhibit
less
knockdown
cell
henc
suggest
dominantli
contribut
cell
growth
canin
melanoma
conclus
like
glucos
transport
promis
therapeut
target
canin
melanoma
plasma
without
mg
data
analyz
use
pair
ttest
signific
set
p
level
blood
sampl
dog
includ
cortisol
valu
significantli
differ
plasma
serum
sampl
without
mg
cortisol
concentr
measur
edta
plasma
higher
serum
sampl
respect
p
addit
mg
plasma
significantli
decreas
measur
cortisol
concentr
p
p
respect
addit
mg
cortisol
concentr
measur
edta
plasma
longer
significantli
differ
measur
serum
howev
concentr
measur
edta
plasma
remain
significantli
differ
serum
use
edta
plasma
significantli
increas
measur
concentr
cortisol
obtain
immulit
addit
mg
plasma
sampl
overcom
effect
edta
measur
cortisol
thu
edta
plasma
use
maxim
cortisol
stabil
mg
ad
sampl
assay
via
immulit
osmot
diuresi
consid
caus
polyuria
diabet
mellitu
howev
peopl
mutat
renal
sodiumglucos
cotransport
diabet
patient
treat
drug
block
transport
profound
glycosuria
without
polyuria
purpos
studi
determin
isol
renal
glycosuria
induc
polyuria
cat
studi
approv
univers
anim
ethic
committe
studi
consist
four
studi
period
separ
washout
period
eight
healthi
male
cat
randomli
alloc
control
treatment
dapagliflozin
daili
base
previou
pilot
studi
four
studi
period
record
daili
food
water
intak
urin
output
urin
aliquot
collect
blood
obtain
begin
end
studi
period
data
analyz
linear
mixedeffect
model
includ
treatment
dayoftreat
fix
effect
cat
random
effect
statist
signific
set
dapagliflozin
induc
increas
urin
glucos
loss
mmold
vs
mmold
differ
daili
urinari
excret
sodium
potassium
chlorid
group
also
differ
water
intak
vs
ml
bodi
weight
vs
g
urin
product
vs
ml
result
call
question
gener
accept
hypothesi
glycosuriainduc
osmot
diuresi
primari
caus
polyuria
diabet
mellitu
note
adulthood
speci
express
shown
contribut
reprogram
exocrin
cell
insulinproduc
induct
arx
express
lead
reprogram
recent
discov
diabet
cat
increas
number
cell
exocrin
pancrea
stain
posit
marker
prolifer
prolifer
cell
nuclear
antigen
pcna
particular
nearbi
islet
prolifer
increas
reprogram
effici
rodent
hypothes
cell
may
anticip
reprogram
cat
aim
studi
test
diabet
cat
increas
number
cell
endocrin
exocrin
pancrea
express
development
marker
suggest
reprogram
diabet
wellmatch
control
cat
pancrea
col
predict
longeract
compar
glargin
uml
peopl
durat
action
hour
allow
flexibl
daili
schedul
administr
hypothes
would
longer
durat
action
compar
healthi
cat
six
healthi
purposebr
cat
receiv
ukg
sq
inject
two
differ
day
week
apart
blood
glucos
bg
measur
everi
min
glucos
administ
intraven
variabl
rate
goal
maintain
bg
mgdl
isoglycem
clamp
glucos
infus
rate
use
measur
exogen
insulin
action
shapirowilk
test
use
assess
normal
normal
distribut
paramet
compar
use
pair
ttest
onset
action
oa
similar
min
min
p
end
action
ea
durat
action
dur
ea
oa
longer
vs
dur
min
vs
min
respect
p
ea
min
vs
min
respect
p
signific
differ
two
formul
base
preliminari
data
longeract
therefor
better
suit
oncedaili
insulin
formul
cat
palerm
laura
r
van
vertloo
iowa
state
univers
colleg
veterinari
medicin
ame
ia
usa
iowa
state
univers
ame
ia
usa
renal
proteinuria
associ
subclin
clinic
hypothyroid
peopl
howev
littl
known
effect
renal
proteinuria
thyroid
statu
companion
anim
purpos
studi
determin
thyroid
statu
assess
total
free
thyroidstimul
hormon
tsh
differ
ill
dog
proteinur
versu
nonproteinur
ill
proteinur
dog
defin
urin
proteincreatinin
ratio
upc
neg
urin
cultur
ill
nonproteinur
dog
prospect
enrol
crosssect
studi
dog
underw
physic
examin
complet
blood
count
serum
chemistri
urinalysi
thyroid
panel
urin
proteinur
dog
submit
cultur
upc
descript
statist
student
ttest
use
determin
differ
group
signific
p
twentytwo
ill
proteinur
dog
ill
nonproteinur
dog
enrol
studi
serum
total
protein
concentr
higher
nonproteinur
dog
p
though
albumin
level
differ
group
p
median
upc
proteinur
dog
rang
interestingli
proteinur
dog
significantli
higher
mean
serum
cholesterol
nonproteinur
dog
p
signific
differ
mean
p
p
found
proteinur
nonproteinur
dog
howev
mean
tsh
significantli
higher
proteinur
dog
p
result
suggest
renal
proteinuria
influenc
thyroid
homeostasi
consid
interpret
thyroid
statu
dog
thyroid
stimul
hormon
tsh
stimul
test
use
assess
thyroid
reserv
studi
hypothyroid
dog
howev
limit
data
avail
cat
purpos
studi
assess
effect
mild
moder
concurr
ill
respons
euthyroid
cat
tsh
stimul
test
prospect
studi
clientown
shelterh
matur
adult
cat
full
examin
includ
systol
blood
pressur
routin
hematolog
biochemistri
urinalysi
measur
urin
proteincreatinin
ratio
total
thyroxin
free
thyroxin
tsh
tsh
stimul
test
perform
cat
thought
year
older
recruit
howev
age
shelter
cat
could
alway
verifi
hospit
cat
cat
receiv
thyroidsuppress
medic
exclud
cat
divid
group
base
physic
examin
laboratori
result
group
concurr
ill
detect
group
mild
concurr
ill
eg
moder
dental
diseas
stabl
iri
stage
ii
chronic
kidney
diseas
group
moder
concurr
ill
eg
untreat
moder
sever
hypertens
anemia
hypoalbuminemia
proteinuria
andor
hypokalemia
result
report
median
rang
posttsh
concentr
ratio
concentr
tsh
administr
ratio
compar
group
use
kruskal
walli
htest
twelv
cat
own
cat
shelterh
two
shelterh
cat
diagnos
hyperthyroid
exclud
evalu
remain
cat
baselin
ratio
signific
differ
p
ratio
group
group
group
group
therefor
effect
mildmoder
ill
tsh
stimul
test
result
studi
conclus
diabet
cat
erythrocyt
increas
protein
oxid
byproduct
reduc
antioxid
capac
suggest
increas
oxid
stress
oxid
statu
amelior
treatment
possibl
oxid
stress
persist
need
longer
treatment
durat
decreas
reason
behind
reduc
tbar
diabet
cat
remain
elus
lastli
oxid
statu
differ
cat
without
remiss
hospit
popul
cat
dka
enrol
random
prospect
blind
clinic
trial
cat
blood
glucos
bg
glucosuria
blood
ph
blood
betahydroxybutyr
bohb
concentr
enrol
cat
randomli
assign
receiv
iv
continu
rate
infus
lispro
regular
insulin
administ
initi
dose
hr
adjust
previous
describ
doi
six
cat
enrol
treatment
group
advers
event
observ
associ
iv
lispro
administr
median
time
resolut
hyperglycemia
bg
significantli
shorter
cat
treat
lispro
rang
compar
cat
treat
regular
insulin
p
signific
differ
median
time
resolu
blandaltman
plot
passingbablok
regress
use
assess
agreement
risk
error
respect
proport
error
found
serum
plasma
sampl
acth
cortisol
tsh
systemat
error
also
found
result
confirm
signific
differ
sampl
type
directli
interchang
incomplet
fill
edta
tube
associ
significantli
higher
cortisol
concentr
significantli
lower
acth
concentr
compar
complet
fill
edta
tube
measur
chemiluminesc
immunoassay
serum
use
cortisol
tsh
plasma
complet
fill
edta
tube
use
acth
investig
effect
thyroid
stimul
hormon
administr
radioact
iodin
uptak
hyperthyroid
cat
sponsor
dechra
veterinari
product
hypoadrenocortic
dog
confirm
perform
acth
stimul
test
although
rare
hypoadrenocortic
differenti
diagnosi
mani
clinic
clinicopatholog
find
canin
patient
therefor
simpl
inexpens
way
rule
desir
prospect
studi
perform
test
hypothesi
urin
cortisol
creatinin
ratio
uccr
specif
basal
cortisol
diagnosi
hypoadrenocortic
clientown
dog
clinic
sign
clinicopatholog
abnorm
hypoadrenocortic
reason
differenti
diagnosi
enrol
case
exclud
receiv
prior
therapi
glucocorticoid
mitotan
trilostan
urin
uccr
obtain
dog
prior
perform
acth
stimul
test
total
dog
enrol
dog
diagnos
hypoadrenocortic
preand
postacth
serum
cortisol
mcgdl
dog
diagnos
nonhypoadren
nh
uccr
rang
hypoadrenocortic
dog
nh
group
basal
cortisol
rang
nh
group
diagnosi
hypoadrenocortic
sensit
specif
basal
cortisol
respect
use
cutoff
uccr
sensit
specif
diagnosi
hypoadrenocortic
uccr
significantli
specif
basal
cortisol
basal
cortisol
result
suggest
uccr
allow
hypoadrenocortic
rule
patient
compar
basal
cortisol
purpos
prospect
studi
evalu
accuraci
bayer
detect
glucosuria
cat
litter
hour
glucos
ad
previous
frozen
felin
urin
sampl
achiev
urin
sampl
approxim
glucos
concentr
mgdl
sampl
pad
detect
glucos
cut
reagent
strip
ad
clay
litterfil
petri
dish
soak
drop
one
urin
sampl
estim
urin
glucos
concentr
determin
train
blind
observ
compar
color
chang
piec
color
chart
packag
insert
immedi
per
manu
random
crossov
studi
use
healthi
cat
washout
period
use
assess
effect
dexmedetomidin
iv
salin
glucos
lactat
cortisol
insulin
glucagon
nonesterifi
fatti
acid
nefa
concentr
baselin
min
post
administr
nonparametr
distribut
establish
shapirowilk
test
comparison
group
perform
wilcoxon
match
pair
sign
rank
test
comparison
within
group
perform
friedman
test
use
dunn
multipl
comparison
posthoc
analys
signific
differ
identifi
group
within
salin
group
within
dexmedetomidin
group
insulin
cortisol
lactat
concentr
signific
differ
p
observ
within
dexmedetomidin
group
increas
blood
glucos
concentr
min
mmoll
min
mmoll
compar
mmoll
decreas
serum
glucagon
concentr
min
pgml
min
pgml
compar
prospect
studi
investig
verac
recent
retrospect
studi
found
signific
neg
correl
serum
total
thyroxin
glucos
concentr
cat
end
use
naturallyoccur
hyperthyroid
cat
model
determin
effect
rang
serum
concentr
would
serum
glucos
concentr
studi
approv
univers
anim
ethic
committe
apriori
power
analysi
indic
six
cat
per
group
would
suffic
detect
differ
mgdl
repeat
measur
serum
glucos
cat
power
ten
hyperthyroid
cat
randomli
alloc
crossov
design
receiv
treatment
longact
carbimazol
treatment
withheld
experiment
design
consist
four
studi
period
separ
washout
period
collect
serum
day
four
studi
period
measur
serum
glucos
data
analyz
linear
mixedeffect
model
includ
fix
effect
cat
random
effect
statist
signific
set
object
studi
determin
periop
characterist
outcom
cat
undergo
surgic
treatment
phpt
multiinstitut
retrospect
studi
medic
record
data
collect
via
telephon
followup
cat
undergo
surgic
treatment
histopatholog
evalu
resect
tissu
includ
cat
divid
preoper
ioniz
calcium
ica
group
correspond
rd
th
th
percentil
studi
popul
preoper
ica
result
thirtytwo
cat
includ
studi
mean
cat
age
year
mean
cat
bodi
weight
kg
ica
refer
rang
cat
median
mmoll
iqr
cat
underw
cervic
exploratori
surgeri
abnorm
tissu
identifi
remov
cat
histopatholog
diagnosi
parathyroid
adenoma
cat
parathyroid
endocrin
carcinoma
cat
parathyroid
hyperplasia
cat
parathyroid
cystadenoma
cat
discharg
cat
hypercalcemia
hypocalcemia
cat
ica
within
refer
rang
overal
median
surviv
time
day
ci
surviv
time
significantli
associ
preoper
ica
group
p
hypocalcemia
discharg
p
hypercalcemia
discharg
p
diagnosi
carcinoma
p
cohort
cat
parathyroid
adenoma
common
caus
phpt
surgic
treatment
result
favor
surviv
time
therefor
object
present
studi
determin
chang
circul
aa
concentr
dog
hac
twentyeight
dog
newli
diagnos
pituitarydepend
hyperadrenocortic
pdh
enrol
casecontrol
studi
healthi
beagl
also
includ
control
serum
concentr
aa
alanin
arginin
asparagin
aspart
cystein
glutam
glutamin
glycin
histidin
isoleucin
leucin
lysin
methionin
phenylalanin
prolin
serin
taurin
threonin
tryptophan
tyrosin
valin
analyz
use
mhz
h
nuclear
magnet
reson
spectromet
orthogon
partial
least
squarediscrimin
analysi
oplsda
plot
show
separ
pdh
healthi
dog
dog
pdh
show
signific
increas
median
serum
concentr
arginin
p
aspart
p
signific
decreas
glutamin
p
serin
p
compar
healthi
dog
studi
show
circul
concentr
aa
affect
dog
pdh
indic
chronic
hypercortisolemia
may
precipit
disturb
aa
metabol
studi
necessari
clarifi
associ
aa
profil
consequ
hypercortisolemia
dog
canin
diabet
mellitu
common
diseas
may
parallel
human
type
diabet
recent
identifi
varianc
serum
metabolom
profil
fast
diabet
healthi
dog
similar
previous
identifi
human
patient
given
obtain
fast
sampl
diabet
dog
difficult
practic
purpos
studi
expand
effort
compar
untarget
metabolom
profil
nonfast
diabet
healthi
control
dog
serum
diabet
dog
healthi
control
dog
analyz
liquid
chromatographymass
spectrometri
profil
dog
breed
andor
bodi
weight
match
time
sampl
collect
postfeed
approxim
match
pair
metaboanalyst
util
data
analysi
identifi
differ
metabolom
profil
two
group
base
heat
map
analysi
known
unknown
metabolit
clear
cluster
metabolit
diabet
control
group
observ
diabet
dog
compar
healthi
control
dog
mani
metabolit
significantli
p
downregul
includ
involv
tryptophan
metabol
well
sever
amino
acid
fewer
metabolit
significantli
p
upregul
includ
microbi
deriv
citramal
organ
acid
alphahydroxyisobutyr
acid
multipl
metabol
perturb
includ
list
similar
previous
found
fast
diabet
dog
sum
metabolom
profil
differ
nonfast
diabet
healthi
dog
parallel
found
fast
dog
metabolom
alter
may
give
insight
pathogenesi
canin
diabet
futur
studi
confirm
find
develop
target
assay
detect
metabolit
may
use
biomark
canin
diabet
warrant
studi
shown
serum
cortisol
concentr
increas
corticotrop
hyperplasia
due
environment
stress
agent
observ
explain
physiolog
effect
caus
stress
nevertheless
studi
tri
correl
chronic
exposur
stress
hypothalamicpituitaryadren
axi
activ
dog
hyperadrenocortic
hac
develop
present
work
aim
clarifi
whether
dog
pituitarydepend
hac
pdh
expos
stress
situat
throughout
live
compar
healthi
anim
questionnair
regard
tempera
social
social
interact
level
environment
enrich
daili
habit
develop
owner
recent
diagnos
pdh
healthi
dog
invit
answer
questionnair
twenti
newli
diagnos
pdh
dog
includ
studi
subject
match
forti
healthi
dog
control
group
sex
age
breed
ratio
exclus
criteria
control
group
hac
suspicion
chronic
glucocorticoid
therapi
glucocorticoid
exposur
last
month
odd
ratio
estim
confid
interv
ci
report
pvalu
less
equal
consid
statist
signific
dog
hac
ten
time
expos
neuter
ci
p
howev
significantli
correl
found
social
isol
confin
exposur
can
food
plastic
toy
phobia
separ
anxieti
hac
even
variabl
studi
consid
potenti
stress
reliev
suggest
protect
effect
result
emphas
neuter
potenti
riskfactor
hac
develop
instig
studi
possibl
mechan
behind
use
evalu
pancreat
endocrin
function
predict
patient
becom
diabet
pancreatectomi
purpos
studi
describ
cta
characterist
pancrea
cat
chronic
dm
compar
find
healthi
control
cat
prospect
crosssect
studi
cat
natur
occur
dm
present
year
age
match
healthi
control
cat
util
sedat
cta
exam
pancrea
perform
cat
time
arteri
enhanc
time
peak
portal
enhanc
pancreat
attenu
arteri
portal
attenu
ratio
p
determin
cat
compar
group
student
ttest
use
statist
analys
purpos
studi
examin
ba
metabol
dog
naturallyoccur
dm
relat
find
chang
intestin
microbiota
adult
dog
clinic
diagnosi
dm
prospect
enrol
along
agematch
healthi
control
dog
fecal
microbiota
analyz
rrna
gene
nextgener
illumina
sequenc
fecal
concentr
primari
cholicchenodeoxychol
secondari
lithocholicdeoxycholicursodeoxychol
ba
measur
use
ga
chromatographi
mass
spectrometri
healthi
control
dog
dm
statist
signific
set
p
ten
diabet
dog
healthi
control
enrol
fecal
microbi
divers
lower
dm
dog
compar
healthi
control
pca
base
unweight
unifrac
distanc
metric
reveal
signific
cluster
dog
group
howev
linear
discrimin
analysi
effect
size
lefs
detect
differenti
abund
bacteri
taxa
lda
score
gammaproteobacteria
overrepres
erysipelotrichia
clostridia
bacteroidia
underrepres
dm
dog
compar
healthi
control
p
total
primari
ba
increas
dm
dog
compar
healthi
control
p
lithochol
acid
decreas
p
dog
dm
result
indic
dog
dm
intestin
dysbiosi
associ
ba
alter
pattern
dysbiosi
alter
ba
composit
similar
seen
human
dm
investig
necessari
determin
whether
dysbiosi
caus
consequ
dm
whether
associ
poor
glycem
control
evalu
diagnost
util
ihc
clonal
test
diagnosi
ibd
lsa
cat
assess
level
agreement
eb
sampl
usi
lsi
determin
diagnost
util
procur
lsi
sampl
total
cat
ce
gastrointestin
sign
week
durat
retrospect
n
prospect
n
enrol
veterinari
specialti
hospit
san
diego
ca
cat
uge
lge
perform
eb
sampl
obtain
site
case
retrospect
prospect
review
singl
boardcertifi
pathologist
mra
categor
ibd
possibl
lsa
probabl
lsa
lsa
sampl
also
submit
ihc
clonal
test
previous
describ
base
stain
alon
cat
classifi
ibd
lsa
consider
ihc
clonal
cat
classifi
ibd
lsa
thirteen
case
diagnos
ibd
case
diagnos
possibl
lsa
probabl
lsa
base
stain
alon
subsequ
diagnos
lsa
addit
ihc
clonal
test
use
cohen
kappa
statist
k
agreement
usi
lsi
sampl
moder
k
base
stain
alon
also
moder
six
healthi
adult
research
beagl
subclin
giardia
spp
infect
c
cani
coinfect
administ
fpp
direct
manufactur
mouth
daili
day
fecal
sampl
collect
day
fpp
day
first
day
administr
day
day
start
administr
day
fecal
dna
extract
qpcr
assay
perform
assess
abund
total
bacteria
faecalibacterium
turicibact
e
coli
streptococcu
blautia
fusobacterium
c
hiranoni
calcul
previous
publish
dysbiosi
index
di
bacteri
group
di
compar
across
time
point
use
friedman
test
dunn
posttest
appropri
statist
signific
set
p
abund
fusobacterium
increas
day
p
otherwis
statist
signific
chang
di
abund
bacteri
group
treatment
fpp
addit
di
group
dog
similar
previous
evalu
healthi
dog
dog
transient
increas
di
result
di
pretreat
time
point
ce
group
compos
male
femal
median
age
year
minmax
year
signific
differ
age
sex
identifi
ce
ctrl
dog
serum
concentr
significantli
increas
ce
group
compar
ctrl
dog
result
group
shown
tabl
correl
found
age
sex
serum
cytokin
concentr
use
cutoff
valu
pgml
sensit
discrimin
ce
ctrl
dog
specif
use
cutoff
valu
pgml
sensit
specif
area
curv
tnf
respect
first
princip
compon
pca
explain
varianc
major
contributor
conclus
dog
ce
increas
concentr
unabl
identifi
significantli
alter
concentr
studi
need
assess
util
cytokin
diagnost
prognost
marker
dog
chronic
enteropathi
howev
impact
gi
motil
evalu
studi
assess
effect
metoclopramid
erythromycin
exenatid
gastric
empti
ge
gastric
motil
comparison
placebo
random
doubleblind
crossov
design
healthi
cat
administ
placebo
salin
po
sc
metoclopramid
mgkg
sc
erythromycin
mgkg
po
exenatid
kg
sc
consecut
day
follow
minimum
washout
period
cat
random
treatment
group
sonograph
assess
ge
perform
dorsal
recumb
minut
follow
solid
test
meal
daili
energi
requir
interv
thereaft
hour
mean
crosssect
area
transvers
imag
relax
antrum
obtain
time
point
express
percentag
maxim
antral
area
area
curv
auc
calcul
ge
time
get
determin
motil
index
mi
antral
contract
plot
time
mix
model
anova
cat
random
effect
treatment
fix
effect
use
assess
differ
fraction
get
mi
auc
treatment
posthoc
pairwis
comparison
examin
tukey
test
appropri
rate
ge
follow
metoclopramid
erythromycin
treatment
significantli
faster
compar
placebo
exenatid
statist
signific
differ
fraction
ge
get
follow
metoclopramid
erythromycin
treatment
compar
placebo
p
p
metoclopramid
erythromycin
respect
exenatid
sixti
dog
anesthet
elect
ovariectomi
evalu
ger
dog
identifi
ger
content
ph
includ
studi
esophag
phimped
cathet
milwauke
place
shortli
follow
anesthesia
use
endoscop
guidanc
cathet
tip
place
approxim
cm
cranial
lower
esophag
sphincter
ger
episod
defin
oral
progress
decreas
imped
decrement
ohm
preepisod
esophag
baselin
record
esophag
ph
remain
conclus
surgeri
esophag
lavag
perform
tap
water
ml
aliquot
instil
gastric
tube
care
suction
interv
minut
post
lavag
esophag
ph
still
anoth
aliquot
instil
suction
ph
pair
test
wilcoxon
match
pair
test
spearman
rank
correl
coeffici
use
analyz
parametr
nonparametr
data
dog
strongli
acid
ger
ph
dog
abl
neutral
esophag
lumen
ph
end
procedur
dog
increas
esophag
lumen
ger
ph
anesthesia
p
dog
neutral
esophag
lumen
ger
ph
esophag
lumen
ger
ph
end
procedur
esophag
lavag
tap
water
increas
lumen
ger
dog
p
volum
water
use
lavag
associ
chang
lumen
ger
ph
r
p
present
studi
show
first
time
dog
capabl
neutral
strongli
acid
ger
dog
unabl
clear
acid
ger
possibl
one
predispos
esophag
strictur
format
esophag
lumen
lavag
water
dog
strongli
acid
ph
increas
esophag
lumen
ger
ph
major
dog
suggest
esophag
lavag
might
benefici
prevent
ger
complic
jann
g
lyngbi
jillian
hain
univers
copenhagen
frederiksberg
c
hovedstaden
denmark
washington
state
univers
pullman
wa
usa
megaesophagu
high
mortal
rate
associ
difficulti
manag
patient
feed
current
evidencebas
guidelin
avail
determin
best
diet
consist
dog
aim
studi
compar
esophag
clearanc
time
ect
food
differ
consist
dog
congenit
idiopath
assess
esophag
contrast
videofluoroscopi
use
guid
manag
dog
improv
clinic
sign
qualiti
life
twentyon
dog
congenit
idiopath
includ
evalu
dog
place
bailey
chair
administ
barium
sulfat
oral
three
form
liquid
slurri
within
can
food
meatbal
amount
barium
food
determin
bodyweight
rest
energi
requir
contrast
videofluoroscopi
esophagu
obtain
baselin
everi
minut
minut
stop
sooner
esophag
content
clear
patient
receiv
specif
recommend
manag
base
ect
differ
diet
consist
frequenc
regurgit
presenc
esophag
reflux
decreas
gastric
motil
bodi
condit
score
follow
commun
perform
assess
complianc
respons
manag
chang
clearanc
observ
dog
fed
liquid
dog
fed
slurri
dog
fed
meatbal
signific
differ
p
group
ect
liquid
faster
compar
meatbal
slurri
signific
differ
ect
slurri
meatbal
median
percentag
esophag
clearanc
interquartil
rang
slurri
interquartil
rang
meatbal
hemorrhag
mucos
irregular
polypoid
lesion
intestin
lesion
includ
eros
hemorrhag
irregular
mucosa
mass
duodenum
jejunum
cat
chronic
enteropathi
frequent
undergo
endoscopi
assess
intestin
biopsi
use
histopatholog
immunohistochemistri
clonal
test
pcr
antigen
receptor
rearrang
parr
howev
pauciti
data
find
modal
cohort
healthi
cat
thu
aim
studi
describ
result
histopatholog
immunohistochemistri
parr
endoscop
deriv
duoden
biopsi
specimen
clinic
healthi
clientown
cat
twenti
clinic
healthi
clientown
cat
underw
gastroduodenoscopi
veterinari
medic
teach
hospit
texa
univers
anim
care
use
protocol
ca
tissu
specimen
collect
stomach
cat
duodenum
cat
evalu
accord
wsava
score
system
boardcertifi
pathologist
mra
blind
health
statu
cat
addit
sampl
evalu
routin
immunohistochemistri
clonal
test
without
disclosur
clinic
statu
cat
cat
median
age
year
minmax
year
bodi
weight
kg
minmax
kg
bodi
condit
score
minmax
sampl
qualiti
report
good
case
histolog
evalu
stomach
reveal
mean
gastric
score
mean
duoden
score
immunohistochemistri
duoden
sampl
reveal
epitheliotrop
andor
lamina
propria
infiltr
case
result
clonal
test
duoden
sampl
reveal
clonal
rearrang
cat
polyclon
rearrang
cat
cat
result
suggest
clonal
rearrang
polyclon
background
result
one
cat
report
consist
pseudoclon
due
low
quantiti
target
dna
interpret
small
cell
lymphoma
base
immunohistochemistri
clonal
test
reach
healthi
cat
one
addit
cat
result
interpret
emerg
small
cell
lymphoma
interpret
enter
given
cat
result
one
cat
deem
uninterpret
due
pseudoclon
conclus
intestin
biopsi
clinic
healthi
cat
commonli
show
abnorm
find
use
histopatholog
immunohistochemistri
clonal
test
without
appar
clinic
signific
sensit
clonal
test
report
high
result
impli
assess
specif
diagnost
modal
warrant
total
spot
identifi
differenti
express
chang
healthi
cat
cat
ibd
scl
p
eight
spot
also
differenti
express
cat
ibd
scl
p
lcmsm
identifi
protein
annexin
apolipoprotein
famili
malat
dehydrogenas
differenti
express
spot
result
show
differ
mucos
proteom
healthi
cat
cat
ibd
cat
scl
protein
might
hold
potenti
develop
minimallyinvas
biomark
differenti
ibd
scl
cat
chronic
enteropathi
studi
valid
find
warrant
essenti
amino
acid
tryptophan
degrad
product
eg
serotonin
import
regul
tcell
respons
within
intestin
well
intestin
motil
furthermor
bacteria
metabol
tryptophan
variou
indolederiv
also
serv
signal
molecul
activ
pathway
organ
system
eg
brain
liver
kidney
alter
tryptophan
metabol
associ
inflammatori
bowel
diseas
ibd
human
dietari
supplement
tryptophan
shown
antiinflammatori
effect
experiment
coliti
model
aim
studi
evalu
chang
tryptophanserotoninindol
pathway
dog
intestin
diseas
fecal
sampl
dog
idiopath
ibd
dog
acut
hemorrhag
diarrhea
ahd
collect
fecal
sampl
healthi
dog
includ
control
group
sampl
extract
use
methanolchloroform
target
analysi
tsq
alti
tripl
quadrupol
liquid
chromatographymass
spectrometri
chromatograph
peak
compar
standard
curv
quantif
adjust
initi
fecal
weight
follow
metabolit
measur
acetylcholin
anthranil
acid
indol
acid
acid
serotonin
tryptamin
tryptophan
tyramin
fecal
metabolit
compar
amongst
group
use
kruskalw
test
follow
dunn
multipl
comparison
test
signific
set
p
ahd
group
anthranil
acid
indol
acid
significantli
increas
respect
serotonin
tryptamin
decreas
respect
compar
healthi
control
fecal
tryptophan
increas
dog
ibd
signific
dog
ahd
p
compar
healthi
control
dog
signific
differ
fecal
metabolit
tryptophanserotoninindol
pathway
found
dog
ahd
compar
healthi
control
dog
studi
need
determin
clinic
implic
differ
thirteen
dog
diagnos
idiopath
ibd
previous
fail
respond
treatment
elimin
diet
metronidazol
enrol
stool
sampl
collect
dog
initi
therapi
prednison
week
one
year
begin
treatment
thirteen
healthi
dog
enrol
studi
control
group
stool
sampl
kept
frozen
c
dna
extract
microbiota
character
use
illumina
sequenc
rrna
gene
data
analyz
use
quantit
insight
microbi
ecolog
qiim
beta
divers
evalu
phylogeni
base
unweight
unifrac
distanc
metric
statist
perform
analysi
similar
anosim
ibd
group
clinic
diseas
sever
cibdai
baselin
score
moder
sever
dog
achiev
partial
complet
remiss
clinic
sign
week
treatment
cibdai
score
significantli
reduc
week
treatment
p
baselin
dog
ibd
show
differ
microbi
composit
compar
healthi
dog
unweight
unifrac
distanc
demonstr
significantli
differ
beta
divers
group
differ
ibd
group
includ
increas
firmicut
p
actinobacteria
reduc
bacteroidet
p
fusobacteria
p
proteobacteria
within
ibd
group
beta
divers
still
significantli
chang
week
p
compar
healthi
control
year
follow
divers
metric
place
microbiom
treat
dog
closer
healthi
dog
still
significantli
differ
healthi
control
result
suggest
treatment
effect
improv
clinic
sign
dysbiosi
associ
ibd
still
present
one
year
initi
immunosuppress
therapi
even
dog
clinic
well
control
observ
expect
ratio
dilut
parallel
rang
mean
intraassay
variabl
rang
mean
cv
sampl
machin
interassay
variabl
rang
mean
cv
sampl
machin
sampl
result
two
sampl
even
three
sampl
diagnost
bin
ie
within
refer
interv
gray
rang
suggest
pancreat
experi
new
vetscan
cpl
rapid
test
vetscan
vue
show
poor
linear
clinic
signific
work
rang
assay
narrow
make
dilut
necessari
sampl
higher
cpli
concentr
also
assay
precis
mean
cv
final
interassay
variabl
unaccept
high
mean
cv
affect
actual
diagnost
bin
mani
case
conclus
vetscan
cpl
rapid
test
vetscan
vue
lack
linear
precis
reproduc
rang
overcondit
median
rang
sixtyon
dog
document
weight
loss
time
diagnosi
sever
moder
mild
loss
two
dog
lost
followup
dog
die
euthan
follow
treatment
failur
signific
effect
bodi
condit
score
percentag
weight
loss
bodi
weight
appetit
serum
albumin
cholesterol
cobalamin
folat
concentr
canin
chronic
enteropathi
activ
index
durat
sign
mortal
p
howev
dog
higher
calor
intak
diagnosi
increas
number
day
death
euthanasia
follow
treatment
failur
p
correl
coeffici
paramet
associ
malnutrit
time
diagnosi
ple
due
ce
lymphangiectasia
dog
studi
predictor
mortal
follow
treatment
failur
therefor
use
predict
respons
treatment
howev
altern
measur
malnutrit
may
requir
definit
investig
role
malnutrit
prognosi
canin
ple
total
ffa
concentr
baselin
significantli
increas
dog
ce
rel
healthi
dog
p
healthi
canin
ffa
refer
interv
found
mgmg
dog
ce
increas
ffa
median
sd
minmax
mgmg
p
ffa
concentr
dog
one
month
treatment
significantli
decreas
mgmg
p
longer
statist
differ
healthi
dog
p
longer
exceed
healthi
dog
refer
interv
therefor
analysi
granulomat
gastriti
md
perform
median
age
month
rang
month
male
castrat
femal
spay
dog
six
dog
histori
sutureassoci
granuloma
surgic
resect
month
prior
inclus
studi
fever
commonli
observ
median
c
rang
c
elev
serum
creactiv
protein
mgdl
observ
dog
median
mgdl
rang
mgdl
histopatholog
examin
foreign
materi
detect
case
four
dog
initi
underw
pyloroplasti
gastroduodenostomi
resect
granuloma
subsequ
receiv
immunosuppress
therapi
within
month
surgeri
due
recurr
lesion
n
base
veterinarian
decis
n
dog
initi
treat
immunosuppress
drug
result
dog
receiv
immunosuppress
therapi
prednisolon
mgkg
day
andor
cyclosporin
mgkgday
initi
immunosuppress
clinic
sign
resolv
serum
creactiv
protein
concentr
decreas
refer
rang
dog
within
month
nine
dog
show
recurr
lesion
prednisolon
taper
median
durat
initi
immunosuppress
day
rang
day
respond
well
reinduct
immunosuppress
higherdos
prednisolon
mgkgday
addit
cyclosporin
azathioprin
median
followup
period
day
rang
day
dog
die
day
initi
present
caus
death
aspir
pneumonia
n
hepat
tumor
n
conclus
immunosuppress
therapi
effect
manag
granulomat
gastriti
md
prevent
vomit
ie
aspir
pneumonia
may
import
ensur
good
prognosi
describ
previou
studi
granulomat
gastriti
like
occur
md
histori
sutureassoci
granuloma
seem
risk
factor
howev
sever
case
dog
never
undergon
surgeri
futur
studi
innat
immun
system
dog
case
warrant
hirotaka
igarashi
keisuk
konishi
eri
uchida
takashi
tamamoto
express
level
test
gene
except
significantli
upregul
polypoid
lesion
rate
increas
express
gene
compar
rate
increas
significantli
higher
wherea
rate
increas
significantli
lower
number
treg
polypoid
lesion
significantli
increas
compar
noninflam
colon
mucosa
icrpaffect
md
control
dog
number
macrophag
significantli
differ
group
signific
posit
correl
express
level
gene
gene
r
p
addit
signific
posit
correl
observ
express
level
gene
number
treg
r
p
summari
upregul
significantli
correl
distribut
treg
polypoid
lesion
icrpaffect
md
howev
rate
increas
express
level
rel
low
compar
proinflammatori
cytokin
therefor
increas
number
treg
antiinflammatori
cytokin
polypoid
lesion
consid
reactiv
chang
insuffici
regul
develop
inflamm
analysi
associ
treg
distribut
lesion
prognosi
includ
respons
immunosuppress
therapi
warrantedno
affect
dog
hous
singl
shelter
design
approv
shelter
clinic
review
board
fecal
score
determin
train
observ
mask
diet
group
sampl
compar
standard
score
sheet
stool
hard
dri
firm
hard
normal
littl
segment
moist
moist
log
shape
moist
pile
textur
defin
shape
wateri
puddl
qualifi
studi
dog
present
fecal
score
hematochezia
mucu
strain
dog
random
fed
diet
administ
fenbendazol
mgkg
po
daili
day
metronidazol
mgkg
po
twice
daili
day
dog
studi
least
day
includ
data
analysi
proport
dog
fecal
score
less
day
adopt
last
studi
day
day
proport
stool
group
fecal
score
greater
compar
fisher
exact
test
signific
defin
p
total
dog
enter
pilot
studi
dog
per
diet
complet
protocol
date
dog
fed
high
fiber
diet
fecal
score
less
last
day
studi
statist
differ
dog
fed
control
diet
total
fecal
sampl
dog
acut
diarrhea
treat
either
fmt
g
donor
stoolkg
dilut
cc
salin
via
enema
n
metronidazol
mtz
po
bid
day
n
collect
week
week
intervent
fecal
dna
evalu
quantit
pcr
qpcr
analysi
select
bacteri
group
total
bacteria
faecalibacterium
spp
turicibact
spp
streptococcu
spp
e
coli
blautia
spp
fusobacterium
spp
c
hiranoni
result
use
calcul
dysbiosi
index
di
fece
evalu
use
fecal
score
system
nestl
purina
fecal
score
system
di
fecal
score
compar
group
use
wilcoxon
ranksum
test
presenc
dysbiosi
di
compar
group
use
fisher
exact
test
p
consid
statist
signific
fecal
score
differ
significantli
group
either
p
p
respect
fmt
group
significantli
lower
fecal
score
mtz
group
p
di
differ
significantli
two
group
p
fmt
group
significantli
lower
di
mtz
group
p
p
respect
recoveri
dysbiosi
also
evalu
fmt
group
significantli
lower
rate
dysbiosi
fatload
result
significantli
longer
gastric
transit
time
compar
control
p
also
gastric
retent
capsul
occur
significantli
commonli
dog
fed
either
corn
oil
dairi
cream
p
fatload
studi
result
gastric
retent
capsul
hour
none
control
studi
gastric
retent
addit
gastric
retent
occur
significantli
often
dog
fed
corn
oil
dairi
cream
p
though
gastric
retent
limit
number
case
visual
assess
small
intestin
mucosa
could
perform
fatload
studi
subject
judg
moder
mark
promin
villi
increas
number
dilat
lacteal
compar
control
studi
small
intestin
wall
thick
differ
significantli
control
fatload
dog
howev
mucos
speckl
score
jejunum
significantli
greater
dog
fed
cream
oil
control
dog
p
though
fatload
might
increas
promin
duoden
villi
gastric
transit
time
significantli
prolong
result
inabl
capsul
endoscopi
visual
assess
small
intestin
half
case
studi
futur
studi
investig
fatload
techniqu
includ
use
tradit
push
endoscopi
overcom
limit
allow
consist
assess
intestin
mucos
appear
immunoloc
associ
helicobact
spp
colon
canin
gastric
mucosa
rafael
r
departamento
de
salud
anim
universidad
de
calda
manizal
manizal
calda
colombia
novel
inflammatori
marker
evalu
human
anim
increas
concentr
gastric
mucosa
human
helicobact
pylori
infect
previous
report
gastric
mucosa
dog
frequent
colon
sever
helicobact
speci
howev
poor
associ
helicobact
organ
densiti
mucos
inflamm
purpos
studi
evalu
gastric
tissu
local
immunohistochemistri
ihc
dog
determin
correl
densiti
helicobact
organ
contain
cell
lamina
propria
dog
gastric
diseas
healthi
control
dog
local
posit
cell
helicobact
organ
studi
use
paraffinembed
gastric
biopsi
dog
chronic
gastriti
healthi
control
dog
obtain
postmortem
patient
present
emerg
servic
veterinari
teach
hospit
texa
univers
none
gross
histopatholog
lesion
suggest
gastrointestin
diseas
research
dog
universidad
de
calda
dog
receiv
antibiot
corticosteroid
treatment
last
two
week
prior
collect
gastric
biopsi
ihc
perform
use
antibodi
direct
canin
helicobact
spp
respect
stain
lamina
propria
quantifi
classifi
absent
mild
moder
sever
helicobact
densiti
grade
use
similar
criteria
histopatholog
evalu
conduct
follow
world
small
anim
veterinari
associ
wsava
grade
scheme
spearman
rank
correl
use
evalu
possibl
associ
helicobact
densiti
histopatholog
find
mannwhitney
u
test
use
compar
ordin
variabl
healthi
sick
dog
immunoglobulin
ig
bind
gut
bacteria
like
activ
immun
respons
local
system
howev
never
investig
dog
ibd
yet
therefor
studi
investig
whether
humor
immun
respons
commens
gut
bacteria
ibd
greater
healthi
dog
addit
whether
igbind
bacteria
potenti
trigger
exacerb
immun
respons
aggrav
gut
homeostasi
fresh
fecal
materi
collect
ibd
dog
clinic
healthi
dog
mean
age
sd
year
respect
patient
diagnost
confirm
endoscop
biopsi
histori
receiv
immunosuppress
medic
work
compar
amount
fecal
bacteria
bind
igg
iga
vivo
ibd
healthi
canin
flow
cytometr
analysi
addit
extent
macrophag
phagocytosi
macrophag
activ
fecal
bacteria
deriv
ibd
vs
healthi
dog
investig
flow
cytometr
analysi
elisa
comparison
group
evalu
use
ttest
statist
signific
set
p
level
found
fecal
bacteria
ibd
dog
alreadi
bound
iga
igg
subclass
ig
significantli
higher
level
extens
bacteria
normal
dog
iga
p
igg
p
interestingli
correl
igbound
bacteria
degre
score
index
canin
ibd
activ
index
cibdai
mean
sd
r
canin
chronic
enteropathi
clinic
activ
index
ccecai
r
moreov
result
suggest
igg
bound
gut
bacteria
mainli
deriv
local
mucos
immun
activ
system
sinc
serum
incub
e
coli
isol
differ
ibd
healthi
anim
addit
compar
bacteria
normal
control
anim
ibd
fecal
bacteria
significantli
stimul
higher
level
phagocytosi
canin
primari
macrophag
p
well
cell
canin
macrophag
tumor
cell
line
p
upregul
surfac
activ
marker
mhc
ii
respons
group
compar
phagocytosi
ibd
gut
bacteria
activ
macrophag
stimul
higher
product
normal
gut
bacteria
p
contrast
product
primari
macrophag
incub
ibd
fecal
bacteria
significantli
decreas
compar
normal
flora
healthi
dog
p
overal
result
show
ibd
dog
higher
igbound
fecal
fecal
sampl
obtain
healthi
dog
n
dog
acut
diarrhea
n
dna
extract
analysi
major
bacteri
group
qpcr
target
ga
chromatographymass
spectrometri
assay
use
quantifi
fatti
acid
sterol
bile
acid
concentr
fece
dysbiosi
index
calcul
base
abund
major
bacteri
taxa
di
refer
limit
valu
indic
dysbiosi
statist
analysi
perform
use
mann
whitney
test
signific
set
p
fecal
concentr
stearic
acid
p
arachidon
acid
p
nervon
acid
p
increas
dog
acut
diarrhea
compar
healthi
dog
cholesterol
p
concentr
increas
coprostanol
p
campesterol
p
stigmasterol
p
fucosterol
p
p
sitostanol
p
concentr
decreas
dog
acut
diarrhea
ratio
secondari
bile
acid
total
bile
acid
concentr
decreas
dog
acut
diarrhea
p
dysbiosi
index
significantli
increas
dog
acut
diarrhea
p
compar
healthi
dog
conclus
result
suggest
numer
metabol
chang
occur
concurr
alter
microbiota
dog
acut
diarrhea
fecal
metabolit
pattern
dog
acut
diarrhea
resembl
found
human
bile
acid
fatti
acid
diarrhea
human
mice
pig
paneth
cell
locat
crypt
close
intesti
present
studi
perform
target
resequenc
two
mb
region
includ
newli
identifi
candid
gene
use
customdesign
sequenc
captur
array
selectsur
xt
custom
mb
agil
brief
hybrid
dna
librari
prepar
use
selectsur
xt
librari
prep
kit
agil
follow
manufactur
instruct
target
region
upand
downstream
signific
snp
captur
use
customdesign
sequenc
captur
array
selectsur
xt
custom
mb
agil
subsequ
captur
librari
index
subject
dna
sequenc
illumina
platform
follow
alignmentmap
canin
genom
haplotypecal
use
call
variant
follow
hardfilt
extract
snp
indel
recommend
gatk
best
practic
snp
annot
use
snpeff
variant
effect
predict
vep
tool
variant
divid
differ
group
base
genom
coordin
snp
present
case
diagnos
ibd
control
well
overlap
snp
differ
altern
allel
case
vs
control
group
investig
control
group
known
missens
snp
identifi
exon
gene
identifi
associ
ibd
use
approach
snp
present
con
case
group
found
one
missens
snp
moder
impact
deleteri
base
sift
score
one
splice
region
low
impact
case
sequenc
seventeen
snp
known
new
one
identifi
within
upstream
gene
tss
coordin
snp
known
new
one
downstream
two
snp
modifi
impact
locat
within
upstream
hematopoet
cytokin
drive
develop
myeloid
stem
cell
previous
identifi
associ
ibd
approach
use
enrich
list
gene
involv
human
ibd
two
snp
found
downstream
pdlim
protein
cysteinerich
doubl
zinc
finger
involv
proteinprotein
interact
cytoskelet
organis
involv
ige
synthesi
chitinas
upregul
hyperrespons
mucos
surfac
one
new
snp
found
downstream
interestingli
gene
also
associ
higher
risk
develop
human
ibd
summari
identifi
sever
snp
gene
canin
pdlim
base
known
function
correspond
protein
insight
pathogenesi
ibd
gsd
medic
record
cat
receiv
rbc
transfus
andor
major
crossmatch
januari
decemb
review
retrospect
inform
record
includ
previou
transfus
histori
major
minor
crossmatch
result
tube
method
volum
prbc
administ
preand
posttransfus
pcv
advers
event
patient
outcom
cat
crossmatch
perform
use
gel
tube
method
comparison
rbc
compat
data
avail
transfus
cat
show
degre
incompat
hemagglutin
major
crossmatch
donor
cat
previous
transfus
cat
incompat
hemagglutin
major
crossmatch
donor
significantli
transfus
group
p
pack
rbc
transfus
administ
cat
tube
crossmatch
perform
cat
prior
first
prbc
transfus
remain
cat
receiv
typecompat
noncrossmatch
prbc
median
volum
prbc
administ
first
transfus
mlkg
rang
median
increas
pcv
posttransfus
cat
receiv
crossmatchcompat
prbc
greater
increas
compar
without
crossmatch
febril
transfus
reaction
occur
often
cat
receiv
type
noncrossmatch
prbc
n
cat
administ
crossmatchcompat
prbc
n
p
cat
receiv
prbc
transfus
surviv
hospit
discharg
pretransfus
crossmatch
associ
improv
surviv
discharg
day
posttransfus
crossmatch
perform
use
tube
gel
method
cat
total
crossmatch
recipi
cat
crossmatch
agreement
result
tube
gel
method
except
cat
major
incompat
donor
tube
gel
method
respect
like
result
subject
grade
differ
result
observ
cat
neg
tube
mix
field
agglutin
gel
result
autocontrol
major
crossmatch
test
donor
attribut
mark
rouleaux
microscop
evalu
salin
replac
tube
crossmatch
support
interpret
rouleaux
rather
hemagglutin
rbc
incompat
note
transfus
cat
suggest
preval
natur
occur
nonab
rbc
alloantibodi
suffici
high
justifi
recommend
perform
blood
crossmatch
prior
includ
first
rbc
transfus
cat
use
highdos
igmenrich
human
immunoglobulin
canin
immunemedi
hemolyt
anemia
dog
diagnos
primari
imha
uk
specialti
hospit
prospect
enrol
dog
receiv
prednisolon
dexamethason
alongsid
clopidogrel
patient
random
receiv
pentaglobin
two
occas
control
group
addit
immunosuppress
drug
allow
within
first
day
treatment
support
treatment
given
discret
attend
clinician
remiss
defin
stabl
pcv
hour
ten
dog
treatment
group
dog
control
group
achiev
remiss
surviv
hospit
discharg
surviv
time
remiss
significantli
differ
group
volum
pack
red
blood
cell
transfus
normal
bodi
weight
significantli
differ
group
potenti
advers
reaction
pentaglobin
occur
two
patient
clinic
sign
may
relat
patient
underli
diseas
treatment
highdos
pentaglobin
well
toler
patient
signific
advantag
found
small
studi
larger
studi
warrant
identifi
potenti
benefit
test
end
week
rotat
immedi
follow
pretest
treatment
group
receiv
learn
modul
modul
satisfact
survey
survey
ask
student
rate
level
agreement
statement
scale
strongli
disagre
agre
student
ask
complet
option
retent
test
compos
question
pre
posttest
month
later
total
student
complet
pre
posttest
includ
studi
student
treatment
group
receiv
modul
control
group
thirtythre
student
also
complet
retent
test
treatment
group
control
group
student
treatment
group
score
significantli
higher
posttest
p
retent
test
p
student
receiv
learn
modul
mean
post
test
score
mean
retent
test
score
treatment
control
group
respect
nineteen
student
treatment
group
complet
satisfact
survey
student
take
survey
indic
modul
easi
use
mean
inform
present
clear
manner
mean
student
agre
modul
good
use
educ
time
mean
conclus
transfus
reaction
instruct
modul
deliv
analyz
ph
less
ph
measur
standard
ph
meter
unit
evalu
swirl
evid
visual
clump
platelet
size
distribut
evalu
flow
cytometri
apheresi
protocol
manag
without
advers
reaction
donor
immedi
post
apheresi
count
confirm
consist
harvest
x
x
devic
red
blood
cell
contamin
less
x
ul
white
blood
cell
count
less
x
platelet
prepar
haemonet
techniqu
decreas
ph
increas
lactat
compar
platelet
prepar
terumo
techniqu
howev
differ
statist
signific
flow
cytometr
evalu
suggest
higher
popul
platelet
micron
size
rang
concentr
prepar
haemonet
techniqu
signific
differ
techniqu
use
standard
methodolog
evalu
techniqu
provid
platelet
concentr
met
accept
criteria
standard
apheresi
unit
maria
lyraki
miss
alic
sloan
ian
ramsey
small
anim
hospit
univers
glasgow
langford
bristol
england
unit
kingdom
small
anim
hospit
univers
glasgow
glasgow
scotland
unit
kingdom
evalu
ear
prick
sampl
possibl
altern
venou
sampl
use
pointofcar
poc
meter
assess
haemoglobin
hb
haematocrit
hct
dog
simultan
venou
ear
prick
blood
sampl
collect
dog
consid
anaem
n
nonanaem
n
polycythaem
n
undergo
blood
sampl
part
clinic
investig
hb
hct
measur
sampl
use
poc
meter
requir
microlit
sampl
volum
previous
valid
hospit
shown
correl
r
standard
laboratori
analys
coeffici
variat
less
hb
hct
measur
also
obtain
venou
sampl
use
one
two
refer
analyz
dog
pearson
correl
coeffici
calcul
two
set
poc
result
bia
calcul
express
mean
standard
deviat
agreement
previou
studi
poc
result
hb
hct
venou
sampl
significantli
correl
laboratori
analys
respect
result
hb
hct
ear
prick
sampl
measur
use
poc
devic
significantli
correl
poc
result
venou
sampl
r
calcul
bias
hb
hct
respect
consist
small
degre
peripher
haemoconcentr
howev
sampl
peripher
sampl
differ
venou
sampl
differ
could
clinic
signific
see
figur
measur
hb
hct
use
simpl
ear
prick
test
poc
meter
requir
small
sampl
volum
may
use
altern
convent
venou
blood
sampl
evalu
paramet
dog
howev
small
posit
bia
clinic
signific
variat
pt
teg
analysi
four
activ
rapidteg
tissu
factor
tissu
factor
kaolin
compar
spearman
correl
coeffici
calcul
ratio
peak
baselin
pt
peak
reaction
time
r
teg
baselin
r
teg
antixa
concentr
oral
rivaroxaban
administr
exhibit
predict
anticoagul
effect
well
toler
healthi
dog
clinic
figur
blandaltman
plot
compar
averag
hb
concentr
gdl
differ
hb
concentr
measur
use
venou
peripher
blood
sign
minor
major
hemorrhag
gastrointestin
side
effect
dose
group
highest
antixa
valu
longest
delay
r
teg
pt
observ
h
administr
rivaroxaban
howev
anticoagul
effect
teg
plasma
rivaroxaban
concentr
decreas
significantli
h
administr
interindividu
differ
drug
effect
observ
expect
experi
monitor
anticoagul
effect
perform
result
show
antixa
concentr
pointofcar
pt
ratio
strongli
correl
r
p
r
ratio
rapidtegteg
show
signific
correl
rivaroxaban
concentr
measur
use
antixa
assay
r
p
r
p
r
p
respect
fibrinogen
due
wide
interindividu
variat
plasma
fviii
vwf
level
among
healthi
dog
concern
uniform
standard
potenc
cryo
treat
dog
hemophilia
vwd
greyhound
commonli
use
blood
donor
previou
studi
document
lower
plasma
vwf
fibrinogen
content
greyhound
compar
nongreyhound
greyhound
plasma
therefor
may
yield
high
potenc
cryo
object
studi
determin
plasma
hemostat
protein
content
good
predictor
cryo
potenc
differ
qualiti
cryo
prepar
greyhound
versu
nongreyhound
canin
cryo
produc
protocol
meet
human
blood
bank
standard
ml
unit
blood
collect
greyhound
nongreyhound
enrol
blood
donor
program
cryo
prepar
fresh
frozen
plasma
ffp
use
standard
method
blood
compon
volum
record
aliquot
ffp
cryo
unit
analyz
fviii
vwf
fibrinogen
content
recoveri
percentag
total
factor
content
ffp
retain
cryo
unit
calcul
factor
posit
correl
fviii
vwf
fibrinogen
concentr
ffp
respect
factor
content
cryo
p
median
recoveri
greatest
vwf
follow
fibrinogen
fviii
differ
greyhound
nongreyhound
differ
median
fviii
iuunit
vwf
iuunit
content
cryo
unit
compar
greyhound
nongreyhound
respect
howev
median
fibrinogen
content
cryo
less
greyhound
mgunit
compar
nongreyhound
mgunit
p
nevertheless
differ
greyhound
nongreyhound
number
cryo
unit
meet
human
blood
bank
standard
hemostat
protein
vwf
greyhound
nongreyhound
cryo
vwfdefici
doberman
meet
standard
fibrinogen
greyhound
nongreyhound
fviii
greyhound
nongreyhound
conclus
factor
content
donor
ffp
strongli
associ
cryo
potenc
suggest
prescreen
blood
donor
may
enhanc
cryo
qualiti
cryo
prepar
greyhound
inferior
breed
justifi
use
plasma
retrospect
studi
includ
follow
dog
sir
healthi
chronic
diseas
sir
grade
base
mani
criteria
fulfil
appl
fast
score
alloc
sir
dog
mortal
rate
assess
day
admiss
hemolyt
hemorrhag
disord
exclud
sir
grade
appl
fast
score
group
compar
outcom
type
anemia
nrbc
count
evalu
three
studi
popul
outcom
appl
fast
score
p
sir
grade
p
associ
poor
outcom
sir
group
anemia
present
dog
frequent
type
anemia
mild
moder
microcyt
normocyt
normochrom
anemia
sever
associ
poor
outcom
p
sir
group
show
wors
anemia
pattern
two
group
p
presenc
nrbc
occur
sir
dog
associ
poor
outcom
p
nrbc
count
significantli
higher
sir
group
healthi
dog
p
mildmoder
micronormocyt
normochrom
anemia
frequent
find
canin
sir
result
suggest
circul
nrbc
amount
could
addit
neg
prognost
valu
delay
relaps
remiss
period
day
taper
rate
prednisolon
significantli
higher
acut
relaps
episod
delay
relaps
nonrelaps
episod
respect
result
suggest
rapid
decreas
prednisolon
dosag
caus
earli
recurr
pimt
sarah
shropshir
christin
olver
colorado
state
univers
fort
collin
co
usa
greyhound
sever
hematolog
differ
breed
dog
includ
higher
hematocrit
hemoglobin
concentr
lower
neutrophil
platelet
count
also
observ
greyhound
propens
bleed
excess
hour
follow
minor
trauma
routin
surgeri
exact
etiolog
behind
bleed
unknown
howev
sever
studi
postul
may
occur
due
hyperfibrinolysi
dynam
viscoelast
test
use
thromboelastographi
teg
allow
assess
coagul
also
fibrinolysi
teg
perform
previous
greyhound
studi
investig
fibrinolysi
variabl
via
teg
presenc
tissu
plasminogen
activ
tpa
healthi
greyhound
therefor
purpos
studi
evalu
greyhound
appear
hyperfibrinolyt
compar
nongreyhound
tissu
factoractiv
teg
tpa
ad
tf
tpateg
perform
six
healthi
clientown
greyhound
six
healthi
laboratori
beagl
tf
tpateg
reaction
time
r
clot
time
mrtg
tg
platelet
count
fibrinogen
significantli
lower
k
hematocrit
significantli
higher
greyhound
statist
differ
r
tmrtg
mrl
tmrl
clt
group
note
previou
studi
greyhound
higher
hematocrit
lower
platelet
count
compar
nongreyhound
greyhound
appear
significantli
hypocoagul
increas
k
decreas
mrtg
tg
appear
hyperfibrinolyt
compar
nongreyhound
possibl
hyperfibrinolysi
greyhound
may
relat
respons
tpa
hyperfibrinolysi
detect
via
tf
tpateg
preoper
set
use
predict
bleed
addit
studi
warrant
investig
mechan
bleed
appreci
breed
sarah
shropshir
christin
olver
colorado
state
univers
fort
collin
co
usa
whole
blood
imped
platelet
aggregometri
perform
sever
differ
agonist
evalu
platelet
function
although
manufactur
recommend
dispos
store
reagent
month
viabil
reconstitut
reagent
differ
storag
condit
unknown
reagent
viabil
stabl
long
period
time
assay
cost
could
decreas
dramat
therefor
purpos
studi
determin
viabil
reconstitut
arachidon
acid
aa
adenosin
diphosph
adp
platelet
agonist
store
two
condit
month
aliquot
reconstitut
aa
adp
store
c
c
monthli
six
month
six
healthi
staffown
dog
enrol
studi
physic
examin
complet
blood
count
cbc
diagnost
panel
urinalysi
perform
enrol
dog
platelet
aggregometri
perform
dog
use
fresh
store
aliquot
aa
adp
reagent
day
area
curv
auc
record
platelet
aggregometri
analysi
repeat
measur
rm
analysi
oneway
anova
perform
subsequ
time
point
month
compar
fresh
auc
result
dog
appear
clinic
healthi
cbc
diagnost
panel
urinalysi
normal
differ
auc
obtain
fresh
sampl
time
point
either
temperatur
aa
adp
dog
whole
blood
imped
platelet
aggregometri
reagent
aa
adp
viabl
six
month
store
c
c
conclud
reagent
store
month
obviat
need
discard
viabl
reagent
decreas
assay
cost
object
studi
measur
cytokinechemokin
concentr
lr
ir
canin
store
whole
blood
red
blood
cell
rbc
storag
lesion
caus
irradi
lr
compar
blood
sampl
obtain
healthi
beagl
dog
collect
blood
sampl
divid
four
group
sampl
treatment
lr
ir
lr
ir
leukocyt
remov
filtrat
lr
group
gamma
radiat
appli
ir
group
immunolog
factor
wbc
cxc
motif
chemokin
ligand
tumor
necrosi
factoralpha
storag
lesion
factor
blood
ph
potassium
hemolysi
evalu
day
aliquot
group
concentr
control
treatment
store
whole
blood
significantli
higher
storag
indic
high
probabl
transfus
reaction
fnhtr
hand
lr
group
show
chang
cytokinechemokin
concentr
storag
lesion
rel
mild
compar
group
irradi
significantli
increas
day
storag
irradi
leukoreduc
blood
increas
day
storag
howev
storag
lesion
hemolysi
increas
potassium
low
ph
observ
day
ir
blood
regardless
lr
conclus
lr
benefici
prevent
transfus
reaction
storag
lesion
howev
ir
canin
whole
blood
suitabl
longterm
storag
increas
factor
storag
lesion
ir
leukoreduc
blood
benefici
avoid
immun
reaction
howev
storag
lesion
consid
upon
storag
result
studi
identifi
major
normal
diseas
dog
harbor
rich
divers
bile
microbiom
microbiota
like
contain
previous
unrecogn
benefici
well
deleteri
bacteria
tailor
bile
cultur
media
routin
identifi
bacteria
like
improv
understand
diagnosi
canin
hepatobiliari
diseas
object
studi
determin
whether
increas
potenti
biomark
associ
moder
sever
fibrosi
necroinflammatori
activ
dog
variou
hepatopathi
fortyfour
clientown
dog
clinic
evid
liver
diseas
healthi
purposebr
dog
enrol
undergo
liver
biopsi
laparoscopi
laparotomi
serum
crp
ast
alt
measur
within
one
week
schedul
liver
biopsi
liver
histopatholog
evalu
use
metavir
score
system
use
human
medicin
blind
clinic
present
median
serum
approxim
twice
high
dog
high
fibrosi
score
pgml
rang
pgml
compar
dog
low
fibrosi
score
pgml
rang
pgml
margin
signific
p
median
serum
significantli
higher
dog
activ
necroinflamm
pgml
rang
pgml
compar
dog
without
detect
necroinflamm
pgml
rang
pgml
p
consider
overlap
group
neither
serum
crp
ast
alt
ratio
significantli
differ
base
fibrosi
necroinflammatori
score
descript
statist
use
analyz
categor
variabl
age
gender
breed
side
effect
cy
continu
variabl
cy
dose
time
remiss
alt
concentr
mean
median
rang
standard
deviat
calcul
continu
data
wilcoxon
student
ttest
fisher
exact
test
surviv
analysi
use
evalu
impact
prognost
factor
pretreat
clinic
score
hypoalbuminemia
hyperbilirubinemia
ascit
fibrosi
histopatholog
prolong
ptaptt
remiss
twentyf
differ
breed
repres
age
rang
year
median
year
fiftytwo
percent
femal
spay
male
castrat
common
treatment
sideeffect
gastrointestin
sign
rang
mild
inappet
vomit
diarrhea
gingiv
hyperplasia
seventi
six
percent
achiev
remiss
median
time
remiss
month
month
median
dose
time
remiss
mgkg
day
mgkgday
associ
found
prognost
factor
remiss
except
hypoalbuminemia
increas
likelihood
remiss
p
decreas
time
remiss
dog
hypoalbuminemia
p
conclus
cy
therapi
toler
effect
achiev
normal
alt
dog
presum
immun
mediat
ch
previous
report
prognost
factor
neg
impact
abil
achiev
alt
normal
cy
therapi
lesli
kibler
cailin
heinz
cynthia
webster
cum
school
veterinari
medicin
tuft
univers
north
grafton
usa
liver
perform
essenti
role
metabol
vitamin
vd
defici
vitamin
k
anoth
fatsolubl
vitamin
common
cat
cholestat
hepatobiliari
diseas
chd
hypothes
vd
level
cat
chd
would
significantli
lower
normal
cat
sick
cat
nonhepatobiliari
disord
prospect
case
control
studi
done
compar
cat
chd
diseas
defin
hyperbilirubinemia
increas
alanin
aminotransferas
sick
cat
without
hepatobiliari
diseas
normal
cat
repr
sixtynin
studi
includ
seven
confer
abstract
report
periop
andor
clinic
andor
surgicalintervent
outcom
dog
manag
one
surgicalintervent
techniqu
andor
medic
manag
cehpss
identifi
studi
design
prospect
studi
includ
one
nonblind
random
control
clinic
trial
one
nonblind
nonrandom
control
clinic
trial
uncontrol
clinic
trial
major
studi
show
overal
high
risk
bia
evalu
low
low
number
case
per
treatment
group
clearli
character
subject
enrol
criteria
direct
comparison
ameroid
constrictor
versu
thin
film
band
reveal
statist
signific
differ
two
techniqu
regard
surgic
outcom
ameroid
constrictor
superior
direct
comparison
also
suggest
ameroid
constrictor
placement
might
better
periop
clinic
surgicalintervent
outcom
ligat
howev
none
comparison
statist
signific
direct
comparison
techniqu
possibl
due
lack
data
indirect
comparison
suggest
ameroid
constrictor
placement
complet
ligat
techniqu
better
periop
clinic
surgic
intervent
outcom
follow
thin
film
band
coil
embol
partial
ligat
outcom
assess
amplatz
vascular
plug
medic
manag
base
small
number
case
allow
accur
interpret
conclus
combin
systemat
review
metaanalysi
provid
object
evalu
treatment
option
cehpss
ameroid
constrictor
shown
techniqu
higher
likelihood
provid
good
outcom
complet
ligat
thin
film
band
coil
embol
partial
ligat
shown
effect
techniqu
treatment
cehpss
although
less
ameroid
constrictor
blind
random
studi
low
overal
risk
bia
good
number
case
compar
differ
treatment
modal
routin
includ
postop
imag
assess
cehpss
closur
andor
acquir
portosystem
shunt
develop
essenti
four
dog
two
cat
tent
diagnos
infect
ehbdo
enrol
studi
upc
perform
cholecystocentesi
remov
bile
decompress
gallbladd
cytolog
culturesensit
less
ml
iodixanol
inject
gallbladd
ventrodors
left
obliqu
ventrodors
left
later
right
later
project
abdomen
made
minut
upc
everi
minut
first
hour
everi
minut
contrast
medium
note
duodenum
patient
cbd
dilat
mm
diamet
contrast
note
duodenum
five
patient
one
dog
diagnos
complet
obstruct
cbd
given
contrast
duodenum
hour
upc
rest
diagnos
cbd
dilat
gallbladd
delay
empti
time
upc
minut
upc
feasibl
techniqu
patient
dilat
cbd
use
confirm
complet
obstruct
cbd
base
studi
term
extrahepat
bile
duct
diseas
use
instead
ehbdo
diagnost
upc
rommaneeya
leelaarporn
hiroshi
ohta
noriyuki
nagata
kazuyoshi
sasaoka
tatsuyuki
osuga
keitaro
morishita
noboru
sasaki
kensuk
nakamura
mitsuyoshi
takiguchi
may
retrospect
review
examin
breed
age
sex
predisposit
hcc
case
came
huvth
studi
period
use
refer
popul
possibl
relat
factor
includ
clinicopatholog
find
concurr
disord
hcc
determin
comparison
two
breedand
age
match
control
dog
hcc
case
preval
histolog
confirm
hcc
case
dog
diagnos
hcc
significantli
older
median
year
rang
year
p
refer
popul
median
year
rang
year
welsh
corgi
significantli
predispos
hcc
odd
ratio
ci
p
breedand
age
match
case
control
analysi
reveal
thrombocytosi
case
increas
alt
case
increas
alp
case
hypercalcemia
case
significantli
associ
hcc
addit
dog
hcc
least
one
concurr
disord
common
concurr
disord
hyperadrenocortic
dog
odd
hyperadrenocortic
dog
hcc
time
control
cl
p
find
indic
age
increas
risk
develop
hcc
welsh
corgi
predispos
hcc
addit
signific
associ
hcc
hyperadrenocortic
present
suggest
hyperadrenocortic
might
play
role
develop
hcc
dog
lyme
diseas
endem
part
north
america
emerg
diseas
other
although
tick
prevent
avail
vaccin
increasingli
common
though
controversi
method
use
prevent
canin
lyme
infect
report
efficaci
canin
lyme
vaccin
highli
variabl
rang
object
research
follow
determin
efficaci
vaccin
borrelia
burgdorferi
north
american
dog
compar
vaccin
dog
receiv
vaccin
use
systemat
review
metaanalysi
address
object
monoval
multival
vaccin
consid
elig
intervent
main
outcom
interest
reduct
clinic
ill
follow
exposur
b
burgdorferi
outcom
data
extract
binari
outcom
follow
clinic
sign
assess
separ
lame
anorexia
pyrexia
depress
lymphadenopathi
experiment
analyt
observ
studi
consid
elig
inclus
addit
grey
literatur
search
follow
electron
databas
search
languag
restrict
medlin
web
scienc
cab
abstract
last
search
perform
novemb
thirteen
challeng
trial
three
observ
studi
identifi
elig
twelv
challeng
trial
contain
suffici
data
includ
metaanalysi
metaanalysi
could
perform
observ
studi
due
insuffici
number
studi
none
challeng
trial
assess
lymphadenopathi
remain
four
clinic
sign
separ
random
effect
metaanalysi
perform
except
anorexia
summari
odd
ratio
less
null
valu
overal
find
metaanalysi
suggest
north
american
lyme
vaccin
reduc
odd
clinic
ill
dog
follow
exposur
b
burgdorferi
howev
result
interpret
caution
sinc
number
issu
relat
small
sampl
size
studi
qualiti
public
bia
identifi
experiment
field
trial
identifi
highlight
major
gap
literatur
topic
futur
studi
focu
larger
sampl
size
field
condit
data
dog
natur
infect
b
rossi
healthi
control
dog
retrospect
evalu
owner
consent
obtain
enrol
case
togeth
approv
univers
anim
ethic
committe
mpxi
gener
autom
cell
counter
advia
cytokin
concentr
determin
use
caninespecif
multiplex
assay
fifteen
babesiainfect
dog
die
mpxi
significantli
higher
babesiainfect
dog
p
nonsurvivor
p
compar
control
dog
die
signific
correl
found
mpxi
r
p
r
p
r
p
granulocyticmacrophag
coloni
stimul
factor
r
p
monocyt
chemoattract
r
p
find
suggest
signific
neutrophil
activ
present
dog
b
rossi
infect
addit
increas
mpxi
associ
diseas
outcom
correl
sever
cytokinedriven
proinflammatori
host
respons
observ
expect
ratio
dilut
parallel
sampl
rang
mean
sd
intraassay
sampl
interassay
sampl
coeffici
variat
cv
rang
respect
observ
expect
ratio
mixtur
two
serum
sampl
known
concentr
pair
rang
mean
sd
comparison
tridelta
assay
show
nonlinear
relationship
rsquar
especi
appar
valu
greater
mgl
refer
interv
mgl
measur
tridelta
assay
gentian
result
higher
expect
use
suggest
cutoff
valu
mgl
gentian
assay
mgl
tridelta
assay
agreement
result
moder
cohen
kappa
statist
evalu
assay
gentian
shown
precis
reproduc
accur
nonlinear
relationship
result
comparison
assay
tridelta
especi
high
concentr
sampl
shown
conclus
gentian
assay
appear
suffici
use
work
need
determin
optim
diagnost
cutoff
valu
use
assay
sarah
shropshir
steven
dow
michael
lappin
colorado
state
univers
fort
collin
co
usa
depart
clinic
scienc
colorado
state
univers
fort
collin
co
usa
direct
flow
cytometri
techniqu
use
detect
immunoglobulinassoci
platelet
dog
howev
present
requir
sampl
must
process
within
hour
assess
current
avail
assay
limit
wide
spread
use
purpos
studi
develop
clinic
applic
direct
flow
cytometr
assay
detect
canin
iggassoci
platelet
express
percent
igg
igg
direct
flow
cytometri
assay
first
optim
cutoff
valu
differenti
neg
posit
classif
determin
serial
direct
flow
evalu
platelet
healthi
dog
assay
perform
sampl
healthi
beagl
clientown
thrombocytopen
dog
four
time
point
fresh
hour
storag
c
igg
record
repeat
measur
analysi
oneway
anova
perform
storag
time
point
compar
fresh
sampl
use
dunnett
method
averag
coeffici
variat
cv
calcul
sampl
thrombocytopen
dog
evalu
intraassay
variabl
use
sampl
healthi
dog
differ
among
fresh
hour
sampl
differ
fresh
hour
sampl
differ
among
fresh
hour
sampl
thrombocytopen
dog
base
cutoff
valu
healthi
thrombocytopen
dog
consist
categor
everi
time
point
averag
intraassay
cv
thrombocytopen
dog
sinc
sampl
process
evalu
within
hour
assay
use
sampl
requir
ship
central
laboratori
direct
flow
cytometr
assay
reproduc
repres
access
potenti
clinic
use
test
detect
iggassoci
platelet
dog
compar
rna
qualiti
quantiti
extract
canin
blood
use
commerci
avail
rna
extract
kit
dahlia
h
tesfamichael
jessica
c
pritchard
michael
w
wood
uwmadison
school
veterinari
medicin
madison
wi
usa
quantit
revers
transcript
pcr
rtqpcr
increasingli
use
studi
diagnos
diseas
small
anim
perform
assay
reli
upon
first
obtain
qualiti
rna
suffici
quantiti
mani
commerci
avail
kit
optim
extract
rna
human
blood
one
design
specif
anim
blood
purpos
studi
use
store
canin
blood
assess
perform
commerci
avail
rna
extract
kit
use
rna
yield
puriti
benchmark
rna
extract
perform
ribopur
thermofish
md
extract
rna
store
analysi
result
rna
yield
puriti
calcul
use
spectrophotometr
absorb
peak
measur
determin
nucleic
acid
concentr
assess
protein
contamin
median
rna
concentr
compar
amongst
group
kruskalw
test
dunn
test
multipl
comparison
signific
defin
p
ribopur
extract
result
significantli
higher
nucleic
acid
concentr
rneasi
protect
anim
blood
p
rneasi
mini
p
kit
figur
differ
median
rna
concentr
ribopur
trizol
p
differ
median
amongst
kit
indic
signific
differ
protein
contamin
extract
mean
kit
ribopur
trizol
rneasi
protect
anim
blood
rneasi
mini
kit
respect
result
indic
ribopur
kit
isol
greatest
quantiti
genet
materi
evalu
util
rtpcr
revers
transcriptas
control
assess
genom
dna
contamin
extract
necessari
fulli
evalu
rna
puriti
research
use
find
appropri
select
rna
extract
kit
base
prioriti
object
studi
investig
risk
factor
associ
develop
candida
urinari
tract
infect
dog
cat
eighteen
dog
eight
cat
cultureconfirm
candiduriawer
evalu
retrospect
casecontrol
studi
identifi
risk
factor
associ
candiduria
control
dog
cat
bacteri
cystiti
cutan
malassezia
infect
dog
univari
exact
logist
regress
use
estim
odd
ratio
confid
interv
pvalu
statist
signific
administr
antibacteri
drug
day
diagnosi
associ
candiduria
dog
use
control
bacteri
cystiti
ci
malassezia
infect
antibacteri
drug
administr
also
associ
candiduria
cat
ci
immunosuppress
associ
candiduria
dog
compar
control
malassezia
infect
ci
significantli
bacteri
cystiti
control
ci
lower
urinari
tract
diseas
infect
associ
candiduria
cat
ci
significantli
dog
ci
neither
diabet
mellitu
histori
hospit
significantli
associ
candiduria
either
speci
recent
administr
antibacteri
drug
therapi
potenti
risk
factor
develop
candiduria
popul
judici
use
may
help
prevent
fungal
infect
dog
within
hip
group
demonstr
lower
shock
index
mark
p
differ
still
observ
mark
p
blood
lactateconcentr
lower
mark
hip
dog
compar
placebo
dog
p
although
statist
differ
mark
p
differ
durat
hospit
group
p
overal
surviv
hip
group
compar
placebo
group
p
hip
well
toler
advers
event
note
drug
administr
result
studi
indic
hyperimmun
plasma
improv
cardiovascular
paramet
first
hour
hospit
studi
identifi
differ
clinic
sever
improv
durat
hospit
mortal
compar
hip
placebo
dog
futur
studi
evalu
hip
dose
time
hip
administr
rel
diseas
onset
need
better
determin
clinic
benefit
product
studi
retrospect
preval
casecontrol
studi
one
studi
demonstr
borrelia
seroreact
dog
pln
associ
clinicopatholog
distinct
syndrom
compar
type
pln
earli
recognit
syndrom
base
clinic
find
potenti
improv
outcom
specif
aggress
earli
treatment
therefor
aim
evalu
clinic
need
antibiot
common
condit
suspect
primarycar
veterinarian
overus
antibiot
chose
studi
haemorrhag
diarrhoea
dog
two
antibiot
often
administ
standard
amoxicillinclavulan
acid
metronidazol
typic
prescrib
sever
case
haemorrhag
diarrhoea
evid
benefici
patient
clinic
trial
design
determin
whether
dog
haemorrhag
diarrhoea
improv
clinic
outcom
receiv
amoxicillinclavulan
acid
metronidazol
whether
administr
amoxicillinclavulan
acid
alon
suffici
dog
present
privat
primarycar
veterinari
hospit
haemorrhag
diarrhoea
day
durat
recruit
ethic
approv
prospect
placebo
control
blind
treatment
trial
owner
consent
case
randomis
receiv
either
metronidazol
salin
blind
manner
addit
receiv
standard
support
therapi
amoxicillinclavulan
acid
intraven
fluid
therapi
analgesia
gastroprotect
diagnost
perform
accord
usual
primarycar
practic
protocol
routin
haematolog
biochemistri
faecal
c
efficaci
treatment
assess
durat
hospitalis
daili
clinic
progress
measur
clinic
score
system
feb
jan
dog
success
complet
clinic
trial
case
receiv
metronidazol
averag
durat
hospitalis
sd
salin
placebo
sd
signific
differ
two
patient
group
dog
trial
show
signific
improv
daili
clinic
score
day
admiss
day
p
statist
signific
differ
daili
clinic
score
compar
patient
group
summari
clinic
trial
two
valuabl
conclus
first
demonstr
two
antibiot
necessari
treatment
haemorrhag
diarrhoea
shown
antibiot
usag
safe
reduc
patient
second
proven
rigor
clinic
trial
perform
primarycar
practic
absenc
extens
diagnost
hope
similar
trial
examin
possibl
overus
antibiot
common
condit
conduct
futur
three
period
preval
fiv
increas
p
preval
felv
decreas
significantli
p
year
studi
significantli
fivposit
male
femal
p
despit
decreas
admiss
third
period
preval
fiv
male
remain
similar
across
year
p
increas
femal
suggest
fiv
test
continu
among
freeliv
commun
cat
san
mateo
counti
particip
report
awar
lyme
diseas
howev
none
report
famili
household
member
diagnos
lyme
diseas
major
respond
state
knew
caus
lyme
diseas
correctli
identifi
tick
vector
lyme
diseas
howev
half
respond
activ
tri
prevent
tick
attach
sometim
tri
prevent
tick
attach
similarli
respond
undertook
nonchem
effort
eg
trim
brush
shrub
reduc
tick
properti
despit
high
awar
lyme
diseas
respond
recal
human
health
care
provid
ever
discuss
lyme
diseas
recal
ever
receiv
inform
lyme
diseas
human
health
care
sourc
major
respond
recal
tick
prevent
discuss
veterinarian
administ
tick
prevent
product
dog
puppi
report
vaccin
lyme
diseas
respond
certain
vaccin
occur
baselin
vectorborn
diseas
test
snap
test
pathogen
neg
enrol
puppi
date
n
evalu
baselin
test
result
confirm
high
petown
knowledg
lyme
diseas
form
basi
ongo
futur
research
effort
util
uniqu
studi
popul
day
ocular
lesion
system
sign
diseas
recogn
oocyst
seen
fece
one
cat
day
one
cat
develop
igm
igg
antibodi
day
one
cat
develop
igg
antibodi
alon
first
detect
day
one
cat
develop
igm
igg
antibodi
day
igg
antibodi
persist
experi
result
confirm
cat
ingest
sporul
gondii
oocyst
becom
infect
shed
lower
level
oocyst
delay
seroconvers
compar
histor
control
fed
tissu
cyst
sampl
collect
use
sporozoit
antibodi
assay
titrat
ongo
studi
natur
expos
cat
comparison
immedi
versu
delay
streak
plate
inocul
urin
bacteri
cultur
sensit
test
commonli
transport
extern
refer
laboratori
prior
inocul
cultur
media
object
studi
compar
result
bacteri
cultur
sensit
test
canin
felin
urin
sampl
streak
plate
inocul
perform
immedi
sampl
collect
versu
streak
plate
inocul
delay
arriv
refer
laboratori
prospect
observ
studi
includ
urin
sampl
canin
felin
submit
routin
urinalysi
urin
cultur
sensit
test
streak
plate
inocul
urin
sampl
perform
immedi
sampl
collect
receipt
outsid
refer
laboratori
cultur
sensit
result
compar
addit
data
collect
includ
signal
comorbid
presenc
lower
urinari
tract
sign
urinalysi
result
antimicrobi
histori
overal
agreement
immedi
delay
cultur
serum
measur
use
commerci
elisakit
brunschwig
result
compar
group
use
kruskalw
test
associ
diseas
group
outcom
test
use
logist
regress
analysi
diagnost
accuraci
day
predict
occurr
lph
test
use
roc
curv
analysi
median
serum
concentr
significantli
higher
dog
aki
ngml
n
dog
lph
ngml
n
compar
heathi
control
ngml
n
p
median
higher
dog
leptospirosi
without
lph
ngml
iqr
n
compar
control
lower
lph
group
differ
reach
statist
signific
day
sampl
avail
analysi
show
similar
trend
highest
dog
lph
ngml
iqr
n
compar
healthi
control
dog
aki
ngml
iqr
n
leptospirosi
without
lph
ngml
iqr
n
howev
differ
healthi
lph
group
statist
signific
p
signific
associ
diseas
group
outcom
day
predict
develop
lph
reason
accuraci
auc
sensit
ci
specif
ci
find
suggest
context
leptospirosi
overexpress
endotheli
may
associ
develop
pulmonari
hemorrhag
examin
data
region
human
pediatr
medic
center
veterinari
clinic
laboratori
veterinari
refer
laboratori
focus
urinari
isol
pediatr
canin
popul
compar
resist
pattern
common
examin
emerg
similar
resist
pattern
examin
resist
e
coli
urinari
tract
isol
five
major
class
antibiot
dog
children
examin
preval
phenotyp
resist
pattern
combin
drug
class
found
canin
urinari
isol
preval
e
coli
resist
class
repres
third
gener
cephalosporin
ceftiofur
higher
resist
human
urinari
isol
ceftriaxon
detect
howev
increas
rate
resist
canin
isol
studi
period
preval
phenotyp
commonli
associ
e
coli
isol
clonal
lineag
featur
resist
cephalosporin
quinolon
also
common
companion
anim
isol
compar
human
isol
find
suggest
higher
rate
e
coli
resist
third
gener
cephalosporin
found
canin
patient
compar
human
pediatr
patient
differ
could
due
differ
felin
fecal
flotat
test
perform
posit
presenc
abstrusu
larva
addit
baermann
test
conduct
also
posit
report
studi
age
signific
risk
factor
cat
month
rel
risk
confid
interv
p
compar
cat
older
month
contrast
associ
observ
infect
statu
sex
signific
variat
overal
sera
elisa
reactiv
result
date
suggest
dog
primari
exposur
dose
strain
contagi
day
goal
studi
evalu
indic
dose
potenti
advers
effect
surviv
discharg
dog
cat
treat
vancomycin
addit
goal
evalu
vancomycin
treatment
base
current
recommend
best
practic
record
retriev
use
keyword
vancomycin
retrospect
review
record
thirtythre
dog
eight
cat
review
common
indic
vancomycin
includ
infect
involv
integu
hepatobiliari
system
endocard
infect
orthoped
implant
medic
record
data
base
idexx
search
felin
case
blood
evalu
pcr
assay
amplifi
dna
bartonella
spp
also
result
avail
complet
blood
cell
count
complet
concurr
case
first
classifi
test
blood
donor
suspect
clinic
ill
sampl
state
low
risk
c
feli
sinc
clinic
inform
like
use
flea
control
antibiot
avail
result
interpret
care
addit
estim
bartonella
spp
preval
data
blood
donor
cat
like
lower
select
cat
low
risk
howev
result
seem
confirm
smaller
studi
fail
link
bartonella
spp
anemia
cat
studi
requir
confirm
weak
associ
bartonella
spp
dna
blood
presenc
thrombocytopenia
pradofloxacin
protocol
use
studi
well
toler
bartonella
hensela
bacteremia
detect
cat
administr
pradofloxacin
even
administr
dose
methylprednisolon
acet
result
suggest
antibiot
effect
organ
clear
spontan
studi
repeat
cat
infect
b
hensela
exposur
infect
c
feli
cat
infect
field
divers
yet
predict
associ
specif
virul
eg
toxin
biofilm
antimicrobi
resist
gene
elucid
collect
e
coli
isol
collect
canin
urin
sampl
previous
character
h
antigen
type
antimicrobi
suscept
abil
form
biofilm
subset
isol
n
character
use
whole
genom
sequenc
miseq
platform
thirteen
differ
e
coli
sequenc
type
recov
two
sequenc
type
found
among
multipl
isol
e
coli
sequenc
type
associ
multipl
sampl
collect
patient
three
month
apart
e
coli
sequenc
type
found
three
differ
dog
number
differ
antimicrobi
resist
gene
identifi
includ
aac
lbcr
aada
aadb
aph
bla
cmi
bla
ctxm
bla
oxa
bla
tem
cat
cml
cmla
dfra
mph
stra
strb
tet
b
presenc
sever
gene
import
classifi
isol
extendedspectrum
beta
lactamas
esbl
produc
sequenc
type
repres
three
isol
lack
associ
resist
gene
sequenc
isol
least
one
fimbriaeassoci
gene
eaeh
gene
associ
e
coli
attach
found
isol
previous
presenc
one
fimbriaeassoci
gene
fimh
strongli
associ
abil
form
biofilm
detect
isol
conclus
escherichia
coli
caus
canin
uti
appear
divers
still
presenc
consist
attach
virul
gene
note
across
sequenc
type
antimicrobi
resist
gene
phenotyp
resist
cephalosporin
detect
sever
sampl
concern
therapeut
choic
anim
handl
consider
work
explor
associ
among
virul
antimicrobi
resist
biofilm
potenti
underway
better
understand
upec
present
pathogenesi
dog
dog
anesthet
propofol
serum
level
sdma
measur
anesthesia
significantli
higher
measur
anesthesia
p
level
scr
bun
tradit
marker
renal
function
also
increas
addit
bun
scr
level
significantli
posit
associ
sdma
level
r
r
respect
alphaxalonetr
dog
averag
serum
level
sdma
anesthesia
increas
anesthesia
wherea
smaller
increas
detect
scr
bun
studi
increas
serum
sdma
observ
propofoland
alphaxalonetr
dog
wherea
level
scr
bun
increas
propofoltr
dog
taken
togeth
data
suggest
serum
sdma
concentr
like
sensit
biomark
kidney
dysfunct
present
data
show
serum
sdma
strong
relationship
sever
paramet
use
evalu
renal
function
serum
creatinin
serum
phosphoru
serum
bun
hematocrit
upc
urinari
densiti
reticulocyt
serum
sdma
weak
relationship
bp
serum
sdma
increas
prior
imag
alter
kidney
ultrasonographi
dog
serum
sdma
also
increas
dog
valu
serum
creatinin
dl
differ
found
iri
stage
consid
serum
sdma
dog
iri
stage
serum
sdma
dl
dog
reclassifi
iri
stage
iri
stage
dog
iri
stage
serum
sdma
dl
dog
reclassifi
iri
stage
iri
stage
conclud
serum
sdma
import
tool
evalu
renal
function
use
routin
evalu
dog
infect
l
infantum
sampl
thaw
batch
analyz
use
catalystsdma
catalyst
chemistri
analyz
use
lcm
refmethod
studi
complet
sever
day
howev
sampl
test
complet
within
four
hour
test
complet
idexx
result
report
confid
limit
parenthes
refmethod
median
sdma
interquartil
rang
iqr
rang
catalystsdma
median
sdma
iqr
rang
statist
differ
exist
sdma
concentr
obtain
two
method
p
mannwhitney
u
test
passingbablok
regress
analysi
intercept
slope
tau
pearson
correl
coeffici
r
mean
differ
blandaltman
plot
standard
deviat
limitsofagr
loa
plot
show
fix
proport
bia
increas
variat
higher
end
dynam
rang
unlik
impact
clinic
decis
loa
upper
limit
loa
lower
limit
assay
result
nearest
whole
number
assign
one
three
categori
percentag
agreement
concord
two
assay
calcul
good
agreement
result
classif
minim
bia
good
concord
excel
correl
refer
method
provid
confid
catalystsdma
use
inclin
measur
felin
sdma
fast
uca
cr
collect
initi
evalu
consid
increas
ratio
base
previous
publish
data
dog
includ
studi
caox
urolithiasi
confirm
via
quantit
calculi
analysi
ioniz
calcium
ica
routin
serum
chemistri
cbc
urinalysi
avail
evalu
dog
divid
hypercalciur
andnonhypercalciuricstoneform
group
mannwhitney
test
use
compar
group
renalrel
death
rd
rd
ac
dog
iri
stage
biopsi
significantli
shorter
surviv
post
biopsi
spb
iri
stage
rd
p
ac
p
rd
ac
dog
alb
g
dl
significantli
shorter
spb
dog
alb
g
dl
rd
p
ac
p
rd
ac
dog
ascit
edema
time
biopsi
significantli
shorter
spb
compar
dog
without
rd
p
ac
p
ac
dog
histori
ht
significantli
shorter
spb
compar
ac
dog
without
histori
ht
p
rd
dog
gs
affect
glomeruli
significantli
shorter
spb
rd
dog
gs
p
upc
significantli
associ
spb
rd
ac
dog
retrospect
studi
fsg
similar
preval
previous
report
femal
continu
overrepres
sever
hypoalbuminemia
iri
stage
associ
poorer
prognosi
dog
fsg
hypertens
associ
shorter
surviv
dog
die
caus
wherea
biopsi
sampl
least
global
glomerulosclerosi
associ
poorer
prognosi
dog
known
renalrel
death
purpos
studi
describ
popul
dog
biofilmform
escherichia
coli
e
coli
uti
determin
whether
clinic
differ
dog
biofilmform
e
coli
uti
dog
nonbiofilmform
e
coli
uti
hypothes
would
differ
two
popul
characterist
dog
wherea
biofilmform
would
preval
dog
whose
uti
chronic
complic
andor
asymptomat
retrospect
crosssect
studi
evalu
clientown
anim
e
coli
uti
divid
two
group
base
vitro
biofilmform
capabl
e
coli
isol
biofilm
format
establish
use
crystal
violet
assay
medic
record
dog
review
popul
characterist
age
sex
breed
weight
bodi
condit
score
infect
characterist
infect
class
chronic
exposur
antibiot
pyuria
multidrug
resist
clinic
sign
compar
major
isol
show
biofilmform
capabl
dog
biofilmform
e
coli
uti
lower
likelihood
multidrug
resist
p
nonbiofilmform
e
coli
uti
statist
signific
differ
popul
characterist
infect
characterist
two
group
conclud
reliabl
clinic
indic
biofilmform
rule
consider
given
possibl
biofilmform
whenev
e
coli
uti
diagnos
addit
associ
mdr
nonbiofilmform
e
coli
may
antimicrobi
toler
confer
biofilm
format
uremia
associ
chronic
kidney
diseas
ckd
shown
profoundli
affect
composit
gut
microbiom
peopl
rat
model
toxic
product
gener
dysbiosi
may
contribut
morbid
progress
ckdindoxyl
sulfat
pcresol
sulfat
pc
urem
toxin
produc
colon
bacteria
first
studi
object
compar
fecal
microbiom
healthi
older
year
cat
n
cat
stabl
ckd
iri
stage
n
second
object
measur
serum
pc
healthi
older
cat
n
compar
ckd
cat
n
crosssect
studi
cat
complet
blood
count
chemistri
panel
total
urinalysi
blood
pressur
fecal
flotat
enrol
ckd
cat
creatinin
mgdl
usg
elev
creatinin
least
two
time
point
addit
elev
sdma
ugdl
healthi
cat
year
age
creatinin
mgdl
usg
exclus
criteria
histori
antibiot
probiot
antacid
administr
week
prior
enrol
histori
uncontrol
hyperthyroid
known
suspect
gastrointestin
diseas
fresh
fecal
sampl
number
observ
speci
chao
significantli
decreas
ckd
cat
compar
healthi
cat
p
p
respect
shannon
divers
index
decreas
ckd
cat
compar
healthi
cat
howev
signific
p
signific
differ
overal
cluster
microbi
commun
ckd
cat
healthi
cat
p
howev
individu
bacteri
group
analyz
base
lda
effect
size
lefs
sever
bacteri
taxa
identifi
significantli
differ
among
group
compar
healthi
cat
ckd
cat
ckd
cat
significantli
decreas
bacteri
popul
belong
genera
holdemania
adlercreutzia
eubacterium
slackia
mogibacterium
signific
differ
function
potenti
microbiota
found
ckd
cat
healthi
cat
correct
multipl
comparison
level
found
significantli
higher
ckd
cat
compar
healthi
cat
p
healthi
control
cat
significantli
lower
level
compar
stage
p
stage
p
ckd
cat
signific
differ
found
stage
stage
ckd
cat
group
pc
level
significantli
differ
ckd
healthi
control
conclus
felin
ckd
associ
decreas
divers
gut
microbiom
significantli
elev
felin
ckd
merit
explor
potenti
therapeut
target
addit
iri
stage
cat
may
suffer
similar
urem
toxin
burden
cat
later
stage
diseas
addit
work
need
understand
interplay
fecal
microbiom
urem
toxin
twenti
percent
cat
n
exclud
due
urinari
tract
infect
uti
present
mean
sdma
creatinin
significantli
higher
cat
mgdl
respect
compar
without
uti
mgdl
respect
p
twentysix
cat
met
inclus
criteria
signific
posit
correl
sdma
creatinin
time
uo
p
associ
initi
sdma
sdma
postdecompress
hour
p
day
p
mean
sdma
creatinin
present
mgdl
respect
significantli
higher
compar
final
valu
mgdl
respect
p
sdma
appear
use
marker
postren
azotemia
cat
uo
predecompress
sdma
reflect
underli
kidney
diseas
uti
may
frequent
cat
uo
histor
suggest
screen
consid
especi
sdma
creatinin
concentr
elev
seventeen
cat
identifi
inclus
studi
median
age
year
rang
year
spay
femal
n
preval
castrat
male
n
anorexia
lethargi
vomit
common
present
complaint
common
physic
exam
abnorm
includ
muscl
wast
hypothermia
cardiac
murmur
clinic
sign
classic
associ
pyelonephr
renal
pain
pyrexia
present
cat
respect
serum
chemistri
complet
blood
count
avail
cat
respect
common
clinic
patholog
abnorm
includ
azotemia
hyperphosphatemia
nonregen
anemia
cat
respect
cat
urinalysi
data
avail
bacteriuria
isosthenur
urin
cat
urinalysi
perform
four
also
urin
sampl
submit
cultur
subcutan
ureter
bypass
sub
devic
placement
altern
tradit
ureter
surgeri
howev
outcom
describ
treatment
benign
ureter
obstruct
dog
purpos
evalu
preoper
periop
day
short
day
longterm
day
paramet
dog
treat
benign
ureter
obstruct
hypothesi
associ
favor
technic
outcom
compar
altern
place
use
fluoroscopicand
surgicalassist
medic
record
review
pre
intra
postop
data
twelv
place
nine
dog
bilater
caus
obstruct
includ
ureterolithiasi
extralumin
compress
strictur
eleven
uret
stent
place
prior
need
recurr
strictur
ureter
stent
migrat
placement
success
uret
median
creatinin
preoper
month
postop
mgdl
mgdl
respect
seven
dog
histori
urinari
tract
infect
prior
placement
longterm
complic
includ
infect
miner
dog
miner
devic
histori
urolithasi
histor
preoper
infect
commonli
postop
infect
periop
procedurerel
death
dog
worsen
azotemia
shortterm
median
surviv
time
day
still
aliv
use
devic
dog
safe
effect
treatment
option
benign
ureter
obstruct
associ
good
prognosi
high
rate
miner
infect
consid
longterm
object
studi
identifi
patient
stone
characterist
juvenil
dog
caox
urolithiasi
compar
matur
urolithform
inform
juvenil
year
matur
year
dog
caox
urolithiasi
obtain
submiss
minnesota
urolith
center
fisher
exact
test
use
identifi
breed
overrepres
juvenil
group
chisquar
test
perform
determin
whether
sex
stone
locat
upper
vs
lower
urinari
tract
salt
type
monohydr
vs
dihydr
differ
compar
matur
group
english
p
french
p
bulldog
overrepres
juvenil
group
differ
sex
observ
juvenil
matur
group
juvenil
adult
english
french
bulldog
male
stone
locat
differ
juvenil
matur
dog
howev
stone
group
upper
urinari
tract
juvenil
dog
like
form
dihydr
stone
compar
matur
dog
p
although
monohydr
predomin
group
respect
object
prospect
studi
investig
use
minim
invas
transcutan
gfr
tgfr
monitor
nickidney
assess
renal
function
cat
natur
occur
hyperthyroid
pre
week
post
radioiodin
treatment
eight
hyperthyroid
cat
includ
euthyroid
three
cat
remain
hyperthyroid
significantli
reduc
serum
concentr
plasma
gfr
pgfr
plasma
halflif
phl
assess
plasma
sinistrin
clearanc
transcutan
halflif
thl
measur
parallel
use
fluoresc
marker
fitcsinistrin
nickidney
devic
plasma
data
use
calcul
speciesspecif
convers
factor
determin
tgfr
thl
overal
pgfr
tgfr
significantli
correl
spearman
correl
r
p
cat
pgfr
decreas
mean
rang
remain
unchang
cat
use
tgfr
decreas
gfr
identifi
cat
decreas
remain
cat
show
mild
increas
respect
although
result
directli
compar
transcutan
gfr
assess
promis
minim
invas
techniqu
allow
gfr
estim
small
anim
research
larger
cohort
necessari
evalu
full
potenti
method
owner
survey
amoxicillinclavulan
acid
side
effect
cat
without
azotem
ckd
cat
chronic
kidney
diseas
ckd
anecdot
increas
frequenc
side
effect
amoxicillinclavulan
acid
decreas
appetit
vomit
diarrhea
comparison
cat
normal
kidney
function
human
patient
decreas
kidney
function
shown
potenti
penicillin
like
amoxicillinclavulan
acid
impair
clearanc
much
sever
renal
impair
impair
clearanc
result
higher
serum
concentr
comparison
patient
normal
kidney
function
reduct
dose
interv
recommend
avoid
side
effect
purpos
studi
determin
frequenc
side
effect
cat
without
azotemia
hypothesi
cat
azotem
ckd
increas
frequenc
side
effect
owner
cat
prescrib
amoxicillinclavulan
acid
colorado
state
univers
ohio
state
univers
sent
survey
regard
occurr
side
effect
ye
specif
type
side
effect
vomit
diarrhea
decreas
appetit
none
whether
treatment
alter
result
signal
clinicopatholog
data
obtain
medic
record
cat
survey
return
cat
includ
azotem
ckd
group
creatinin
mgdl
usg
clinic
design
ckd
cat
includ
without
azotem
ckd
group
creatinin
mgdl
cut
group
creatinin
mgdl
chosen
defin
cohort
impair
clearanc
amoxicillinclavulan
acid
common
human
greater
degre
renal
impair
chi
squar
util
assess
distribut
presenc
side
effect
ye
group
preval
specif
side
effect
chang
therapi
survey
return
exclud
incomplet
data
serum
creatinin
avail
cat
categor
azotem
ckd
consist
male
femal
median
age
year
rang
year
median
creatinin
rang
mgdl
cat
categor
azotem
ckd
consist
male
femal
median
age
year
rang
year
median
creatinin
rang
mgdl
owner
report
cat
azotem
ckd
side
effect
specif
side
effect
includ
diarrhea
cat
vomit
cat
decreas
appetit
cat
cat
one
side
effect
owner
report
cat
cat
without
azotem
ckd
side
effect
specif
side
effect
cat
includ
diarrhea
cat
vomit
cat
decreas
appetit
cat
cat
one
side
effect
differ
distribut
side
effect
ye
distribut
specif
type
side
effect
statist
signific
howev
significantli
azotem
ckd
cat
one
side
effect
p
addit
significantli
owner
azotem
ckd
cat
report
alter
treatment
plan
necessit
side
effect
indic
antibiot
stop
chang
support
care
ad
due
side
effect
owner
cat
without
azotem
ckd
report
alter
treatment
plan
p
side
effect
diarrhea
vomit
decreas
appetit
common
amoxicillinclavulan
acid
administr
cohort
may
increas
incid
cat
azotem
ckd
result
alter
treatment
plan
investig
current
underway
determin
find
associ
higher
drug
serum
concentr
urethr
strictur
urethr
conclus
felin
urinari
incontin
rare
condit
commonli
associ
acquir
congenit
spinal
cord
disord
urinari
incontin
cat
gener
associ
poor
prognosi
mani
persist
incontin
despit
therapi
canin
patient
underw
tpe
nsaid
overdos
tuft
foster
hospit
small
anim
januari
may
includ
studi
data
regard
present
hospit
treatment
outcom
collect
eleven
case
includ
studi
nsaid
ingest
ibuprofen
six
naproxen
four
deracoxib
one
six
patient
complic
associ
tpe
treatment
common
complic
hemorrhag
case
surviv
discharg
three
develop
acut
kidney
injuri
hospit
one
went
chronic
kidney
diseas
final
outcom
correl
dose
nsaid
ingest
studi
identifi
plasma
exchang
effect
treatment
nsaid
overdos
none
patient
lethal
outcom
despit
high
nsaid
dose
ingest
present
factor
determin
likelihood
acut
kidney
injuri
apart
initi
nsaid
dose
complic
common
manag
support
care
affect
final
outcom
tpe
consid
patient
present
nsaid
ingest
pmoll
blood
ioniz
calcium
normal
pth
pmoll
cat
mmoll
stage
hyperphosphatemia
seven
healthi
male
cat
age
month
year
evalu
use
random
placebo
crossov
studi
pairwis
fashion
cat
receiv
treatment
everi
hour
twoweek
period
approxim
void
urin
sampl
collect
end
treatment
period
sampl
analyz
ph
sodium
potassium
chlorid
calcium
phosphor
magnesium
citrat
oxal
ammonia
creatinin
rel
supersatur
calcium
oxal
struvit
estim
use
iter
comput
program
equil
univers
florida
gainesvil
fl
data
assess
normal
distribut
use
shapirowilk
pair
ttest
normal
distribut
wilcoxon
sign
rank
nonnorm
distribut
use
statist
analysi
data
analyz
use
statist
test
except
rel
supersatur
urin
volum
test
use
pvalu
consid
signific
data
cat
use
due
incomplet
urin
collect
cat
urin
satur
struvit
significantli
lower
cat
receiv
supplement
compar
placebo
supplement
placebo
p
urinari
excret
phosphor
lower
cat
receiv
supplement
compar
supplement
rang
placebo
p
differ
analyt
bodi
weight
urin
volum
sever
limit
studi
studi
short
durat
includ
small
number
healthi
nonurolith
form
cat
may
complet
urin
collect
despit
use
modifi
litter
box
signific
decreas
struvit
supersatur
even
limit
suggest
determin
rel
supersatur
better
determin
risk
urolith
format
electrolyt
miner
concentr
excret
herbal
supplement
may
benefici
manag
struviteassoci
urinari
diseas
cat
although
steadi
state
last
long
lethal
situat
new
obstruct
hypertrophi
kidney
occur
ureter
obstruct
felin
medic
surgic
treatment
option
research
indic
onemonth
surviv
rate
surgic
treatment
group
ureterotomyureterotomi
ureteroneocystostomi
ureter
resect
anastomosi
medic
treatment
group
individu
one
studi
reveal
stent
subcutan
ureter
bypass
sub
treatment
cat
ureter
obstruct
increas
surviv
rate
paramet
associ
diseas
outcom
howev
prognost
factor
cat
obstruct
nonobstruct
bklk
syndrom
remain
unclear
aim
studi
character
cat
bklk
syndrom
determin
prognosticprogress
factor
cat
bklk
syndrom
obstruct
nonobstruct
uret
state
first
sixteen
healthi
cat
without
abnorm
physic
blood
radiographi
examin
collect
defin
bklk
syndrom
diverg
kidney
abdomin
ventrodors
radiograph
cat
rang
cm
mean
cm
defin
mean
plu
two
standard
deviat
cm
cutoff
valu
howev
consid
observ
error
measur
exceed
histori
ckd
month
set
criteria
bklk
syndrom
studi
fortyfour
cat
bklk
syndrom
divid
obstruct
group
nonobstruct
group
base
ultrasound
find
signific
differ
group
regard
bodi
weight
gender
patient
obstruct
group
neuter
intact
nonobstruct
group
p
length
right
kidney
xray
longer
p
ratio
big
kidney
nd
lumber
higher
obstruct
group
p
presenc
urolith
nephrolith
length
differ
two
kidney
show
signific
differ
two
group
p
p
p
blood
examin
obstruct
group
signific
lower
valu
eosinophil
p
reticulocyt
p
cl
p
higher
valu
mchc
p
bun
p
serum
creatinin
p
compar
nonobstruct
group
control
group
male
proport
significantli
higher
nonobstruct
group
clinic
patholog
variabl
reveal
valu
hb
p
hct
p
rbc
p
alkp
p
urin
ph
p
usg
p
found
significantli
lower
nonobstruct
group
contrast
valu
wbc
p
segment
cell
p
bun
p
serum
creatinin
p
higher
nonobstruct
group
obstruct
group
divid
surviv
group
nonsurviv
group
within
day
surviv
group
significantli
higher
bodi
temperatur
p
hct
p
hb
p
rbc
p
lower
neutrophil
p
ratio
neutrophil
lymphocyt
p
mchc
p
howev
surgeri
intervent
renal
index
includ
bun
serum
creatinin
phosphoru
two
group
meet
signific
differ
except
serum
creatinin
increas
odd
ratio
death
addit
bklk
cat
also
divid
surviv
group
nonsurviv
group
within
day
bodi
temperatur
p
reticulocyt
p
hb
p
rbc
p
higher
surviv
group
nonsurviv
group
higher
ratio
neutrophil
lymphocyt
p
mchc
p
bun
p
creatinin
p
signific
posit
relat
found
serum
creatinin
length
bigger
kidney
obstruct
group
length
bigger
kidney
xray
signific
differ
surviv
nonsurviv
group
p
conclus
bodi
temperatur
hb
rbc
mchc
ratio
neutrophil
lymphocyt
good
prognost
factor
obstruct
nonobstruct
bklk
syndrom
surprisingli
length
bigger
kidney
determin
prognosi
ngal
glycoprotein
belong
lipocalin
superfamili
act
promis
renal
biomark
human
dog
cat
urinari
ngal
report
configur
includ
monom
dimer
complex
matrix
human
laboratori
anim
recent
character
canin
felin
urinari
diseas
research
group
play
import
role
regul
degrad
extracellular
matrix
process
angiogenesi
tumor
growth
metastasi
addit
report
involv
renal
fibrosi
chronic
kidney
diseas
ckd
addit
hjv
upstream
modul
hepcidinferroportin
axi
identifi
novel
renal
biomark
acut
kidney
injuri
aki
ckd
human
renal
diseas
interestingli
hjv
ngal
serv
modul
inflamm
involv
express
ngal
associ
ngal
prevent
autodegrad
henc
possibl
protein
work
cooper
cours
felin
renal
diseas
resolv
unknown
issu
aim
character
overal
express
profil
three
factor
cat
urinari
diseas
felin
ckd
ngal
repres
sever
urinari
ngal
significantli
higher
ckd
stage
ckd
stage
control
group
ckd
stage
howev
urin
may
appropri
indic
ckd
progress
ckd
group
pyuria
group
urinari
ngal
concentr
ratio
urinari
creatinin
signific
correl
spearman
correl
valu
order
howev
correl
could
identifi
aki
group
moreov
detect
felin
hjv
recombin
felin
hjv
prepar
gener
antibodi
felin
hjv
present
express
hjv
detect
felin
urin
western
blot
analysi
quantifi
concentr
hjv
develop
elisa
platform
process
conclus
urinari
promis
biomark
renalurinari
diseas
cat
especi
interpret
urinari
ngal
role
hemojuvelin
felin
renal
diseas
highli
expect
cat
hyperammonemia
document
portal
venou
anomali
advanc
hepat
diseas
defici
cobalamin
arginin
recent
case
seri
report
hyperammonemia
cat
iri
stage
chronic
kidney
diseas
ckd
hypothes
larger
popul
cat
fast
hyperammonemia
would
correl
blood
urea
nitrogen
bun
creatinin
cr
independ
serum
fast
blood
sampl
prospect
collect
ammonia
analysi
clientown
cat
renal
azotemia
iri
stage
creatinin
mgdl
blood
ammonia
immedi
process
analyz
clinic
scienc
laboratori
cat
medic
known
decreas
blood
ammonia
antibiot
lactulos
probiot
previous
diagnos
diseas
state
known
increas
ammonia
level
exclud
studi
data
analyz
use
pearson
correl
coeffici
anova
follow
log
transform
enrol
cat
median
age
year
rang
year
male
femal
five
stage
iri
stage
ckd
respectivelyhyperammonemia
document
catsther
signific
moder
posit
correl
bun
ammonia
r
p
correl
ammonia
cr
r
p
ammonia
r
p
differ
mean
ammonia
level
iri
stage
p
hyperammonem
cat
appear
overt
neurolog
sign
urinari
tract
infect
ureas
produc
bacteria
conclus
pilot
studi
cat
renal
azotemia
correl
exist
bun
ammonia
ammonia
cr
futur
studi
need
larger
popul
cat
determin
true
preval
etiolog
effect
hyperammonemia
long
term
prognosi
sdma
seem
strictli
elimin
renal
excret
concentr
highli
correl
gfr
anim
human
therefor
biomark
earlier
marker
kidney
dysfunct
serum
creatinin
scr
object
prospect
studi
evalu
quantifi
effect
intraven
fluid
therapi
intermitt
hemodialysi
ih
renal
function
random
group
dog
previous
diagnos
iri
stage
chronic
kidney
diseas
ckd
serum
dog
treat
ih
dog
treat
submit
measur
scr
idexx
sdma
dog
treatment
group
receiv
treatment
session
administ
hour
apart
signific
differ
p
seen
treatment
group
howev
dog
hemodialysi
group
figur
western
blot
analysi
confirm
hemojuvelin
felin
urin
repres
hemojuvelin
repres
marker
repres
azotemia
group
n
repres
nonazotemia
group
affect
clearanc
sdma
x
p
scr
x
p
blood
urea
x
p
signific
correl
also
found
urea
reduct
ratio
urr
sdma
increas
urr
dl
decreas
sdma
x
p
tabl
although
sdma
dialys
biomark
highli
recommend
evalu
context
concurr
urr
better
estim
actual
gfr
despit
remov
ih
sdma
still
better
biomark
scr
evalu
gfr
dog
ckd
formanc
sinc
elisa
valid
felin
urin
object
evalu
felinespecif
elisa
kit
quantif
felin
urin
urin
collect
healthi
cat
evalu
michigan
state
univers
veterinari
medic
center
normal
urin
sampl
pool
modifi
mimic
diseas
condit
ad
water
hemolyz
blood
spike
high
medium
low
concentr
recombin
cytokin
concentr
determin
use
commerci
avail
felinespecif
elisa
kit
influenc
urin
matrix
variabl
test
perform
evalu
spikerecoveri
test
linear
test
assess
interand
intraassay
variat
assay
underestim
high
medium
spike
cytokin
concentr
urin
compar
standard
assay
diluent
low
spike
cytokin
concentr
urin
inconsist
detect
urin
spike
achiev
maxim
quantit
recoveri
respect
high
urin
specif
graviti
contribut
significantli
poor
recoveri
felin
idiopath
cystiti
fic
common
lower
urinari
tract
diseas
cat
resembl
interstiti
cystitispain
bladder
syndrom
peopl
condit
pathogenesi
diseas
unknown
specif
treatment
investig
molecular
pathway
diseas
function
potenti
involv
pathogenesi
fic
evalu
bladder
mucosa
transcriptom
affect
healthi
cat
urinari
bladder
tissu
collect
healthi
cat
fic
cat
repres
differ
histolog
phenotyp
ulcer
nonulc
hyperplast
rna
bladder
tissu
isol
sequenc
use
high
throughput
next
gener
sequenc
differenti
gene
express
molecular
pathway
diseas
factor
analysi
perform
use
ingenu
pathway
analysi
ipa
softwar
signific
level
gene
set
enrich
log
p
identifi
sever
annot
diseas
function
categori
inflammatori
respons
function
regul
nonulc
ulcer
phenotyp
zscore
respect
regul
hyperplast
phenotyp
zscore
cellular
growth
prolifer
categori
regul
nonulc
hyperplast
phenotyp
zscore
regul
ulcer
phenotyp
zscore
cell
death
surviv
pathway
regul
nonulc
hyperplast
phenotyp
regul
ulcer
phenotyp
investig
pathway
target
gene
may
provid
insight
pathogenesi
fic
identifi
new
therapeut
target
well
biomark
disord
futur
clinic
applic
aim
studi
followup
ckd
dog
iri
stage
base
serum
creatinin
concentr
also
investig
whether
sdma
disagr
creatinin
concentr
classif
ckd
stage
studi
group
compos
twentyon
ckd
dog
ckd
dog
stage
n
stage
n
followedup
month
death
evalu
mean
serum
creatinin
concentr
two
ckd
dog
stage
chang
classif
stage
followup
also
dog
serum
sdma
increas
concomitantli
howev
three
ckd
dog
stage
increas
sdma
chang
classif
stage
serum
creatinin
show
underestim
stage
base
serum
creatinin
ckd
dog
stage
followup
two
dog
chang
classif
stage
base
serum
creatinin
concentr
howev
take
sdma
concentr
chang
classif
stage
among
dog
serum
creatinin
mgdl
alreadi
stage
sinc
begin
followup
urinari
protein
creatinin
ratio
upc
measur
total
amount
protein
urin
compar
urinari
creatinin
concentr
identifi
origin
individu
protein
qualit
evalu
urinari
protein
immunodetect
could
add
import
inform
natur
renal
diseas
albuminuria
associ
glomerular
diseas
retinolbind
protein
rbp
vitamin
dbind
protein
vdbp
tubular
damag
due
impair
tubular
reabsorpt
low
molecular
weight
protein
normal
found
glomerular
filtrat
hypothesi
studi
qualit
method
eg
western
blot
associ
quantit
method
upc
may
provid
better
assess
evalu
origin
proteinuria
aim
studi
dog
chronic
kidney
diseas
ckd
determin
upc
well
use
immunoassay
western
blot
detect
urinari
albumin
rbp
vdbp
studi
group
compos
ckd
dog
stage
stage
follow
month
death
fifteen
clinic
healthi
dog
differ
breed
age
compris
control
group
coomassi
brilliant
blue
bradford
method
use
upc
determin
antialbumin
abcam
cambridg
antivdbp
abcam
antirbp
abcam
western
blot
urinari
albumin
rbp
vdbp
detect
control
dog
upc
min
max
one
ckd
dog
stage
proteinuria
base
upc
mean
followup
minmax
also
loss
vdbp
tubular
pattern
renal
diseas
remain
ckd
dog
stage
mean
upc
normal
upc
followup
period
howev
qualit
evalu
detect
loss
tubular
protein
rbp
vdbp
loss
glomerular
protein
albumin
loss
tubular
glomerular
protein
level
protein
found
proteinuria
upc
observ
ckd
dog
stage
tubular
pattern
character
predomin
low
molecular
weight
protein
loss
rbp
vdbp
notic
loss
albumin
rbp
similar
magnitud
tubular
glomerular
pattern
nonproteinur
mean
followup
upc
ckd
dog
stage
immunodetect
albumin
rbp
vdbp
observ
slight
amount
albumin
loss
detect
find
suggest
sequenti
qualit
evalu
urinari
protein
add
inform
interpret
upc
result
identif
damag
nephron
segment
caus
specif
pattern
protein
loss
could
help
refin
diagnosi
specif
renal
diseas
well
optim
therapi
importantli
detect
albumin
rbp
vdbp
urin
sampl
normal
upc
might
serv
earli
marker
glomerular
tubular
injuri
respect
studi
aim
describ
p
qt
dispers
well
electrocardiograph
chang
observ
dog
ckd
stage
iv
undergo
ihd
anim
classifi
consid
serum
creatinin
urinari
proteincreatinin
ratio
systol
blood
pressur
ten
dog
weigh
kg
includ
studi
electrocardiograph
examin
perform
first
three
session
ihd
result
analyz
use
anova
friedman
test
consid
signific
level
signific
increas
valu
p
maximum
p
qt
maximum
p
qt
minimum
p
howev
chang
p
qt
dispers
signific
p
increas
pr
interv
p
qt
interv
p
decreas
amplitud
r
wave
p
second
session
three
dog
develop
sinu
arrest
anoth
three
develop
supraventricular
arrhythmia
result
obtain
suggest
employ
ihd
dog
may
caus
electrocardiograph
chang
arrhythmia
interfer
atrioventricular
conduct
well
ventricular
depolar
repolar
process
find
highlight
import
electrophysiolog
monitor
anim
submit
therapeut
modal
kcal
report
increas
urinari
calcium
concomitantli
increas
water
intak
consequ
urin
volum
compar
food
contain
approxim
kcal
food
similar
ca
p
mg
restrict
rel
high
kcal
low
kcal
sodium
content
compar
observ
rel
supersatur
rss
calcium
oxal
similar
calcium
excret
significantli
greater
high
sodium
food
suggest
benefit
ascrib
lower
urinari
satur
due
increas
urinari
water
offset
increas
urin
calcium
content
long
term
studi
perform
cat
compar
rss
calcium
oxal
recurr
rate
urolith
howev
correl
exist
human
anoth
surrog
calcium
oxal
risk
bonn
risk
index
describ
laub
et
al
propos
better
predictor
futur
calcium
oxal
risk
rel
super
satur
studi
examin
low
high
sodium
felin
dri
food
use
calcium
oxal
titrat
cot
test
first
describ
davidson
similar
human
bonn
risk
index
test
cot
test
centrifug
unalt
bodi
temperatur
urin
titrat
sodium
oxal
solut
monitor
precipit
occur
cot
valu
determin
divid
urin
ca
result
amount
oxal
ad
point
precipit
therefor
cot
test
measur
urin
stabil
capac
influenc
composit
urin
reflect
interact
inhibitor
promot
crystal
format
group
healthi
adult
cat
fed
two
commerci
avail
food
b
kcal
sodium
kcal
seri
week
hour
urin
sampl
collect
end
period
evalu
cot
test
perform
equil
softwar
use
calcul
rss
urin
concentr
nh
ca
cl
citrat
mg
oxal
po
k
na
urin
ph
version
use
analys
repeat
measur
regress
model
use
valu
analyt
depend
variabl
food
independ
variabl
leastsquar
mean
pairwis
differ
calcul
diet
comparison
analyt
twosid
test
perform
alpha
use
determin
statist
signific
urin
ph
p
rss
struvit
p
rss
calcium
oxal
p
significantli
differ
food
urin
cat
fed
low
sodium
food
significantli
p
greater
urin
specif
graviti
vs
phosphoru
ppm
vs
ppm
citrat
concentr
umol
vs
umol
significantli
lower
calcium
ppm
vs
ppm
cot
vs
compar
high
sodium
food
compar
high
sodium
food
low
sodium
food
improv
urinari
crystal
capac
measur
cot
test
lower
urin
calcium
concentr
respect
calcium
oxal
crystal
format
factor
associ
increas
urin
stabil
includ
urin
citrat
urin
phosphoru
significantli
increas
respect
felin
urin
typic
metast
calcium
oxal
complex
affect
mani
factor
increas
urin
water
may
help
reduc
satur
crystal
compon
may
also
dilut
inhibitor
crystal
format
data
support
dynam
natur
calcium
oxal
precipit
test
provid
addit
inform
capac
urin
resist
induc
crystal
reflect
tradit
super
satur
calcul
elev
sodium
content
food
influenc
calcium
excret
appear
lower
urin
resist
induc
crystal
format
studi
relationship
rss
cot
long
term
risk
crystal
stone
format
warrant
cannula
system
allow
fluid
flow
one
direct
time
one
way
flow
cystoscop
work
well
small
anim
practic
year
still
work
well
diagnost
simpl
correct
procedur
system
work
well
advanc
complex
transurethr
intervent
procedur
especi
use
laser
radiofrequ
one
way
flow
visual
field
quickli
obscur
debri
blood
smoke
repeat
fluid
exchang
requir
maintain
adequ
imag
qualiti
discontinu
procedur
drain
refil
bladder
time
consum
frustrat
increas
risk
bladder
trauma
overdistensioncontinu
flow
cannula
avail
cystoscop
allow
ingress
egress
fluid
occur
simultan
maintain
constant
bladder
distens
clear
visual
field
system
standard
instrument
human
cystoscopi
hyperthyroid
mask
chronic
kidney
diseas
ckd
hyperfiltr
muscl
loss
symmetr
dimethylarginin
sdma
shown
increas
earlier
creatinin
cat
ckd
unlik
creatinin
sdma
impact
lean
muscl
mass
reason
postul
sdma
could
sensit
indic
renal
function
hyperthyroid
cat
aim
studi
describ
relationship
sdma
creatinin
bodi
weight
evalu
sdma
potenti
renal
biomark
hyperthyroid
cat
cat
retrospect
identifi
us
idexx
refer
laboratori
databas
sdma
creatinin
measur
sampl
sdma
creatinin
compar
concentr
entir
studi
popul
cat
spearman
correl
test
conduct
cat
hyperthyroid
treat
group
identifi
decreas
minimum
bodi
weight
laboratori
result
avail
one
visit
hyperthyroid
cat
compar
control
group
agematch
euthyroid
cat
use
evalu
bodi
weight
creatinin
sdma
pretreat
day
posttreat
cat
met
criteria
euthyroid
grey
zone
hyperthyroid
boxplot
illustr
relationship
creatinin
sdma
concentr
neg
relationship
found
creatinin
p
although
also
slight
neg
relationship
sdma
statist
signific
p
mean
bodi
weight
hyperthyroid
treat
cat
n
pretreat
posttreat
time
point
significantli
less
control
cat
n
p
valu
hyperthyroid
cat
significantli
lower
mean
weight
pretreat
day
day
versu
day
p
valu
pretreat
creatinin
significantli
decreas
comparison
posttreat
time
point
p
valu
creatinin
significantli
increas
day
comparison
time
point
p
valu
mean
creatinin
hyperthyroid
cat
significantli
less
control
cat
pretreat
day
posttreat
time
period
p
valu
pretreat
sdma
significantli
decreas
comparison
posttreat
time
point
p
valu
howev
increas
sdma
day
signific
differ
mean
sdma
concentr
throughout
remaind
treatment
period
addit
compar
control
cat
mean
sdma
hyperthyroid
cat
significantli
lower
pretreat
p
posttreat
time
point
creatinin
significantli
decreas
increas
concentr
wherea
sdma
sdma
creatinin
concentr
increas
immedi
posttreat
period
treatment
creatinin
continu
increas
cat
gain
weight
contrast
sdma
remain
stabl
treatment
compar
agematch
control
cat
therefor
sdma
may
reliabl
biomark
renal
function
creatinin
hyperthyroid
cat
treatment
hypothes
herbal
supplement
would
associ
increas
urin
volum
decreas
urin
satur
calcium
oxal
struvit
compar
placebo
fourteen
healthi
clientown
dog
evalu
use
random
placebo
crossov
studi
pairwis
fashion
dog
receiv
treatment
everi
hour
twoweek
period
approxim
void
urin
sampl
collect
end
treatment
period
sampl
analyz
ph
sodium
potassium
chlorid
calcium
phosphor
magnesium
citrat
oxal
ammonia
creatinin
rel
supersatur
calcium
oxal
struvit
estim
use
iter
comput
program
equil
univers
florida
gainesvil
fl
data
assess
normal
distribut
use
shapirowilk
pair
ttest
normal
distribut
wilcoxon
sign
rank
nonnorm
distribut
use
statist
analysi
data
analyz
use
statist
test
except
rel
supersatur
urin
volum
test
use
pvalu
consid
signific
data
dog
use
due
incomplet
urin
collect
dog
femal
male
includ
labrador
mix
havanes
pit
bull
great
dane
mix
mix
unknown
breed
urin
satur
calcium
oxal
significantli
lower
dog
receiv
supplement
compar
placebo
supplement
placebo
p
differ
analyt
bodi
weight
urin
volum
sever
limit
studi
studi
short
durat
includ
small
number
healthi
nonurolith
form
dog
twelv
hour
urin
sampl
collect
owner
home
may
introduc
error
urin
volum
collect
addit
urin
collect
overnight
dog
drink
although
access
result
collect
low
volum
urin
signific
decreas
calcium
oxal
supersatur
even
limit
suggest
determin
rel
pa
use
two
agonist
adenosin
diphosph
adp
arachidon
acid
aspi
salin
control
perform
six
healthi
clientown
dog
baselin
week
follow
clopidogrel
administr
establish
cutoff
valu
identifi
respond
r
nonrespond
nr
decreas
adp
hour
post
clopidogrel
administr
defin
r
pa
perform
pln
dog
baselin
week
follow
clopidogrel
aspirin
administr
drug
concentr
pa
measur
hour
post
clopidogrel
administr
week
week
healthi
pln
dog
fourteen
dog
enrol
ten
pln
dog
receiv
clopidogrel
alon
three
receiv
aspirin
alon
one
dog
start
aspirin
switch
clopidogrel
repeat
measur
rm
analysi
oneway
anova
perform
subsequ
time
point
chronic
kidney
diseas
ckd
dog
common
clinic
entiti
character
mark
decreas
renal
function
human
sever
report
uremia
caus
renal
failur
affect
oral
fecal
microbiom
lack
inform
oral
fecal
microbiom
dog
ckd
therefor
object
present
studi
examin
chang
oral
fecal
microbiom
ckd
dog
eleven
dog
ckd
present
azotemia
month
healthi
dog
includ
casecontrol
studi
oral
swab
fecal
sampl
analyz
whole
genom
sequenc
use
illumina
miseq
platform
dyslipidemia
affect
human
chronic
kidney
diseas
ckd
associ
increas
mortal
progress
ckd
addit
risk
factor
ckd
develop
alter
lipoprotein
profil
document
dog
ckd
yet
investig
cat
purpos
studi
compar
serum
lipoprotein
profil
cat
ckd
healthi
control
hypothes
cat
ckd
would
higher
total
lowdens
lipoprotein
ldl
lower
total
highdens
lipoprotein
hdl
compar
healthi
cat
clientown
healthi
cat
cat
naturallyoccur
ckd
prospect
enrol
studi
healthi
cat
urin
specif
graviti
greater
serum
creatinin
mgdl
normal
sdimethylarginin
sdma
cat
ckd
compat
clinic
histori
serum
creatinin
mgdl
urin
specif
graviti
fast
serum
collect
analysi
lipoprotein
profil
use
continu
lipoprotein
densiti
profil
clpdp
techniqu
serum
cholesterol
triglycerid
also
measur
use
commerci
chemistri
analyz
area
curv
triglyceriderich
lipoprotein
trl
total
ldl
total
hdl
calcul
statist
analysi
data
analyz
use
wilcoxon
rank
sum
test
signific
set
p
thirteen
cat
ckd
six
healthi
control
met
inclus
criteria
base
creatinin
valu
time
studi
enrol
cat
ckd
classifi
intern
renal
interest
societi
iri
stage
cat
classifi
iri
stage
triglycerid
rich
lipoprotein
total
ldl
total
hdl
significantli
differ
cat
ckd
healthi
control
p
p
p
respect
serum
cholesterol
concentr
serum
triglycerid
concentr
within
refer
rang
cat
significantli
differ
group
p
p
respect
studi
suggest
dyslipidemia
may
occur
cat
ckd
impli
possibl
differ
pathophysiolog
ckd
cat
rel
dog
human
studi
larger
sampl
size
cat
advanc
ckd
need
confirm
find
avail
evalu
efficaci
drug
treatment
human
comput
tomographi
ct
magnet
reson
imag
mri
use
follow
adpkd
progress
evalu
total
kidney
volum
tkv
purpos
studi
examin
efficaci
biomark
imag
modal
evalu
diseas
progress
felin
adpkd
eleven
adpkd
cat
mutat
imag
use
ultrasonographi
ct
mri
cbc
serum
chemistri
urianalysi
symmetr
dimethylarginin
level
glomerular
filtrat
rate
also
measur
adpkd
cat
clinic
normal
except
presenc
multipl
bilater
renal
cyst
tkv
measur
ct
correl
estim
use
ultrasonographi
mri
tkv
correl
age
fraction
cyst
volum
fcv
ml
obtain
ct
moder
correl
age
month
spearman
rank
correl
coeffici
p
howev
fcv
per
age
show
outlier
renal
cyst
known
increas
time
cat
adpkd
howev
data
indic
cyst
progress
differ
rate
determin
ctbase
fcv
per
age
cat
signific
increas
age
tkv
variabl
fcv
per
age
support
diseas
progress
individu
suggest
modifi
like
influenc
progress
fcv
evalu
diseas
progress
felin
adpkd
character
therapeut
efficaci
drug
adpkd
one
compon
assess
chronic
kidney
diseas
cat
creatinin
cr
concentr
blood
urin
measur
use
autom
system
base
reaction
enzymebas
assay
evid
speci
suggest
cr
overestim
reaction
clear
assumpt
accur
cat
studi
compar
autom
assay
method
mgdl
correct
part
methodolog
measur
cr
concentr
serum
scr
urin
ucr
cr
data
use
void
urin
volum
uvol
calcul
endogen
creatinin
glomerular
filtrat
rate
gfr
compar
serum
symmetr
dimethylarginin
sdma
concentr
fortyeighthr
uvol
healthi
domest
shorthair
cat
n
femal
yr
sd
occur
individu
hous
inert
litter
finish
blood
sampl
collect
scr
sdma
gfr
determin
use
cr
assay
method
mean
reaction
scr
ucr
gfr
overestim
p
ucr
p
overestim
becom
greater
increas
cr
concentr
overal
mean
se
minmax
rang
scr
ucr
gfr
base
enzym
method
mgdl
mgdl
mlminkg
bw
ucr
gfr
differ
age
sex
wherea
scr
differ
age
p
sex
p
older
cat
lower
scr
yr
versu
middleag
cat
yr
addit
uvol
rang
mlkgd
usg
rang
gml
differ
age
sex
wherea
sdma
rang
ugdl
differ
age
p
sex
p
lower
sdma
older
se
versu
middleag
cat
se
therefor
part
framework
success
manag
ckd
cat
time
select
diagnost
laboratori
measur
cr
use
enzym
method
appear
improv
accuraci
elimin
detect
noncr
compound
particularli
import
data
demonstr
cr
increasingli
overestim
jaff
method
cr
concentr
increas
intermitt
fast
numer
benefit
speci
includ
increas
insulin
sensit
improv
neuron
repair
follow
spinal
injuri
increas
keton
aim
studi
examin
immunolog
metabol
hormon
effect
associ
dog
ten
healthi
dog
underw
three
isocalor
feed
regimen
latin
squar
design
daili
lowfat
feed
kcal
dlf
lowfat
diet
iflf
highfat
kcal
diet
ifhf
bodi
weight
intak
activ
lymphocyt
prolifer
macrophageneutrophil
phagocytosi
respiratori
burst
along
fast
blood
glucos
betahydroxybutyr
bhob
leptin
ghrelin
insulin
measur
nmr
spectroscopi
use
identifi
chang
fast
plasma
metabolom
dog
iflf
lost
weight
mean
lower
voluntari
food
intak
dog
activ
night
fed
daili
fed
intermitt
mean
fast
bhob
concentr
highest
ifhd
phase
lowest
dld
phase
mean
fast
plasma
glucos
greatest
fed
daili
lowest
ifhd
phase
intermitt
daili
feed
separ
metabolom
analysi
hormon
concentr
differ
biolog
signific
differ
immun
assay
dietari
phase
unlik
human
rodent
short
term
fast
dog
produc
detriment
immunolog
effect
increas
plasma
bhob
high
fat
diet
highlight
potenti
benefici
feed
regim
dog
spinal
diseas
obes
becom
common
health
problem
reduc
longev
increas
risk
mani
chronic
diseas
advers
affect
qualiti
life
dog
continu
calor
restrict
ccr
regimen
appli
obes
treatment
creat
daili
neg
energi
balanc
howev
ccr
lead
decreas
energi
expenditur
make
difficult
continu
lose
excess
bodi
fat
maintain
bodi
weight
weight
loss
object
studi
compar
effect
ccr
intermitt
calori
restrict
icr
regimen
bodi
fat
loss
postweight
loss
mainten
energi
requir
mer
obes
dog
thirti
natur
obes
dog
bc
random
two
group
base
mer
bodi
weight
bodi
fat
dog
ccr
group
fed
baselin
mer
month
dog
icr
group
fed
repeat
baselin
mer
one
week
baselin
mer
one
week
month
calor
restrict
group
adjust
baselin
mer
addit
month
icr
ccr
led
similar
bodi
fat
end
studi
vs
p
dog
ccr
group
significantli
p
lower
postweight
loss
mer
compar
baselin
mer
howev
dog
icr
group
numer
increas
postweight
loss
mer
p
obes
diabet
lead
nutritionrel
disord
among
pet
north
america
signific
impact
anim
morbid
mortal
glycem
index
gi
measur
postprandi
blood
glucos
respons
shown
human
significantli
impact
glucos
control
insulin
sensit
weight
manag
chronic
diseas
risk
purpos
research
determin
gi
commerci
avail
pet
food
contain
differ
carbohydr
sourc
addit
effect
postprandi
glycem
insulinem
respons
hormon
relat
satieti
also
investig
four
commerci
extrud
diet
contain
differ
carbohydr
sourc
test
diet
classifi
base
type
carbohydr
sourc
contain
tradit
grain
corn
wheat
whole
grain
oat
rye
barley
grainfre
pea
lentil
chickpea
vegan
anim
ingredi
diet
test
eleven
healthi
adult
siberian
huski
control
glucos
solut
test
twice
per
dog
random
crossov
design
meal
control
provid
avail
carbohydr
preand
postprandi
blood
sampl
minut
collect
measur
whole
blood
glucos
concentr
use
handheld
blood
glucos
monitor
serum
insulin
ghrelin
gastric
inhibitori
polypeptid
gip
glucagonlik
peptid
leptin
total
peptid
tyrosinetyrosin
pyy
pancreat
polypeptid
pp
concentr
also
analys
time
point
use
magnet
bead
multiplex
assay
glycem
index
calcul
postprandi
increment
area
curv
iauc
glucos
test
diet
divid
iauc
control
glycem
indic
compar
use
twoway
anova
concentr
glucos
insulin
satieti
hormon
time
compar
treatment
use
repeatedmeasur
anova
studi
approv
univers
guelph
anim
care
committe
aup
effect
diet
gi
insignific
p
although
numer
differ
observ
diet
contain
tradit
grain
present
highest
gi
grainfre
diet
present
lowest
gi
whole
grain
diet
vegan
diet
gi
valu
respect
signific
effect
diet
observ
postprandi
glycem
respons
insulinem
respons
satieti
hormon
measur
p
lack
observ
differ
could
relat
gelatin
starch
extrus
process
result
high
content
rapidli
digest
starch
result
suggest
differ
carbohydr
sourc
commerci
extrud
diet
may
signific
effect
gi
satieti
dog
research
investig
appropri
use
gi
methodolog
human
necessari
due
high
variabl
postprandi
glucos
respons
observ
studi
unknown
health
benefit
low
glycaem
food
dog
water
intak
hydrat
evalu
healthi
dog
offer
nutrientenrich
water
nw
supplement
fed
mainten
dri
food
maintain
bw
ad
libitum
tap
water
tw
bucket
baselin
day
urin
specif
graviti
usg
analyz
beagl
n
year
select
usg
equal
divid
group
balanc
usg
group
receiv
either
tw
nw
contain
whey
protein
poultri
flavor
glycerol
bowl
day
dose
dog
watertocalori
ratio
ml
kcal
med
day
ml
kcal
med
day
base
baselin
calori
intak
food
calori
total
liquid
intak
tli
gd
sum
nw
tw
bowl
bucket
water
record
daili
use
calcul
weekli
mean
intak
amount
usg
measur
day
linear
mix
effect
model
perform
main
effect
treatment
time
timebytreat
interact
calori
intak
differ
p
timebytreat
interact
signific
p
versu
baselin
signific
p
day
gml
gml
versu
baselin
gml
studi
indic
dog
offer
nw
supplement
free
access
tw
increas
tli
produc
dilut
urin
suggest
improv
overal
hydrat
diabet
mellitu
chronic
disord
result
hyperglycemia
hyperlipidaemia
insulin
defici
sometim
lead
fatal
complic
studi
evalu
effect
pea
barley
starch
sourc
lipid
profil
diabet
dog
twelv
diabet
dog
receiv
randomli
doubl
blind
way
three
diet
differenc
fat
level
starch
sourc
ba
mix
rice
pea
barley
g
pb
pea
barley
g
co
corn
g
plasmat
cholesterol
triglycerid
curv
perform
everi
hour
hour
begin
immedi
morn
meal
insulin
inject
day
diet
treatment
statist
test
perform
p
pea
barleybas
diet
caus
lesser
plasmat
lipid
concentr
mainli
cholesterol
compar
corn
diet
tabl
pb
diet
result
lipid
valu
ba
diet
allow
decreas
lipid
level
higher
fat
content
diet
probabl
happen
due
better
glycem
control
diabet
dog
receiv
slow
assimil
starch
phenol
compound
present
pea
barley
ingredi
believ
pea
barley
could
interest
starch
sourc
hyperlipidem
diabet
dog
shadow
trend
human
nutrit
percept
exist
among
veterinarian
mani
pet
owner
prefer
natur
holist
diet
process
food
purpos
studi
determin
dog
cat
owner
feed
pet
compar
studi
publish
ten
year
ago
laflamm
et
al
studi
involv
pet
owner
survey
laflamm
colleagu
questionnair
administ
student
phone
randomli
select
telephon
directori
present
questionnair
administ
onlin
distribut
pet
owner
social
media
survey
promot
gener
pet
own
pet
appreci
group
veterinari
nutrit
special
interest
group
open
share
reach
wide
audienc
acquir
sampl
repres
gener
popul
pet
pet
owner
studi
approv
research
ethic
board
particip
institut
reb
descript
data
report
percentag
signific
differ
two
studi
determin
use
chi
squar
analysi
signific
set
p
inform
australia
unit
state
includ
analysi
result
survey
summaris
tabl
data
compar
signific
differ
feed
practic
time
includ
increas
feed
homemad
raw
diet
decreas
daili
feed
treat
decreas
feed
commerci
diet
main
food
sourc
dog
cat
increas
exclus
feed
homemad
diet
also
detect
cat
essenc
trend
appear
shift
pet
nutrit
away
complet
balanc
diet
current
recommend
veterinarian
favour
homeprepar
human
food
raw
meat
diet
chang
practic
may
predispos
nation
pet
dietari
imbal
nutritionallyrespons
diseas
infecti
diseas
given
inform
clinician
gener
specialti
practic
must
awar
risk
associ
homemad
raw
diet
obtain
comprehens
dietari
histori
client
prepar
diagnos
treat
associ
diseas
fecal
sampl
collect
healthi
dog
n
owner
complet
survey
inform
health
statu
dietari
histori
nutrient
content
obtain
onlin
product
guid
inform
provid
pet
food
compani
contact
directli
dysbiosi
index
di
evalu
combin
quantit
polymeras
chain
reaction
valu
e
coli
streptococcu
turicibact
faecalibacterium
fusobacterium
blautia
clostridium
hiranoni
statist
signific
set
p
correl
abund
bacteri
taxa
macronutri
perform
use
spearman
correl
signific
set
p
conclus
signific
correl
found
crude
fiber
fusobacterium
result
suggest
macronutri
content
commerci
diet
modest
impact
abund
major
bacteri
taxa
canin
microbiota
studi
lipid
biolog
fluid
led
substanti
advanc
diagnosi
therapeut
human
obes
cancer
kidney
diseas
consid
condit
also
afflict
cat
hypothes
lipid
could
also
serv
biomark
studi
diagnos
diseas
cat
howev
studi
lipid
felin
plasma
limit
number
lipid
speci
mainli
fatti
acid
triacylglycerol
wherea
yet
unknown
felin
urin
contain
lipid
consid
gap
knowledg
object
studi
character
lipid
composit
plasma
urin
sampl
collect
clinic
healthi
youngadult
cat
plasma
sampl
obtain
clinic
healthi
youngadult
yearsold
intact
femal
cat
collect
ml
blood
tube
contain
citrat
centrifug
x
g
min
urin
sampl
collect
ultrasoundguid
cystocentesi
immedi
centrifug
x
g
min
everi
cat
given
baselin
complet
histori
physic
examin
laboratori
evalu
normal
complet
blood
count
serum
chemistri
urinalysi
lipid
analyz
use
liquid
chromatographyquadrupol
timeofflight
mass
spectrometri
total
lipid
character
felin
plasma
urin
sampl
origin
metabolit
mainli
food
endogen
compound
plasma
glycerophospholipid
show
higher
number
chemic
speci
detect
follow
sphingolipid
glycerolipid
fatti
acyl
sterol
lipid
urin
highest
structur
divers
observ
polar
lipid
name
glycerophospholipid
sphingolipid
chemic
speci
identifi
within
categori
respect
figur
show
rel
abund
lipid
categori
base
signal
intens
found
felin
plasma
urin
sampl
note
lipid
identifi
studi
report
previous
cat
first
studi
describ
lipid
composit
plasma
urin
healthi
cat
comprehens
mani
lipid
found
studi
use
biomark
human
medicin
differ
patholog
includ
linol
arachidon
acid
kidney
diseas
sm
sm
insulin
resist
nonalcohol
fatti
liver
diseas
lpc
lpc
pc
pc
pc
cholesterol
hepatocellular
carcinoma
among
other
thu
novel
inform
gener
studi
could
lead
discoveri
novel
biomark
candid
detect
studi
felin
diseas
individu
treatment
cat
sol
rivera
nicola
villarino
washington
state
univers
colleg
veterinari
medicin
pullman
wa
usa
glycat
nonenzymat
reaction
carbonyl
group
reduc
sugar
free
amino
group
protein
figur
percentag
categori
lipid
found
felin
plasma
fatti
acyl
fa
glycerolipid
gl
glycerophospholipid
gp
sphingolipid
sp
sterol
lipid
st
b
signal
intens
mean
ae
sem
known
lipid
detect
felin
urin
process
plasma
protein
form
varieti
heterogen
structur
known
advanc
glycat
end
product
age
compound
associ
sever
patholog
includ
obes
diabet
cirrhosi
cardiovascular
diseas
renal
failur
neurolog
disord
contrast
human
medicin
littl
attent
given
age
veterinari
medicin
note
fructosamin
biomark
use
monitor
blood
sugar
concentr
provid
inform
earli
glycat
product
convers
carbonyl
group
form
earli
late
stage
protein
glycat
consid
fact
canin
albumin
contain
similar
glycosylat
amino
acid
lysin
arginin
human
hypothes
abnorm
high
level
glucos
dog
plasma
lead
format
age
process
protein
glycat
order
address
hypothesi
plasma
healthi
dog
enrich
glucos
level
similar
report
diabet
patient
good
poor
glycem
control
glucoseenrich
control
sampl
incub
day
c
high
level
glucos
glycat
plasma
protein
led
format
age
determin
assay
carbonyl
content
plasma
increas
p
glucos
concentrationdepend
manner
p
figur
posit
associ
concentr
fructosamin
p
fructosamin
level
obtain
studi
compar
found
dog
suffer
diabet
plasma
fructosamin
level
first
studi
report
content
protein
carbonyl
canin
plasma
result
demonstr
protein
carbonyl
form
higher
amount
dog
plasma
glucos
level
similar
diabet
patient
compar
plasma
control
although
result
obtain
use
ex
vivo
system
provid
new
inform
occurr
age
glycat
canin
plasma
protein
certainli
futur
studi
perform
use
sampl
diabet
patient
order
expand
knowledg
format
clinic
impact
compound
dog
studi
format
protein
carbonyl
due
glycat
protein
could
repres
new
tool
elucid
metabol
pathway
lead
format
age
consequ
aid
develop
new
therapeut
strategi
treatment
diabet
patient
dog
alyssa
bryce
tracey
rossi
colleen
tansey
lisa
murphi
reid
nakamura
ruth
murphi
southern
california
veterinari
specialti
hospit
irvin
ca
usa
inland
valley
veterinari
specialist
emerg
center
upland
ca
usa
veterinari
special
center
delawar
newcastl
de
usa
veterinari
emerg
special
center
thousand
oak
ca
usa
beaumont
hospit
dublin
ireland
galway
galway
ireland
multipl
studi
found
veterinarian
higher
risk
suicid
compar
gener
popul
risk
factor
associ
psycholog
distress
veterinarian
includ
practic
associ
practic
less
year
practic
shelter
medicin
human
physician
patient
complaint
lead
increas
risk
depress
anxieti
suicid
secondari
effect
complaint
physician
includ
practic
medicin
defens
avoid
high
risk
procedur
patient
perform
unnecessari
diagnost
veterinari
medicin
due
need
owner
use
dispos
incom
lead
differ
potenti
sourc
conflict
veterinarian
client
purpos
studi
investig
effect
client
complaint
small
anim
veterinari
internist
welfar
job
satisfact
well
way
practic
veterinari
medicin
webbas
anonym
questionnair
made
avail
american
colleg
veterinari
intern
medicin
subspecialti
small
anim
intern
medicin
email
list
serv
januari
st
march
st
survey
obtain
avail
review
respond
receiv
client
complaint
within
preced
month
cost
care
common
reason
major
respond
worri
vari
degre
client
complaint
made
concern
almost
report
verbal
assault
client
within
preced
six
month
report
threaten
litig
major
report
chang
way
practic
veterinari
medicin
avoid
complaint
made
said
consid
chang
career
client
complaint
studi
confirm
client
complaint
common
sourc
distress
veterinari
internist
high
percentag
conflict
due
cost
care
illustr
central
problem
veterinari
medicin
issu
veterinarian
control
veterinarian
need
consid
client
educ
cost
care
achiev
also
need
way
forum
allow
veterinarian
openli
discuss
client
complaint
deal
support
environ
veterinari
medicin
becom
advanc
offer
expens
treatment
procedur
issu
client
complaint
commun
like
continu
grow
strategi
improv
case
outcom
referr
afford
referr
internist
often
best
interest
patient
particularli
case
involv
chronic
refractori
undiagnos
condit
unfortun
mani
pet
owner
afford
cost
referr
instanc
gener
practition
challeng
treat
complic
case
limit
budget
owner
may
even
elect
euthanasia
due
cost
care
gener
practition
may
seek
guidanc
internist
order
discuss
diagnost
treatment
option
patient
need
referr
care
whose
owner
afford
consult
frequent
limit
singl
phone
convers
email
outcom
therefor
unknown
consult
internist
addit
strategi
improv
option
outcom
financi
challeng
case
may
benefici
gener
practition
patient
furthermor
increas
awar
prepared
veterinari
student
challeng
may
improv
abil
approach
case
effici
owner
limit
budget
descript
studi
perform
determin
use
onsit
consult
board
internist
case
followup
internist
written
diagnost
therapeut
protocol
select
intern
medicin
condit
fourthyear
veterinari
student
particip
weekli
onsit
consult
develop
protocol
total
veterinarian
small
anim
veterinari
practic
particip
studi
practic
visit
three
time
cours
one
year
total
consult
conduct
collect
protocol
differ
intern
medicin
condit
given
practition
data
collect
preand
postparticip
survey
fourthyear
veterinari
student
particip
veterinarian
prior
particip
veterinari
student
feel
confid
choos
best
diagnost
therapeut
approach
intern
medicin
case
owner
budget
could
afford
referr
student
felt
train
area
part
educ
particip
onsit
consult
protocol
develop
student
felt
confid
choos
best
approach
case
highli
like
use
protocol
gener
practic
lack
diagnosi
uncertainti
appropri
diagnost
need
special
procedur
three
common
reason
gener
practition
recommend
referr
particip
veterinarian
note
dog
owner
agre
referr
veterinarian
note
expens
primari
reason
owner
declin
referr
veterinarian
alway
comfort
case
sometim
comfort
veterinarian
express
desir
lowercost
option
treatment
protocol
owner
afford
referr
complet
project
veterinarian
note
onsit
consult
protocol
highli
benefici
area
greatest
improv
comfort
level
treat
referrallevel
case
gener
practic
case
outcom
patient
care
veterinarian
believ
patient
qualiti
life
improv
want
continu
particip
onsit
consult
summari
onsit
intern
medicin
consult
costeffect
diagnost
treatment
protocol
variou
intern
medicin
condit
benefit
veterinari
student
gener
practition
cost
veterinari
care
especi
referr
medicin
afford
mani
owner
veterinari
student
expos
challeng
train
costeffect
approach
case
similarli
gener
practition
may
abl
success
effici
diagnos
treat
challeng
intern
medicin
case
propos
strategi
owner
declin
referr
hypothesis
ckc
irrespect
diseas
statu
would
increas
fibrosi
multipl
organ
compar
breed
postmortem
sampl
ckc
collect
prospect
though
donat
scheme
avail
owner
veterinarian
collect
irrespect
diseas
state
antemortem
diagnosi
clinic
inform
obtain
possibl
liver
pancrea
kidney
lung
store
formalinfix
paraffinimbed
sampl
tissu
match
age
histopatholog
diagnosi
tissu
nonckc
breed
dog
siriu
red
stain
highlight
fibrosi
perform
slide
digit
object
analysi
softwar
analys
red
stain
score
proport
tissu
volum
analys
blind
breed
patholog
diagnosi
forti
ckc
liver
pancrea
kidney
lung
nonckc
liver
pancrea
kidney
lung
includ
compris
breed
signific
differ
organ
fibrosi
score
ckc
control
howev
ckc
moder
signific
correl
identifi
liver
fibrosi
pancrea
lung
fibrosi
addit
signific
correl
found
lung
renal
fibrosi
insuffici
case
multipl
organ
preclud
analysi
nonckc
conclus
ckc
show
increas
fibrosi
compar
match
control
fibrosi
correl
across
organ
studi
indic
assess
multipl
organ
dog
breed
confirm
signific
find
decis
make
also
cancer
stage
prognost
purpos
studi
describ
presenc
number
size
shape
attenu
enhanc
pattern
abdomin
lymph
node
ct
healthi
cat
assess
correl
patient
characterist
sixteen
healthi
cat
without
clinic
biochem
evid
diseas
underw
sedat
preand
postcontrast
ct
exam
entir
abdomen
number
size
shape
attenu
enhanc
pattern
presenc
intranod
fat
follow
lymph
center
evalu
two
reader
includ
boardcertifi
radiologist
aortic
lumbar
renal
hepat
splenic
gastric
pancreaticoduoden
jejun
ileocec
colic
caudal
mesenter
medial
iliac
sacral
inguin
assess
compar
patient
characterist
pearson
correl
student
ttest
use
statist
analysi
total
abdomin
lymph
node
readili
identifi
ct
caudal
mesenter
colic
hepat
inguin
pancreaticoduoden
lymph
node
identifi
cat
bodi
weight
sex
associ
differ
overal
number
lymph
node
identifi
p
respect
lymph
node
size
shape
vari
lymph
center
nearli
lymph
node
homogen
contrast
enhanc
signific
neg
correl
identifi
length
p
width
hospit
dog
treat
intraven
fluid
studi
period
elig
inclus
initi
fluid
therapi
rate
mlkg
fluid
type
inhospit
adjust
fluid
rate
record
discharg
death
well
manag
servic
ecc
surgeri
acvim
base
specialti
data
normal
assess
use
shapirowilk
test
analyz
ttest
p
consid
signific
two
hundr
eightythre
dog
includ
receiv
dogday
fluid
therapi
median
durat
day
rang
examin
thoroughli
stewart
method
fencl
semiquantit
method
along
monitor
nitric
oxid
plasma
measur
studi
evalu
effect
hhe
control
hemorrhag
shock
dog
model
compar
four
convent
fluid
three
aspect
volum
expans
system
tissu
perfus
respons
acidbas
statu
aspect
volum
expans
lr
he
hhe
resuscit
significantli
larger
volum
hs
hhe
lr
he
consid
overexpans
intravascular
volum
p
hemodynam
data
coincid
volumetr
result
three
percent
hhe
well
four
fluid
provid
suffici
system
oxygen
perfus
yet
examin
conduct
hemorrhag
shock
model
base
oxygen
debt
infus
hhe
benefici
acidot
state
hemorrhag
shock
without
dilut
acidosi
owe
transient
hypernatremia
hyperchloremia
conclus
data
suggest
hhe
support
suffici
volum
expans
without
overload
return
system
oxygen
indic
lactat
control
level
superior
resuscit
benefit
acidbas
statu
inflammatori
stabil
reperfus
injuri
convent
resuscit
fluid
thu
hhe
could
best
altern
solut
compens
dosag
disadvantag
convent
crystalloid
colloid
administr
oxid
stress
primarili
assess
activ
antioxid
enzym
concentr
endogen
antioxid
byproduct
oxid
damag
byproduct
lipid
peroxid
determin
best
marker
oxid
injuri
rodent
model
oxid
stress
stabl
easili
measur
urin
peopl
gold
standard
measur
urinari
ga
chromatographymass
spectrometri
gcm
anim
major
studi
util
enzymelink
immunosorb
assay
elisa
measur
previou
studi
compar
two
method
small
popul
dog
cat
hors
cow
poor
agreement
method
identifi
dog
hors
cow
howev
fair
agreement
method
identifi
cat
object
studi
evalu
agreement
gcm
elisa
measur
urinari
larg
popul
cat
includ
rang
healthi
clinic
ill
cat
skelet
matur
cat
recruit
health
statu
cat
determin
physic
examin
complet
blood
count
cbc
serum
chemistri
profil
thyroid
hormon
urinalysi
cat
defin
system
ill
evid
ill
identifi
physic
examin
persist
fever
inject
mucou
membran
andor
evid
inflamm
andor
organ
system
dysfunct
urin
collect
noninvas
free
catch
cat
unless
otherwis
indic
due
diseas
process
system
ill
cat
urinari
measur
gcm
elisa
urin
sampl
fifti
cat
enrol
studi
twentyf
cat
determin
healthi
determin
system
ill
urin
sampl
detect
level
signific
neg
correl
identifi
two
method
signific
correl
identifi
healthi
system
ill
cat
compar
subgroup
analysi
pass
bablok
regress
show
poor
agreement
two
method
comparison
demonstr
nonlinear
relationship
proport
bia
concentr
urinari
measur
elisa
significantli
lower
system
ill
cat
compar
healthi
cat
signific
differ
identifi
urinari
measur
gcm
result
indic
gcm
method
recommend
assess
urinari
cat
expect
increas
urinari
system
ill
cat
identifi
caution
still
warrant
interpret
test
regardless
method
futur
research
use
gcm
identifi
normal
refer
rang
variabl
urinari
cat
express
induc
nitric
oxid
synthas
ino
significantli
oneway
anova
decreas
lpsstimul
raw
cell
cocultur
canin
msc
compar
lpsstimul
raw
cell
alon
furthermor
antiinflammatori
effect
canin
msc
significantli
increas
compar
canin
msc
express
cyclooxygenas
prostaglandin
e
pge
likewis
significantli
increas
prime
canin
msc
level
ino
protein
lpsstimul
raw
cell
cocultur
prime
canin
msc
decreas
increas
cell
treat
pge
inhibitor
conclus
compar
canin
msc
cell
prime
caus
greater
reduct
releas
antiinflammatori
cytokin
lpsstimul
raw
cell
mechan
upregul
pathway
matthew
e
miller
kamoltip
thungrat
jey
w
koehler
dawn
booth
auburn
univers
colleg
veterinari
medicin
auburn
al
usa
endocannabinoid
system
ec
compris
endogen
signal
molecul
known
endocannabinoid
gproteincoupl
receptor
bind
recent
decad
research
found
relationship
ec
memori
nocicept
inflamm
appetit
metabol
interest
provid
framework
eventu
develop
safe
effect
cannabinoid
therapi
veterinari
speci
paper
sought
character
two
predomin
cannabinoid
quantif
local
tissu
sampl
acquir
live
adult
dog
present
ausath
surgeri
depart
procedur
relat
tissu
obtain
follow
collect
tissu
sampl
place
either
formalin
sampl
store
process
formalin
sampl
submit
histopatholog
process
tissu
sampl
collect
collect
formalin
rna
extract
tissu
store
convert
cdna
quantifi
use
quantit
pcr
qpcr
data
report
ratio
gene
express
constitutivelyexpress
housekeep
gene
immunohistochemistri
run
use
previouslydescrib
antibodi
select
stain
verifi
western
blot
previous
undescrib
find
immunohistochemistri
limit
receptor
stain
darkli
endotheli
cell
membran
tissu
lesssignific
stain
scatter
throughout
parenchyma
local
microscop
cell
membran
quantif
show
high
express
gene
blood
brain
testicl
ovari
uteru
low
express
kidney
lung
liver
lymph
node
express
valu
gene
somewhat
limit
show
high
express
blood
lymph
node
mani
find
previou
studi
confirm
high
concentr
gray
matter
high
concentr
blood
lymph
node
studi
also
found
unexpectedli
high
quantiti
male
femal
gonad
addit
unexpectedli
low
level
express
found
lung
liver
compar
human
mous
model
result
invit
futur
investig
reproduct
applic
cannabinoid
well
possibl
upregul
follow
exogen
exposur
explain
rel
low
express
liver
lung
tissu
quantif
specif
region
canin
brain
may
also
prove
use
develop
pharmaceut
cannabinoid
goal
studi
evalu
pharmacodynam
pd
mpa
week
vari
oral
dose
mmf
healthi
cat
pd
mpa
evalu
follow
oral
administr
mmf
po
bid
po
bid
po
tid
week
cat
blood
sampl
taken
prior
first
administr
mmf
hour
treatment
day
hour
last
oral
dose
mmf
isol
peripher
blood
mononuclear
cell
pbmc
perform
use
standard
method
blood
draw
sampl
cryopreserv
later
thaw
subsequ
flow
cytometri
analyz
batch
percentag
posit
stain
cell
antibodi
determin
flow
cytometri
total
isol
pbmc
number
variabl
cat
test
premed
initi
oral
mpa
day
day
hour
last
dose
oral
mmf
minim
chang
averag
lymphocyt
count
bid
bid
group
mild
reduct
lymphocyt
cat
treat
tid
mmf
overal
ratio
nearli
bid
bid
tid
treatment
group
studi
describ
pd
multiday
oral
administr
mmf
healthi
cat
littl
chang
lymphocyt
count
bid
group
mild
reduct
tid
group
lymphocyt
ratio
show
littl
chang
group
result
studi
show
appreci
reduct
cell
suppress
may
due
short
treatment
period
due
presenc
unactiv
lymphocyt
cat
healthi
futur
studi
evalu
pd
mpa
clinic
affect
felin
patient
receiv
mmf
recent
studi
highlight
potenti
variat
suscept
sever
common
phenotyp
includ
cancer
object
studi
analyz
sequenc
canin
gene
ncbi
access
thirteen
clientown
dog
mct
grade
iiiii
investig
pattern
sequenc
variat
relat
clinic
respons
therapi
fisher
exact
test
use
assess
correl
snp
clinic
respons
patient
receiv
vinblastin
show
sign
toxic
includ
vomit
anorexia
thrombocytopenia
three
set
point
mutat
found
patient
silent
c
n
missens
g
n
chang
amino
acid
frameshift
mutat
n
code
sequenc
three
patient
show
missens
n
frameshift
mutat
n
present
recurr
mct
vinblastin
chemotherapi
could
repres
step
toward
predict
clinic
respons
anticanc
chemotherapi
patient
control
clinic
sign
versu
uncontrol
diseas
common
diseas
treat
enceph
n
immunemedi
hemolyt
anemia
thrombocytopenia
n
inflammatori
bowel
diseas
ibd
n
n
eg
atop
dermat
anal
furunculosi
uveiti
csa
peak
level
control
ngml
versu
uncontrol
patient
ngml
fail
demonstr
statist
differ
p
control
patient
hr
significantli
longer
uncontrol
patient
hr
p
signific
variabl
found
peak
csa
level
cotreat
prednisolon
leflunomid
ketoconazol
diseas
also
increas
variabl
variabl
csa
disposit
support
need
tdm
establish
patient
therapeut
rang
idexxsdma
tm
test
noninvas
test
market
diagnos
monitor
chronic
kidney
diseas
cat
dog
object
studi
determin
serum
concentr
sdma
creatinin
increas
cat
meloxicaminduc
kidney
damag
femal
cat
alloc
experiment
group
control
group
meloxicam
group
cat
control
meloxicam
group
treat
salin
meloxicam
respect
serum
sdma
idexx
tm
creatinin
concentr
assess
administr
treatment
histopatholog
perform
kidney
cat
meloxicam
group
sever
tubular
chang
observ
cat
start
administr
treatment
cat
compar
serum
concentr
creatinin
mgdl
sdma
unexpectedli
sdma
concentr
rose
normal
refer
rang
cat
meloxicaminduc
kidney
damag
time
requir
sdma
creatinin
surpass
refer
concentr
similar
cat
studi
first
one
report
chang
serum
concentr
sdma
healthi
cat
develop
nsaidkidney
damag
result
studi
suggest
serum
concentr
sdma
detect
kidney
tubular
damag
induc
repeat
administr
meloxicam
earlier
creatinin
cat
ii
clinician
may
unabl
detect
extens
kidney
tubular
damag
cat
use
sdma
creatinin
least
glomerulu
sever
affect
multiinstitut
studi
univers
hospit
patient
prescrib
oral
fluconazol
confirm
suspect
fungal
diseas
enrol
dose
protocol
determin
treat
clinician
one
three
serum
sampl
collect
opportunist
time
per
fluconazol
dose
interv
sampl
multipl
visit
encourag
sampl
store
frozen
analyz
valid
liquid
chromatographi
mass
spectrometri
method
clinic
sign
includ
fever
cough
tachypnea
regurgit
ptyalism
hematemesi
hemoptysi
cbc
peripher
neutrophilia
neutropenia
note
band
neutrophil
toxic
common
balf
cytolog
degener
neutrophil
intracellular
bacteria
observ
secondari
bacteri
pneumonia
blind
diagnosi
obtain
measur
later
radiograph
number
intercost
space
first
rib
carina
ic
distanc
caudal
aspect
manubrium
carina
mc
standard
vertebr
score
draw
mc
fourth
thorac
vertebra
count
number
includ
vertebr
bodi
vs
distanc
first
rib
carina
rc
two
factor
anova
use
data
report
seventyeight
cat
includ
mass
group
increas
ic
mc
vs
rc
compar
group
compar
normal
cat
cpe
ncpe
increas
ic
cpe
cat
increas
mc
rc
radiograph
measur
may
aid
clinician
differenti
mediastin
mass
pleural
effus
cat
morgan
canonn
elodi
roel
freder
billen
ghita
benchekroun
clercx
ecol
nation
de
maison
alfort
franc
maison
alfort
iledefr
franc
na
lieg
belgium
na
maison
alfort
iledefr
franc
despit
widespread
use
vaccin
bordetella
bronchiseptica
bb
infect
still
commonli
diagnos
dog
lower
airway
infect
fatal
pneumonia
chronic
present
may
observ
effici
treatment
requir
aerosol
gentamicin
histor
describ
maxim
local
drug
deliveri
minim
system
absorpt
clinic
respons
standard
protocol
report
object
studi
compar
clinic
respons
two
differ
protocol
aerosol
gentamicin
dog
confirm
respiratori
bb
infect
posit
bacteri
cultur
pcr
bronchoalveolar
lavag
fluid
dog
recruit
year
period
dog
gentamicin
aerosol
minut
twice
daili
week
use
face
mask
variou
type
ultrason
nebul
either
dose
mgkg
gentamicin
dilut
part
salin
use
protocol
fix
amount
undilut
gentamicin
protocol
first
recheck
week
treatment
either
stop
pursu
increment
clinic
cure
clinic
cure
defin
resolut
clinic
sign
absenc
cough
radiograph
lesion
improvementresolut
proport
dog
clinic
cure
first
recheck
median
total
durat
treatment
compar
treatment
protocol
addit
effect
factor
age
breed
coinfect
bacteria
includ
cyno
presenc
alveolar
lesion
previou
steroid
therapi
sever
neutrophilia
lavag
cure
treatment
durat
analys
chisquar
mannwhitney
test
thirtyseven
dog
recruit
male
femal
median
age
month
median
bw
kg
brachycephal
breed
yorkshir
chihuahua
overrepres
dog
dog
previous
treat
oral
antimicrobi
therapi
poor
respons
twenti
dog
alveolar
pattern
thorac
radiograph
suggest
bronchopneumonia
differ
demograph
clinic
data
dog
includ
protocol
treatment
well
toler
dog
undesir
effect
observ
clinic
cure
first
recheck
tend
frequent
observ
dog
treat
protocol
dog
compar
protocol
dog
median
durat
treatment
shorter
protocol
week
rang
compar
protocol
week
rang
none
clinic
patholog
paramet
studi
associ
clinic
respons
conclus
timeconsum
oral
antimicrobi
therapi
aerosol
gentamicin
appear
safe
promis
treat
dog
bb
infect
particularli
case
refractori
oral
antimicrobi
therapi
protocol
use
undilut
solut
minut
allow
deliveri
gentamycin
amount
proport
individu
minut
volum
could
offer
shorter
durat
treatment
abnorm
vfss
categor
gastroesophag
reflux
ger
hiatal
hernia
dysmotil
aspir
thirtytwo
case
met
inclus
criteria
median
iqr
age
year
identifi
breed
sex
predisposit
median
iqr
durat
cough
month
thorac
radiograph
unremark
dog
evid
aspir
pneumonia
abnorm
vfss
detect
dog
abnorm
includ
ger
dog
larg
volum
ger
dog
later
diagnos
laryng
paralysi
dog
diagnos
via
vfss
slide
hiatal
hernia
pharyng
andor
esophag
hypomotil
found
dog
megaesophagu
note
dog
macroaspir
identifi
dog
final
respiratori
diagnos
dog
abnorm
vfss
includ
chronic
bronchiti
laryng
paralysi
laryng
polyp
tracheal
collaps
devast
diseas
primarili
affect
small
breed
dog
medic
manag
fail
surgic
therapi
cervic
tracheal
ring
andor
tracheal
stent
may
use
palliat
clinic
sign
tracheal
ring
may
prefer
case
cervic
thorac
inlet
collaps
order
prevent
stentassoci
complic
granul
tissu
persist
cough
stent
fractur
howev
tracheal
collaps
consid
progress
dog
initi
improv
follow
tracheal
ring
placement
may
recurr
intrathorac
airway
obstruct
requir
intrathorac
stent
palliat
purpos
studi
evalu
characterist
outcom
dog
receiv
tracheal
stent
follow
earlier
placement
tracheal
ring
electron
medic
record
search
dog
underw
placement
tracheal
ring
record
retriev
record
dog
subsequ
underw
placement
tracheal
stent
evalu
breed
age
placement
ring
durat
ring
stent
identifi
fortyseven
dog
underw
tracheal
ring
placement
studi
period
includ
yorkshir
terrier
nonyorkshir
terrier
two
dog
ring
stent
place
singl
hospit
prior
discharg
one
dog
euthan
ring
placement
follow
develop
suspect
ard
fortyfour
dog
discharg
follow
isol
tracheal
ring
placement
nine
yorkshir
terrier
subsequ
underw
tracheal
stent
placement
median
year
rang
year
follow
initi
placement
tracheal
ring
dog
underw
tracheal
ring
stent
significantli
p
younger
dog
ultim
procedur
time
origin
ring
placement
year
year
one
dog
underw
procedur
seizur
die
home
two
day
follow
discharg
two
dog
subsequ
euthan
due
progress
airway
obstruct
stentassoci
granul
tissu
one
dog
die
due
pneumonia
tracheal
stent
may
perform
earlier
ring
placement
dog
progress
airway
diseas
younger
age
initi
ring
placement
well
yorkshir
terrier
may
increas
likelihood
undergo
subsequ
tracheal
stent
epiglott
retrovers
concurr
diseas
manag
outcom
case
taylor
elizabeth
rozanski
j
gladden
tuft
univers
north
grafton
usa
epiglott
retrovers
er
displac
epiglotti
lumen
larynx
result
inspiratori
airflow
limit
andor
distress
unclear
often
er
primari
diseas
dog
versu
condit
develop
secondarili
upper
airway
obstruct
diseas
goal
studi
describ
concurr
diseas
manag
outcom
dog
er
electron
medic
record
system
search
epiglott
retrovers
epiglott
entrap
epiglottopexi
diagnosi
made
upon
sedat
oral
examin
tracheoscopi
without
doxapram
administr
record
review
data
collect
descript
analysi
thirteen
dog
met
inclus
criteria
follow
breed
repres
yorkshir
terrier
one
chihuahua
havanes
miniatur
schnauzer
parson
russel
terrier
pomeranian
pug
shih
tzu
toy
poodl
seven
dog
male
neuter
six
femal
spay
mean
age
year
mean
weight
kg
two
dog
er
evid
concurr
upper
airway
diseas
remain
eleven
dog
combin
concurr
tracheal
collaps
elong
soft
palat
laryng
paralysi
concurr
elong
soft
palat
common
treatment
includ
epiglottopexi
perform
dog
epiglottectomi
perform
one
dog
four
dog
staphylectomi
one
dog
underw
arytenoid
later
procedur
dog
recov
discharg
epiglott
retrovers
may
contribut
respiratori
distress
commonli
associ
airway
diseas
addit
epiglottopexi
dog
er
may
help
reduc
clinic
sign
attribut
er
poch
lydia
pan
christin
savidg
pierr
amsellem
stephani
hamilton
atlant
veterinari
colleg
univers
princ
edward
island
charlottetown
pi
canada
atlant
veterinari
colleg
univers
princ
edward
island
charlottetown
pi
canada
object
studi
compar
effect
alfaxalon
propofol
laryng
function
evalu
laryng
function
numer
object
score
system
via
computer
softwar
ten
healthi
beagl
dog
randomli
assign
receiv
either
propofol
alfaxalon
crossov
prospect
studi
propofol
administ
mgkgmin
intraven
alfaxalon
administ
mgkgmin
intraven
dog
mouth
could
open
videolaryngoscopi
two
week
later
dog
evalu
use
anesthet
agent
video
analyz
glotantool
imag
j
softwar
valu
area
rima
glottidi
major
length
axi
l
figur
process
second
increment
final
second
record
normal
measur
comput
al
repres
elongated
rima
glottidi
small
larg
valu
correspond
thin
thick
shape
along
length
axi
breath
greatest
laryng
movement
identifi
differ
maxim
minim
valu
breath
cycl
calcul
shape
valu
rang
pixel
length
differ
maxim
minim
valu
rang
pixel
length
final
statist
model
show
signific
drug
effect
variabl
shape
alfaxalon
ci
propofol
propofol
prove
superior
evalu
laryng
function
healthi
beagl
softwar
program
provid
object
number
comparison
